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UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
FACULTY OF MEDICINE, HEALTH & LIFE SCIENCES 
Doctor of Medicine 
BONE TISSUE ENGINEERING 
HARNESSING INTERDISCIPLINARY APPROACHES FOR CLINICAL APPLICATION 
By James Oliver Smith 
There  is  an  acute  requirement  for  novel  clinical  approaches  to  combat  loss  or 
dysfunction  of  skeletal  tissue.  Inherent  disadvantages  of  current  reconstructive 
strategies  combined  with  the  ageing  population  and  a  continuing  increase  in 
musculoskeletal  pathology  and  patient  expectations,  highlight  a  pressing  need  to 
augment current practice with osteoregenerative techniques. Tissue engineering shows 
promise  as  a  discipline  to  meet  these  needs  by  the  systematic  selection  and 
manipulation of cells, matrices and biological stimuli to produce the required tissue. 
 
This thesis examines current and emerging clinical strategies available for replacement 
of  skeletal  tissue  and  discusses  the  requisite  properties  that  novel  approaches  are 
required to possess before successful progress to clinical application can be achieved. 
Each chapter in this thesis details a specific aspect of the continuous process in the 
development  of  a  novel  tissue  engineering  strategy,  considering  also  the  wider 
scientific, logistical, clinical, financial and practical issues that must be addressed for 
successful outcomes: 
 
  The  effects  of  cells,  cytokines  and  material  properties  are  explored  in  the 
context of recreating normal biological structure and function. 
  The limitations of current clinical cell enrichment techniques are discussed and 
a novel intra-operative strategy is shown to enrich skeletal stem cells from bone 
marrow by acoustic filtration, suitable for potential orthopaedic application. 
  A tissue engineering approach applied to an established orthopaedic implant 
(Tantalum Trabecular Metal) is shown to support osteogenic differentiation and 
enhance bone-implant interface strength, with potential clinical applicability. 
  A murine model for skeletal regeneration is used to evaluate a novel ternary 
polymer blend scaffold for efficacy in a tissue engineering approach. 
  An ovine model for skeletal regeneration is defined and evaluated along with a 
candidate binary polymer blend scaffold for tissue engineering strategies. 
  Many  of  the  hurdles  to  successful  clinical  translation  that  are  commonly 
overlooked are discussed with particular reference to the cellular toxicity of local 
anaesthetics. 
 
This  thesis  demonstrates  the  considerable  potential  of  skeletal  tissue  engineering 
approaches,  but  highlights  the  requirement  for  a  concerted  multidisciplinary 
appreciation to achieve successful clinical translation. II 
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Chapter I 
 
General Introduction 
 
 
 
 
A review article based upon the work in this chapter has recently been published in  Tissue 
Engineering Part B: Reviews 
 
Figure 1.8 of this chapter was chosen as the front cover illustration to Tissue Engineering Part 
B: Reviews, October 2011 2 
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1.1  Scale of the problem in the context of clinical need 
 
Pathology  affecting  the  musculoskeletal  system  is  a  global  source  of  considerable 
morbidity. In addition to the acute life-threatening dangers associated with trauma, the 
pain and disability from chronic orthopaedic disease frequently has widespread, long-
term effects on patients and their families. These impacts extend to general health and 
psychological  status  and  have  considerable  economic  implications  with  escalating 
costs of treatment, social support and loss of economic activity (Kilgore et al. 2009, 
Heckman et al. 1997, Dahabreh et al. 2007). 
 
Bone possesses a high intrinsic regenerative potential. Consequently, the majority of 
fractures  and  bone  defects  heal  spontaneously  through  a  recapitulation  of  the 
embryonic developmental process (Gerstenfeld et al. 2003). Despite this, one of the 
most frequent challenges for the orthopaedic surgeon is to restore skeletal tissue that 
has been lost, deformed or damaged as a consequence of injury or disease. Various 
factors  such  as  tissue  loss,  a  compromised  wound  environment  or  biomechanical 
instability can result in persistent defects with impaired healing capacity. In addition, 
pathology of other skeletal tissues such as cartilage and tendon contribute to morbidity, 
and clinical attempts to restore these tissues have to overcome additional challenges of 
reduced local vascularity and the lack of inherent repair mechanisms (Khan WS et al.  
2010).  Improved  surgical  techniques  and  implant  designs,  as  well  as  novel  peri-
operative management strategies and ancillary products, have significantly decreased 
complication rates in such situations.  
 
Surgical therapies for musculoskeletal pathology were initially limited to debridement of 
the diseased area without replacement. This often led to considerable functional loss, 
particularly for peri-articular pathology, where often the only method to reduce pain was 
by  joint  arthrodesis  (Ahlback  et  al.  1966).  More  recently,  with  the  introduction  of 
arthroplasty, function can be restored by using biologically favourable implant materials 
to replace the specialised skeletal tissues lost. However, considerable disadvantages 
remain  with  this  approach,  which  may  in  itself  contribute  to  latent  morbidity  and 
complications. An example of this is the recent well-publicised failure of some metal-
on-metal  articulations  in  total  hip  arthroplasty,  including  catastrophic  soft-tissue 
reactions (Haddad et al. 2011). Archetypal causes of bone loss that are targets for 
tissue  engineering  therapies  include  trauma,  inflammation  and  the  treatment  of 
infection and tumours. The requirement for restoration of tissue stock and function are 
prerequisites to normal activities following surgical excision for osteomyelitis and bone 4 
 
tumours.  Additionally,  there  is  now  an  escalating  requirement  to  treat  the  elective 
cohort of patients who require bone defect reconstruction during revision arthroplasty 
surgery (McNamara IR 2010) (Fig. 1.1), as well as developing techniques to augment 
union  following  spinal  fusion  procedures  and  for  treating  morbidity  associated  with 
other skeletal tissues (see section 1.3). 
 
 
Fig. 1.1  a) Anteroposterior pelvis and b) lateral left hip radiographs of a female made 
prior to revision total hip arthroplasty. Substantial osteolysis is apparent around both the 
femoral and acetabular components, presenting a significant reconstructive challenge. Images 
courtesy of University Hospital Southampton NHS Foundation Trust. 
 
 
The proportion of people aged over 65 years is projected to increase by nearly 50% in 
the coming 25 years in the UK (Office for National Statistics 2010), and in the US this 
cohort  which  accounted  for  12.8%  of  the  total  population  in  2009,  will  rise  to 
approximately 20% in 2050 (Shrestha et al. 2011). Despite refinements in prosthetic 
design, manufacture and implantation, artificial joint replacements have a finite lifespan 
and frequently present at revision with significant lost bone stock. Given the current 
and  historic  arthroplasty  implantation  rates  and  these  demographic  trends,  an 
attendant  increase  in  orthopaedic  revision  surgery  as  well  as  other  causes  of 
musculoskeletal  morbidity  can  therefore  be  expected,  justifying  the  current  intense 
research  interest  in  this  field.  It  is  likely  therefore,  that  in  the  next  few  years,  the 
revision  of  these  hip  and  knee  arthroplasty  implants  will  represent  the  biggest 
challenge that may be overcome by tissue engineering strategies.   5 
 
1.2  Composition of skeletal tissues 
 
Successful  tissue  engineering strategies to tackle the pathology detailed above are 
likely  to  closely  mimic  the  natural  processes  that  bring  about  skeletal  tissue 
development  and  repair.  An  understanding  of  the  normal  composition  of 
musculoskeletal tissues is therefore essential. 
 
 
1.2.1  Bone 
 
Bone, as an organ composes the largest proportion of the body’s connective tissue 
mass and is unique in that it is constantly regenerated throughout life (Rodan 1992). 
The skeleton serves a variety of functions including: i) structural support; ii) locomotion; 
iii) protection of internal organs; iv) maintenance of mineral homeostasis and acid-base 
balance; v) serving as a reservoir for cytokines and growth factors, and vi) providing a 
space for haematopoiesis (Taichman 2005). Bone tissue can be separated into cortical 
(compact) and cancellous (trabecular) types, which are approximately 5% and 80% 
porous, respectively (Clarke 2008) (Fig. 1.2). 
 
 
Fig. 1.2  High magnification images of a) cancellous and b) cortical bone, demonstrating 
the significant differences in composition and porosity. Image from Fyhrie and Kimura 1999. 
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Collagen  fibrils  are  laid  down  by  osteoblasts  in  a  lamellar  pattern  with  alternating 
orientations.  Osteoblasts  become  osteocytes  once  they  have  been  surrounded  by 
mineralised  bone.  The  cancellous  compartment  is  filled  with  bone  marrow,  which 
contains haematopoietic and skeletal tissue progenitor niches (Yang et al. 2009). 
 
Cortical bone is surrounded by periosteum on the outer surface and endosteum on 
the inner surface; both layers contain blood vessels, osteoblasts and osteoclasts, and 
periosteal surface activity is important for appositional growth and fracture repair. Bone 
undergoes longitudinal and radial growth during normal development, and continually 
models and remodels in response to physiological influences, in obedience to Wolff’s 
law to meet its mechanical demands (Chen et al. 2010). The process of remodelling is 
normally  tightly  controlled  by  osteoblastic  matrix  production  coupled  with  bone 
resorption by osteoclasts. Osteoblasts are derived from multipotent stem cells within 
the  bone  marrow  stromal  compartment,  whereas  osteoclasts  originate  from 
mononuclear  cells  of  the  monocyte-macrophage  lineage  (Del  Fattore  et  al.  2010). 
Multinucleated  cells  are  recruited  by  the  action  of  Macrophage  Colony-Stimulating 
Factor  (M-CSF)  and  Receptor  activator  of  nuclear  factor  kappa-B  ligand  (RANKL), 
which  then  adhere  to  bone  and  undergo  differentiation  into  mature  osteoclasts. 
Osteoclastic bone resorption is initiated by integrin-mediated binding to bone matrix, 
principally the integrin αvβ3 (Robey and Boskey 2008). Upon binding, the cells develop 
a ruffled border that seals that portion of matrix before releasing hydrogen ions (H
+), to 
dissolve  the  mineralised  portion  and  also  activate  released  enzymes,  cathepsin  K 
(CATK) and tartrate-resistant acid phosphatase (TRAP), which digest the extracellular 
matrix (Boyle et al. 2003) (Fig. 1.3). 
 
 
Fig. 1.3  Osteoclast action: a) A multinucleated cell is recruited by the action of M-CSF and 
RANKL, which then adheres to bone and undergoes differentiation into a mature osteoclast. b), 
RANKL stimulates osteoclast activation by inducing secretion of protons (H
+) and lytic enzymes 
(TRAP, CATK) into a sealed resorption vacuole formed between the osteoclast and the bone 
surface. Acidification of this compartment by secretion of protons leads to the enzyme activation 
and degradation of bone mineral and collagen matrices. From Boyle et al. 2003 7 
 
The  Extracellular Matrix (ECM)  of bone consists of mineral, collagen, water, non-
collagenous proteins and lipids, in decreasing proportion. The mineral phase is mostly 
hydroxyapatite [Ca10(PO4)6(OH)2], with small quantities of carbonate, magnesium, and 
acid phosphate. This provides mechanical rigidity with compressive strength, whereas 
the organic matrix provides elasticity and flexibility (Clarke 2008). The organic matrix is 
mostly composed of collagen type I with small amounts of type III, V and non-fibrillar 
collagens. Approximately 10-15% of the organic matrix is made up of non-collagenous 
proteins including serum-derived proteins (such as albumin,  α2-HS-glycoprotein and 
growth  factors)  and  non-collagenous  proteins  synthesised  by  osteoblasts 
(proteoglycans,  glycosylated  proteins,  glycosylated  proteins  with  potential  cell 
attachment activities, and γ-carboxylated proteins) (Table 1.1). 8 
 
Table 1.1  Extracellular Matrix proteins in bone 
Protein  Function/ Location 
Disease (of absence or 
dysfunction) 
C
o
l
l
a
g
e
n
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r
e
l
a
t
e
d
 
p
r
o
t
e
i
n
s
 
Type I  Binds and orientates other proteins  Osteogenesis imperfecta 
Type X  Present in hypertrophic cartilage  Metaphyseal chondroplasia 
Type III  Trace, may regulate collagen fibril diameter  Ehlers Danlos syndrome 
Type V  Trace, may regulate collagen fibril diameter  Disrupted fibrils in mouse model 
S
e
r
u
m
 
 
p
r
o
t
e
i
n
s
  Albumin  Inhibits HA crystal growth  None 
AHSG 
Promotes endocytosis 
Monocyte chemoattractant 
Inhibits calcification 
Ectopic calcification in mouse 
knockout 
G
l
y
c
o
s
a
m
i
n
o
g
l
y
c
a
n
 
c
o
n
t
a
i
n
i
n
g
 
m
o
l
e
c
u
l
e
s
 
Aggrecan 
Matrix organisation and strength 
Retention of H2O, Ca, PO4 
Spondyloepiphyseal dysplasia 
Versican 
Regulates chondrogenesis 
Defines space destined to ossify 
Wagner syndrome 
Decorin 
May regulate collagen fibril size 
May modulate TGF-β activity 
Progeroid form of Ehlers Danlos 
(with double decorin-biglycan 
knockout)  Biglycan 
Determines peak bone mass 
May regulate growth factor  activity 
Asporin  Regulates collagen structure 
Human polymorphism 
associated with OA 
Hyaluronan  May define space destined to ossify  None 
G
l
y
c
o
p
r
o
t
e
i
n
s
 
Alkaline Phosphatase 
Hydrolyses inhibitors of mineral deposition 
Increases local PO4 concentration 
Hypophosphatasia – poor 
growth and mineralisation 
Osteonectin 
Regulates collagen organisation 
May regulate HA deposition 
Regulates growth factors 
Low mineral content Osteopenia 
in knockout mouse  
S
I
B
L
I
N
G
 
p
r
o
t
e
i
n
s
 
Osteopontin 
Binds to cells, controls proliferation 
May regulate mineralisation 
Inhibits Nitric oxide synthase 
Poor osteoclast remodelling 
Increased mineral content in 
knockout mouse  
Bone Sialoprotein 
Binds to cells 
May initiate mineralisation 
None 
MEPE  Regulation of PO4 metabolism  Oncogenic osteomalacia 
R
G
D
-
c
o
n
t
a
i
n
i
n
g
 
g
l
y
c
o
p
r
o
t
e
i
n
s
 
Thrombospondins 
Cell attachment 
Binds to collagens, platelets, thrombin, 
fibrinogen, laminin, plasminogen and PAI 
Pseudoachondroplasia 
Fibronectin 
Cell attachment 
Binds to fibrin, heparin, gelatin, collagens 
Lethal before skeletal 
development in knockout mouse 
Vitronectin 
Cell attachment 
Binds: collagens, plasminogen, PAI, heparin 
None 
Fibrillin 1 and 2  Regulates elastic fibre formation 
Marfan syndrome in Fibrillin 1 
mutation 
γ
-
c
a
r
b
o
x
y
 
g
l
u
t
a
m
i
c
 
a
c
i
d
-
c
o
n
t
a
i
n
i
n
g
 
p
r
o
t
e
i
n
s
 
Matrix Gla protein  Inhibitor of mineralisation 
Keutel syndrome (excessive 
cartilage mineralisation) 
Osteocalcin 
Regulates osteoclasts 
Inhibits mineralisation 
May coordinate bone turnover 
Knockout mouse - osteopetrosis 
Protein S  May be synthesised by osteoblasts  Osteopenia 
HA  =  Hydroxyapatite,  AHSG  =  ⍺2HS  glycoprotein,  H2O  =  water,  Ca  =  calcium,  PO4  = 
phosphate, TGF-β = Transforming Growth Factor Beta, OA = Osteoarthritis, SIBLING = Small 
Integrin Binding Ligand N-Glycosylated, MEPE = Matrix extracellular phosphoglycoprotein, PAI 
= Plasminogen Activator Inhibitor, RGD = Arginyl-glycyl-aspartic acid DNA motif. Adapted from 
Robey and Boskey 2008 and Clarke 2008. 9 
 
1.2.1.1 Fracture repair 
Normal fracture healing is a complex of events involving a coordinated interplay of 
cells, growth factors and ECM. Two basic types of fracture healing exist: Primary bone 
healing is rare, requiring absolute contact of the bone fragments, with absolute stability, 
so that cells within the cortical bone can directly re-establish continuity (Giannoudis et 
al.  2007).  The  vast  majority  of  fractures  undergo  secondary  bone  healing, 
characterised  by  callus  formation  due  to  the  processes  of  intramembranous  and 
endochondral ossification. This does not require absolute stability of bone ends; in fact 
the  small  movements  associated  with  relative  stability  have  to  shown  to  be  a 
prerequisite  for  callus  formation  (Giannoudis  et  al.  2007).  Certain  aspects  of  bone 
healing parallel the events of skeletal development, and although the repair process is 
characterised by a number of sequential cellular and molecular phases, these are, in 
practice, poorly delineated (Gerstenfeld et al. 2003): 
 
During the initial inflammatory stage, soft tissue disruption and bleeding lead to non-
specific  wound-healing  pathways,  stimulated  by  platelet  degranulation  and 
mononuclear  inflammatory  cell  activation.  These  cells  release  cytokines  and  pro-
coagulant factors, which modify the initial haematoma into a fibrinous thrombus and 
form a positive feedback loop, activating and recruiting further cells (Gerstenfeld et al. 
2003). Over  the subsequent days, infiltration of macrophages and other phagocytic 
cells  facilitate  the  reorganisation  of  the  thrombus  into  granulation  tissue.  These 
processes  take  place  under  the  control  of  cytokines  and  growth  factors  (including 
Transforming Growth Factor Beta (TGF-β), Platelet Derived Growth Factor (PDGF), 
Basic Fibroblast Growth Factor (FGF-2), Vascular Endothelial Growth Factor (VEGF), 
Macrophage  Colony-Stimulating  Factor  (M-CSF),  Bone  Morphogenetic  Proteins 
(BMPs),  Interleukin  (IL)  -1  and  -6  and  Tumour  Necrosis  Factor-alpha  (TNF-α)) 
produced by the infiltrating cells. These factors recruit and stimulate the differentiation 
of stem cells from bone marrow, periosteum, blood vessels and surrounding soft tissue 
(Shapiro et al. 2008). 
 
In  the  second  phase  of  fracture  healing,  endochondral  ossification  commences 
through soft fibrocartilaginous callus formation. Growth factors stimulate chondrocytes 
and fibroblasts to replace areas of granulation tissue with fibrocartilage. These areas 
eventually fuse to form a semi-rigid cartilaginous template, which splints the fracture. 
Hard callus formation is then initiated by pro-angiogenic factors, such as VEGF, BMPs, 
FGF-1 and TGF-β, which stimulate callus vascularisation, chondrocyte hypertrophy and 
apoptosis.  Hard  callus  formation  is  characterised  by  local  ingress  of  Skeletal  Stem 10 
 
Cells  (SSCs)  from  periosteum,  bone  marrow,  the  vasculature  and  surrounding  soft 
tissues. Specific growth factors, such as the BMPs, stimulate differentiation of these 
cells  into  osteoblasts  and  their  production  of  mineralised  bone  matrix,  to  produce 
woven bone (Schindeler et al. 2008). 
 
The final stage encompasses bone remodelling of the woven hard callus into lamellar 
bone  and  eventual  restoration  of  the  original  trabecular  and  cortical  bone 
conformations.  This  remodelling  process  is  driven  by  osteoclast  activity  in  a  tightly 
coupled  catabolic-anabolic  response  requiring  coordinated  matrix  synthesis  by 
osteoblasts.  The  underlying  mechanism  governing  this  has  not  yet  been  fully 
established, but the local release of osteoid breakdown products and growth factors 
during remodelling are thought to drive the osteoblastic response (Martin and Sims 
2005).  The  final  result  of  successful  fracture  healing  through  these  means  is  a 
restoration of normal bone structure and function, without the formation of permanent 
scar  tissue.  However,  it  is  clear that  this  can only  take  place  through  the complex 
interaction of growth factors, cells, ECM and the mechanical environment (Giannoudis 
et al. 2007). 
 
 
 
1.2.2  Cartilage 
 
Cartilage  is  a  versatile  connective  tissue  found  in  many  areas  of  the  body.  It  has 
varying properties dependent upon its exact composition to suit specific functions and 
requirements.  Within the adult skeletal system, cartilage is found: as hyaline articular 
cartilage in synovial joints (Fig. 1.4); as fibroelastic cartilage within the menisci of 
articulations,  and  as  fibrocartilage  at  tendon  and  ligament  insertions  into  bone 
(Brinker and O’Connor 2008). Fibrocartilage is also formed during fracture healing (see 
section 1.2.1.1) and articular cartilage repair.  
 
The  ECM  which  provides  structure  and  function  to  cartilage  is  produced  and 
maintained  by  chondrocytes,  spread  sparsely  throughout  the  matrix  (Bhosale  and 
Richardson  2008).  Cartilage  is  avascular,  aneural  and  alymphatic,  so chondrocytes 
derive their nutrition primarily through matrix diffusion, driven by mechanical stimulation 
(Buckwalter et al. 1998). The avascular, anti-angiogenic nature of cartilage is important 
for normal function, with a loss of resistance to vascularisation being a key event in the 
pathogenesis of osteoarthritis (Smith et al. 2003). 11 
 
 
Fig. 1.4  Safranin-O  staining  demonstrating  reducing  proteoglycan  content  of  human 
articular cartilage with severity of osteoarthritis in a) normal cartilage, b) early osteoarthritis, 
c) severe osteoarthritis. Scale bars: 400 µm, from Smith et al. 2003. 
 
 
The  main  function  of  articular  cartilage,  to  reduce  friction  and  distribute  loads,  is 
achieved  by  a  hydrated  ECM.  Indeed  water  is  the  major  constituent  of  articular 
cartilage  (65-80%  of  wet  weight),  which  allows  load-dependent  deformation  and 
provides a medium for nutrition and lubrication (Bhosale and Richardson 2008). The 
principal organic components are collagens (10-20% of total weight) and proteoglycans 
(10-15%), with collagen type II being most abundant. This forms a fibrillar meshwork 
around  aggrecan  (the  most  abundant  proteoglycan)  and  provides  the  high  tensile 
strength required at articular surfaces. Other collagens are present in smaller quantities 
and have diverse functions (Table 1.2). 
 
Table 1.2  Collagens present in articular cartilage and their functions  
Collagen type  Morphological location  Functions 
II  Principal component of macrofibril (>90%)  Tensile strength 
VI  Pericellular matrix  Aids matrix-cellular adherence 
IX  Cross-linked to surface of macrofibril 
Tensile strength 
Inter-fibrillar adherence 
X 
Related to hypertrophic chondrocytes in 
calcified layer 
Structural support 
Aids mineralisation 
XI  Within macrofibril core 
Nucleates fibril formation 
Limits macrofibril diameter 
Adapted from Bhosale and Richardson 2008 
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Proteoglycans  are  protein  polysaccharides  that  form  large  aggregates  within  the 
collagen network and are composed of highly sulphated glycosaminoglycans (keratin 
and chondroitin sulphate) linked to the protein core. Their high negative charge attracts 
water molecules and increases the osmolarity of cartilage, which provides compressive 
strength and elasticity (Bhosale and Richardson 2008). 
 
Chondrocytes  produce  collagen,  proteoglycans  and  some  enzymes  for  cartilage 
metabolism and breakdown, including matrix metalloproteinases and tissue inhibitors of 
matrix metalloproteinases (TIMPs) (Brinker and O’Connor 2008). Given the avascular 
structure  of  cartilage  and  low  chondrocyte  metabolism,  the  tissue  possesses  poor 
inherent repair mechanisms to damage (Richter et al. 2009). Surface damage has a 
negligible healing response, whereas injury that extends into the calcified zone of the 
osteochondral  junction  causes  an  inflammatory  reaction  that  may  heal  with 
fibrocartilage, produced by SSCs within the subchondral bone. This repair cartilage 
however, contains a high proportion of collagen type I and is thus not as durable as 
normal hyaline cartilage (Brinker and O’Connor 2008). 
 
Menisci deepen the articular surface of many synovial joints, broadening the contact 
area  and  distributing  load  (Brinker  and  O’Connor  2008).  Menisci  are  composed  of 
specialised fibroelastic cartilage, with an interlacing network of collagen fibres (90% 
collagen type I), proteoglycans and glycoproteins. Fibrochondrocytes that maintain this 
composition are found within the ECM, but in contrast to hyaline cartilage, menisci also 
contain mechanoreceptor nerve endings and peripheral blood vessels (Wilson et al. 
2009). Thus peripheral tears in the vascularised region can heal by fibrovascular scar 
formation, and surgical repair is often indicated, however, more central tears in the 
avascular region do not heal, and are therefore debrided (Jarit and Bosco 2010). 
 
The long-term outcome following chondral, osteochondral or meniscal injury depends 
on many factors, including age, size and location of the defect, joint alignment and 
stability; however if left untreated, many of these injuries can become symptomatic and 
progress to osteoarthritis (Bhosale and Richardson 2008). It is clear that the inherent 
mechanisms of cartilage repair are not adequate in many situations, providing a strong 
mandate for developing alternative strategies for cartilage repair and reconstruction. 
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1.2.3  Tendon and ligament 
 
Whilst this study is centred upon bone and cartilage regeneration strategies, tendons 
and ligaments are synthesised by cells of a comparable stromal lineage to cartilage 
and bone. Consequently, there is considerable overlap within and amongst research 
groups investigating skeletal tissue regeneration and it is therefore informative to derive 
data from studies into tendons and ligaments and possess knowledge of their structure 
and function. 
 
Ligaments are dense connective tissues composed primarily of collagen type I with 
small amounts of collagen type III and elastin in a wave-like conformation (Gloria et al. 
2010).  Ligaments  attach  bone  to  bone  and  stabilise  joints,  and  although  their 
ultrastructure  is  similar  to  tendon,  they  have  a  higher  elastin  content  and  contain 
abundant mechanoreceptors for proprioception (Brinker and O’Connor 2008). Unstable 
ligamentous injuries are often reconstructed using autologous tendon, which is suitable 
due to its similar structure and strength characteristics. However, in many situations, 
such as in multiple or recurrent ligament injuries, alternatives may have to be found, 
and a tissue engineering approach may be appropriate (Gloria et al. 2010). 
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1.3  Rationale for research into skeletal tissue engineering 
 
The  last  decade  has  witnessed  a  revolution  in  techniques  to  treat  orthopaedic 
morbidity, with (amongst other advances) the introduction of bone tissue engineering 
strategies to overcome the problems inherent in entirely synthetic prosthetic materials. 
The  gravity  of  this  conceptual  shift  has  been  recognised  by  the  World  Health 
Organization  and  United  Nations,  proclaiming  the  years  2000-2010  ‘The  Bone  and 
Joint Decade’ (Horan et al. 1999). 
 
Bone possesses a unique capacity for regeneration upon damage together with the 
ability for constant turnover in response to demands of mechanical stress and mineral 
homeostasis (Giannoudis et al.  2007). Such dynamic properties imply the existence of 
a  renewable  source  of  progenitors  able  to  replenish  the  bone-forming  cells.  These 
cells,  the  osteoblasts,  generate  mineralised  bone  matrix  in  a  healing  process  that 
parallels  osteochondral development  pathways, following  complex  well-orchestrated, 
biological patterns (Gerstenfeld et al. 2003). Thus, tissue engineering principles – the 
use of a combination of cells, materials and biochemical factors to improve biological 
functions – appear particularly well suited to skeletal tissues, and in particular bone, 
giving substantial promise to the use of regenerative medicine techniques to tackle 
orthopaedic pathology (Muschler and Midura 2002). 
 
Initial translational efforts have centred on bone and cartilage reconstruction for several 
reasons, not least because the differentiation pathways for osteo- and chondrogenesis 
are almost completely established and can now be modulated (Charbord et al. 2011). 
Once  the  process  of  bone  and  cartilage  manipulation  and  regeneration  has  been 
proven in practice, such approaches may also be extended to other skeletal tissues 
such as tendon and ligament, although the cellular responses in these tissues appear 
harder to characterise (Charbord et al. 2011). 
 
The  development  of  new  regenerative  technology  is  timely,  both  in  the  nature  of 
pathology encountered and its sheer scale. There is now a real urgency to refine these 
techniques and bring them to regular clinical use, in order to address the burgeoning 
healthcare needs of a growing population, with an ageing demographic. 
 
The potential therapeutic niches for novel orthopaedic tissue engineering strategies are 
examined in Table 1.3. 
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Table 1.3  Potential  therapeutic  niches  for  novel  orthopaedic  tissue  engineering 
strategies 
Situation  Examples 
Acute trauma 
Segmental bone loss 
Chondral damage 
Osteochondral defects 
Tendon rupture 
Ligamentous injury 
Meniscal injury 
Tumour 
Surgically-induced bone and soft tissue defects 
Tissue-destructive lesions 
Infection 
Post-traumatic osteomyelitis 
Tuberculosis 
Iatrogenic 
Degenerative/Inflammatory 
Osteoarthritis 
Rheumatoid arthritis 
Congenital 
Dwarfism 
Maxillofacial defects 
Tendon lengthening 
Prosthetic-related  Orthopaedic/Maxillofacial implants 
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1.4  Skeletal tissue engineering 
 
Tissue engineering was first described by Langer and Vacanti in 1993 and can  be 
defined as the application of scientific principles to create or induce the formation of a 
specific tissue, in a specific location through the selection and manipulation of cells, 
matrices and biological stimuli (Langer and Vacanti 1993, Muschler and Midura 2002). 
With respect to skeletal applications, the fundamental requisites for a successful tissue 
engineering approach include suitable progenitor cells delivered in conjunction with a 
non-toxic bio-resorbable scaffold that will maintain structural support to the construct 
and appropriate spatial alignment of the cells whilst incorporation into existing tissues 
occurs.  This  should  take  place  within  a  local  microenvironment  that  contains 
endogenous or exogenous nutrients. Success of this approach would be heralded by 
eventual  appropriate  lineage  differentiation  of  the  implanted  progenitor  cells.  With 
regard  to  bone  regeneration,  this  process  would  require  a  stimulation  of  vascular 
ingress, cellular infiltration and attachment, cartilage formation and eventual calcified 
tissue deposition, so that the construct becomes indistinguishable from regenerated 
native tissue. Clinical success requires structural integration with surrounding tissues 
and reliable remodelling to provide mechanical properties of load bearing and fatigue 
resistance necessary for durable function (Fleming et al. 2000). A number of elements 
are important for a successful bone regeneration strategy, and these same processes 
can be applied to other skeletal tissues (Albrektsson and Johansson 2001): 
 
1.  Osteoconduction  –  The  process  of  bone  tissue  growth  throughout  the  site, 
supported by a physical three-dimensional (3D) scaffold or matrix. 
 
2.  Osteoinduction – The stimulation of osteoprogenitor cells to differentiate into 
osteoblasts that produce bone matrix. 
 
3.  Osteogenesis – The growth of new bone, brought about through the processes 
of osteoconduction and osteoinduction. 
 
Even if all these conditions are met optimally, there is also a requirement for local 
vascularity  and  mechanical  stability  to  prevent  micromotion  and  non-union.  These 
conditions are largely dependent on surgical factors and clinical expertise, and rely on 
meticulous tissue handling to prepare the graft bed, to ensure preservation of a good 
local blood supply, and to stabilise the construct and adjacent tissues (Fleming et al. 
2000). 17 
 
1.5  Stem cells 
 
A successful skeletal tissue engineering strategy requires the isolation and delivery of 
progenitor  cells  that  have  been  modulated  or  stimulated  to  undergo  selective 
differentiation  into  the  required  skeletal  genotype.  Stem  cells  are  found  in  all 
multicellular organisms and are defined by two properties – self-renewal and potency 
(Watt and Driskell 2010, Mitalipov and Wolf 2009): 
 
1.  Self-renewal – the ability to go through numerous cycles of cell division while 
maintaining an undifferentiated state. This is ensured through the processes of 
obligatory  asymmetric  replication  (where  cell  division  produces  one  identical 
undifferentiated  cell  and  one  differentiated cell)  and  stochastic  differentiation 
(when one stem cell develops into two differentiated cells, another stem cell 
undergoes mitosis to produce two undifferentiated stem cells identical to the 
original) (Lin 1998). 
 
2.  Potency – the capacity to differentiate into specialised cell types.  Totipotent 
cells can differentiate into any of the three germ layers: endoderm, mesoderm 
or  ectoderm,  and  can therefore give  rise  to  any  fetal  or  adult  cell  type  and 
potentially  develop  into  a  whole  organism  (Watt  and  Driskell  2010).  In 
mammalian  tissue,  this  is  only  true  for  the  zygote  and  early  embryonic 
blastomeres.  As  embryonic  development  progresses,  the  individual 
blastomeres  that  comprise  the  embryo  differentiate  into  either  the  inner  cell 
mass, that gives rise to the fetus and trophectoderm, or the extra-embryonic 
outer  layer  of  cells,  that  develops  into  placental  tissue.  These  cells  are 
pluripotent, as they can form all the cell types of the adult organism. Multipotent 
stem  cells  are  lineage-restricted,  but  have  the  ability  to  form  all  the 
differentiated cell types of a given tissue (Lovell-Badge 2001). Most adult or 
somatic  stem  cells  are multipotent  and  are  referred  to  by  their  tissue  origin 
(Barrilleaux et al. 2006). Their normal function is in repairing and regenerating 
tissues within the body (Tare et al. 2010). 
 
 
 
 
 
 18 
 
1.6  Stem cells in skeletal tissue engineering 
 
An  advantage  to  skeletal  tissue  engineering  is  the  ready  supply  of  suitable 
osteoprogenitors from the non-haematopoietic stromal compartment of post-natal bone 
marrow. Bone marrow can be relatively easily obtained with little morbidity, and the 
stromal fraction can be readily isolated and separated from haematopoietic precursors 
(Bianco et al. 2006). Its use avoids the potential ethical issues of embryonic stem cell 
harvest and enables potential therapies to use autologous cells, essentially negating 
the risk of rejection.  A small subset  of stem cells derived from non-haematopoietic 
bone marrow stroma was first described by Friedenstein as spindle-shaped stromal 
cells (Friedenstein 1968). These cells possess the capacity for self-renewal and the 
ability to differentiate along multiple mesodermal lineages to generate cartilage, bone, 
myelosupportive stroma, adipose and fibrous connective tissue (Fig. 1.5) (Friedenstein 
1976). 
 
 
Fig. 1.5  The  multi-differentiation  potential  of  stem  cells  derived  from  non-
haematopoietic bone marrow stroma. Adapted from Caplan 2009. 
 
These  cells  form  a  developmental  continuum  within  the  bone  marrow  stromal 
compartment, with indistinct boundaries between cell populations, gradually losing self-
renewal  capacity  and  gaining  lineage  commitment  with  each  cycle  towards 
differentiation  (Pittenger  et  al.  1999,  Oreffo  et  al.  2005).  Given  this  temporal 19 
 
heterogeneity and also because no single specific skeletal stem cell marker has been 
defined, homogenous osteoprogenitor populations have yet to be isolated (Tare et al. 
2010). Furthermore, the interconversion of skeletal cell precursors by dedifferentiation 
has  also  been  reported,  with  implications  in  defining  lineage  plasticity  (Park  et  al. 
1999).  This  is  particularly  attractive  as  it  may  enable  pluripotent  stem  cells  to  be 
induced from a patient’s own somatic cells without the controversial use of embryos. 
Furthermore, use of induced Pluripotent Stem Cells (iPSCs) may avoid immunological 
rejection responses (Taylor et al. 2011). Since their discovery, varying nomenclature 
has been attributed to these cells (Bianco and Robey 2001, Muschler and Midura 2002, 
Triffitt  2002,  Goshima  et  al.  1991,  Tare  et  al.  2008),  but  for  consistency  the  term 
Skeletal Stem Cell (SSC) will be used throughout this thesis (Table 1.4). 
 
Table 1.4  Nomenclature for the multipotent stem cell derived from non-haematopoietic 
bone marrow stroma 
Homonym  Abbreviation 
Skeletal Stem Cell  SSC 
Osteogenic Stem Cell  OSC 
Osteoprogenitor cell  OPC 
Marrow Stromal Fibroblastic Cell  MSFC 
Human Bone Marrow Stromal Cell  HBMSC 
Colony Forming Unit-Fibroblastic  CFU-F 
Mechanocyte  None 
Connective Tissue Progenitor  CTP 
Note that the precise definition and biologic capabilities indicated by these terms by various 
authors are not entirely synonymous 
 
Given the difficulty in defining the SSC and because all markers defined so far are non-
specific,  isolation  and  enrichment  have  been  a  challenge  (Tuan  et  al.  2003). 
Consequently,  many  isolation  and  identification  techniques  exist,  including  tissue 
culture  plastic  adherence,  induction  of  lineage-specific  phenotypes  under  standard 
culture conditions and sorting with respect to a panel of cell surface markers. When 
used together, these methods can select SSCs with high discrimination (Seong et al. 
2010) (Fig. 1.6). 
 
An important landmark in the isolation of SSCs was the identification and generation of 
the  STRO-1  antibody,  which  recognises  stage  –  and/or  lineage-specific  stromal 
antigens expressed by a sub population of bone marrow mononuclear cells (Simmons 20 
 
et al. 1991, Gronthos et al. 1994). Other cell surface markers have also been proposed 
for positive selection, including Cluster of Differentiation (CD) 105, CD73, CD90, CD71, 
CD63, CD 49a, CD44, CD166 (Activated Leukocyte Cell Adhesion Molecule: ALCAM), 
CD146 (Melanoma Cell Adhesion Molecule: MCAM), CD106 (Vascular Cell Adhesion 
Molecule-1: VCAM-1), CD54 (Intercellular Adhesion Molecule-1: ICAM-1) and CD29. 
Negative  markers  (CD45,  CD34,  CD14,  CD19  and  Human  Leukocyte  Antigen-DR 
(HLA-DR)) further distinguish SSCs from haematopoietic mononuclear cells (Kanczler 
et al. 2011). Research continues to identify a simple technique to reliably isolate and 
expand SSCs for tissue regeneration strategies (Sengers et al. 2010). 
 
 
Fig. 1.6  Culture-expanded human SSCs at confluence, stained with CellTracker
™ Green 
to confirm viability. Scale bar: 50 µm 
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1.7  Cellular and molecular approaches to skeletal regeneration 
 
1.7.1  Skeletal Stem Cells and bone repair 
 
The use of bone marrow alone as an effective osteogenic graft has been applied to 
augment  the  healing  capacity  in  Distraction  Osteogenesis  (DO)  and  also  for  the 
treatment of Avascular Necrosis (AVN) and fracture non-union (Hernigou et al. 2005a, 
Hernigou et al. 2005b, Hernigou et al. 2006, Hernigou et al. 2009, Kitoh et al. 2007a, 
Kitoh  et  al.  2007b).  DO  is  an  osteotomy-distraction  technique,  first  described  by 
Codivilla  in  1905  to  correct  and  lengthen  limb  deformities  (Codivilla  2008).  The 
procedure  has  since  been  refined  by  Ilizarov  and  others  to  maintain  gradual 
lengthening of soft tissues whilst correcting bone deformities (Aronson 1997), and is 
frequently  used  with  excellent  functional  outcomes.  The  traumatic  or  surgical 
osteotomy is stabilised by external fixators while distraction of approximately 1 mm per 
day generates ossification through the formation of microfractures (Shearer et al. 1992, 
Tsuchiya et al. 1997) (Fig. 1.7). 
 
 
Fig. 1.7  Distraction  Osteogenesis,  a)  in  this  case  for  treatment  of  a  low-grade  tibial 
osteosarcoma,  b) following  wide  local  excision  of  the  tumour  and  application  of  a  unilateral 
lengthening external fixator, note the proximal osteotomy. c) At the end of bone transport, note 
the final position of the fixator. d) Excellent bone formation 62 months following initial operation. 
Images from Tsuchiya et al.1997. 
 
Current  indications  for  DO  include  the  regeneration  of  bone  lost  through  surgical 
debridement, fracture non- and mal-union, congenital deformity, for limb lengthening in 
dwarfism and for some skeletal sequelae of poliomyelitis (Rozbruch et al. 2008, Schep 22 
 
et al. 2009). However, because this method relies entirely on the inherent regeneration 
potential of bone, large defects often require extended treatment periods, with further 
procedures to release soft-tissues as fixation pins are distracted. Intensive specialist 
support,  patient  education  and  co-operation  are  integral  to  the  success  of  this 
treatment. Unsurprisingly, complications occur frequently: pin tract infection is almost 
universal,  and  cellulitis,  osteomyelitis,  non-  and  mal-union  and  psychological 
consequences are common (Aronson 1997). In addition, failure to manage pain from 
distraction of surrounding soft tissues can affect patient compliance (Ghoneem et al. 
1996). 
 
The  considerable  complication  rates  in  DO  correlate  with  the  total  treatment  time 
(Aldegheri  1999),  so recent research  has  targeted  this  with  the  supplementation of 
SSCs and cellular  products  to reduce the total treatment time.  Bone marrow alone 
contains  SSCs,  platelets  and  mononuclear  cells  that  are  rich  in  cytokines.  It  also 
provides  a  degradable  biological  fibrin  matrix  (Fleming  et  al.  2000).  Successful 
treatment of 18 of 20 tibial non-unions was reported with internal fixation augmented by 
percutaneous local injection of autologous bone marrow (Connolly et al. 1991). Another 
study  of  24  femoral  and  tibial  osteotomies  treated  with  concentrated  autologous 
Platelet-Rich  Plasma  (PRP)  and  SSCs  found  the  healing  index  dropped  from  36.2 
days/cm  in  the  32  control  osteotomies  (i.e.  without  additional  cell  therapy),  to  27.1 
days/cm in the treatment group (Kitoh et al. 2007a). However, due to the study design, 
it  was  not  possible  to  deduce  if  this  effect  was  due  to  the  SSCs,  the  PRP  or  the 
combination. 
 
Concentrated autologous SSCs from human bone marrow have also been used in the 
treatment of femoral head avascular necrosis (Hernigou et al. 2009). In a series of 534 
hips in 342 patients, enduring bone architecture was demonstrated following treatment, 
particularly in the earlier stages of the disease. This technique was also applied to the 
management  of  tibial  non-union,  achieving  sound  bone  healing  in  53  of  60  cases 
following  treatment  with  concentrated  autologous  SSCs  (Hernigou  et  al.  2005a). 
Retrospective analysis of the seven cases that failed to unite confirmed that they were 
implanted with significantly lower initial SSC concentrations (less than 1000 SSCs/ml) 
than those cases that united soundly (between 2000 and 4000 SSCs/ml), suggesting a 
requirement for delivery of a critical concentration of SSCs to the defect site. The SSC 
concentration in untreated iliac crest aspirate is therefore often sub-therapeutic, and 
this emphasises the requirement for cell-enrichment approaches. 23 
 
In addition to bone reconstruction, the applications of SSCs have been extended to 
treat  osteochondral  defects  of  articular  cartilage.  These  focal  lesions  involve  full 
thickness loss of cartilage and present most commonly in adults as a consequence of 
trauma,  and  in  children  from  either  trauma  or  microvascular  pathology,  such  as 
osteochondritis dissecans (Green and Banks 1953, Widuchowski et al. 2008). Current 
therapeutic  options  include  microfracture  treatment,  which  involves  the  creation  of 
multiple  perforations  (microfractures)  in  the  subchondral  bone  in  areas  that are 
cartilage  deficient.  This  stimulates  a  healing  response  through  the  release  of 
endogenous factors. Unfortunately this response is mostly manifested as fibrocartilage, 
which  is  mechanically  inferior  to  hyaline  cartilage  that  is  native  to  synovial  joints 
(Salzmann et al. 2011). Despite improved function and reduced pain in the short and 
mid-term  following  microfracture  treatment,  substantial  scope  still  remains  for 
improvements  in  the  longer  term  (Marder  et  al.  2005).  A  recent  equine  study  has 
combined microfracture treatment with SSC implantation (Fortier et al. 2010). Twelve 
horses with iatrogenic full thickness cartilage defects  in the  lateral femoral trochlea 
were  treated,  either  with  microfracture  alone  or  microfracture  augmented  with  a 
concentrated fraction of Bone Marrow Aspirate (BMA). Subsequent analysis at eight 
months showed improved hyaline cartilage production in the group treated with the 
additional  aspirate  both  in  terms  of  amount,  integration  with  surrounding  native 
cartilage and quality (as judged by glycosaminoglycan and collagen type II content). 
Clinical trials have also shown some success, for example Haleem et al. used platelet-
rich fibrin glue as a scaffold to carry culture-expanded SSCs, which were implanted into 
5 patients with full-thickness cartilage lesions (Haleem et al. 2010). Beneficial results 
were observed in all patients, both in terms of symptomatic relief, and actual cartilage 
regeneration as measured by magnetic resonance imaging and arthroscopically after 
12 months. 
 
Despite these successes of SSC therapy in isolation in skeletal tissue defects, these 
strategies  do  not  ensure  the  necessary  cells  are  distributed  throughout  the  graft 
volume. Consequently, the healing response is not always contiguous and regenerated 
tissue  may fail  to  integrate  fully  with  adjacent  tissue. Thus,  true  tissue  engineering 
strategies for cartilage regeneration require the supportive functions of a scaffold to 
supply the ideal conductive and inductive stimulus for maximal tissue regeneration. 
 
Successful translation of tissue engineering strategies to heal ligamentous damage or 
tendon rupture  in humans remains a significant challenge  and no studies have  yet 
shown  benefit  in  human  trials.  Marrow-derived  SSCs  used  in  conjunction  with  a 24 
 
collagen  I  construct  have  enhanced  the  biochemical  and  mechanical  properties  of 
tendo-achilles repairs in rabbits, however this was not seen at a functional level (Young 
et al. 1998).  Neo-tendon formation has also been demonstrated in a rat tendo-achilles 
model  using  adenoviral  modification  of  SSC  differentiation  by  transfection  of  the 
biologically  active  Smad8  signalling  molecule  (Hoffmann  et  al.  2006).  Ligament 
regeneration  is  at  an  even  earlier  stage,  with  current  SSC  strategies  directed  at 
enhancing the fibrocartilage junction strength in anterior cruciate ligament repairs in 
rabbits  (Ekdahl  et  al.  2008).  It  appears  that  fibroblasts  are  highly  sensitive  to 
mechanical stimuli and tensile strength so stretch-loading is essential for the proper 
formation  and  alignment  of  ligament  and  tendon  structure  (Tuan  et  al.  2003). 
Replication of in vivo mechanical conditions to direct stem cell fate may therefore be a 
major hurdle for successful tissue engineering strategies. 
 
 
 
1.7.2  Growth factors 
 
Growth factors are a group of naturally-occurring cytokines that regulate a variety of 
cellular functions, such as growth, proliferation and differentiation (Yin et al. 2010). The 
pivotal  role  of  growth  factors  and  their  complex  interactions  with  cells,  in  the 
maintenance and healing of skeletal tissues, is widely recognised (Devescovi  et al. 
2008). It therefore follows that control of the temporal release of appropriate growth 
factors during tissue healing is a fundamental process in the development of successful 
tissue engineering strategies. Several growth factors within bone are expressed during 
the process of fracture healing, suggesting a role in osteochondral development and in 
fracture repair (Table 1.5).  
 
1.7.2.1 Transforming growth factor beta (TGF-β)  
TGF-β is a multifunctional polypeptide sequestered within the bone matrix with diverse 
actions:  It  has  been  shown  to  stimulate  cellular  proliferation,  hypertrophy  and 
osteogenic  differentiation,  and  it  up-regulates  the  production  of  collagen  from 
osteoblasts,  whilst  enhancing  mineralisation  (Salgado  et  al.  2004).  Despite  these 
effects in vitro, fracture repair models incorporating TGF-β have produced inconclusive 
results,  requiring  continuous  dosing  to  demonstrate  efficacy,  which  may  have 
unwanted effects on other non-skeletal tissues (Kanczler et al. 2011). Members of the 
TGF-β super-family (particularly TGF-β3), have been implicated in chondrogenesis and 
the repair of articular cartilage following damage (Tang et al. 2009).  25 
 
Table 1.5  Growth factors associated with fracture repair  
Growth 
factor 
Cellular source  Biologic effects  Actions on bone 
BMP-2 
SSC, osteoblast, 
chondrocyte, 
endothelial cell  
Chondro- and 
osteogenesis, 
Osteoinduction 
SSC migration, induction, 
differentiation, proliferation, 
matrix synthesis 
FGF 
Macrophage 
monocyte, SSC, 
chondrocyte, 
osteoblast, 
endothelial cell 
Angiogenesis, 
Proliferation of 
fibroblasts and 
vascular smooth 
muscle cells 
Chondrocyte maturation (FGF-1) 
Osteoblast proliferation, 
differentiation 
Inhibition of osteoblast apoptosis 
Induction of osteocyte apoptosis 
Bone resorption (FGF-2) 
IGF 
Osteoblast, 
chondrocyte, 
hepatocyte, 
Endothelial cell 
Growth regulation 
 
Osteoblast proliferation 
Bone matrix synthesis 
Bone resorption 
PDGF 
Platelet, monocyte, 
macrophage, 
osteoblast, 
endothelial cell 
Smooth muscle cell 
proliferation, 
chemotaxis, 
angiogenesis 
SSC migration, proliferation and 
differentiation 
TGF-β 
Platelet, SSC, 
osteoblast, 
chondrocyte, 
fibroblast, 
endothelial cell, 
macrophage 
Immunosuppression, 
Angiogenesis, 
stimulation of cell 
growth, ECM 
synthesis 
SSC proliferation and 
differentiation, but inhibits 
terminal chondrocyte 
differentiation, osteoclast 
recruitment, ECM production 
VEGF  Osteoblast, platelet  angiogenesis 
Osteoblast proliferation, 
vascularisation, cartilage 
mineralisation. 
BMP = Bone morphogenetic protein, SSC = Skeletal stem cell, FGF = Fibroblast Growth Factor, 
IGF  =  Insulin-like  Growth  Factor,  PDGF  =  Platelet  Derived  Growth  Factor,  TGF-β  = 
Transforming Growth Factor beta, ECM = Extracellular Matrix, VEGF = Vascular Endothelial 
Growth Factor. Adapted from Devescovi et al. 2008 and Southwood et al. 2004. 
 
 
1.7.2.2 Bone morphogenetic proteins (BMPs) 
With  the  exception  of  BMP-1,  BMPs  are  structurally  considered  part  of  the  TGF-β 
super-family, with BMP-2, 4, 6 and 7 the most osteoinductive. BMPs are critical to the 
recruitment,  commitment  and  differentiation  of  SSCs  and  they  are  responsible  for 
initiating  bone  cell  differentiation  from  SSCs,  enhancing  terminal  osteoblast 
differentiation,  and  producing  local  signalling  to  control  endochondral  ossification 
(Kanczler  et  al.  2011).  Given  these  osteoinductive  properties,  BMPs  are  already  in 
clinical use to enhance bone union, although widespread application has been limited 
by their high cost (Zimmermann et al. 2009, Cahill et al. 2009). 26 
 
1.7.2.3 Wnt signalling molecules 
The Wnt signalling pathway has also been shown to be pivotal in the differentiation of 
osteoblasts  and  actions  of  osteoclasts  during  development  and  remodelling. 
Furthermore,  the  mechanisms  of  action  of  this  family  of  glycoproteins  are  closely 
interrelated to BMP pathways (Pederson et al. 2008). Consistent with an important role 
for the Wnt protein family in humans, are the findings that activating mutations of the 
Wnt pathway (either primary or secondary, through the deletion of SOST (the gene 
encoding sclerostin), which inhibits the Wnt signalling pathway through LRP5 and 6 
receptor binding) can result in increased bone mass (Semenov et al. 2006). 
 
1.7.2.4 Local growth factors 
Local growth factors, such as IGFs, FGFs, PDGF and VEGF are also sequestered 
within bone matrix, and their actions may be harnessed by developing regenerative 
strategies: 
 
1.7.2.4.1  IGF-I  and  IGF-II  activities  are  regulated  by  IGF-binding  proteins,  and  act 
independently  to  stimulate  osteogenesis  and  chondrogenesis.  IGF-I  specifically 
stimulates intramembranous bone formation, and whilst IGF-II has been shown to be 
important  in  skeletal  development,  its  function  in  the  adult  skeleton  is  not  proven 
(Canalis 2009). IGF-I up-regulates type I collagen and down-regulates collagenase 3 
expression, resulting in maintenance of ECM, and it enhances Wnt signalling through 
β-catenin stabilisation, resulting in osteoblastogenesis (Playford et al. 2000). 
 
1.7.2.4.2 FGF-1 and FGF-2 are polypeptides which act locally with potent angiogenic, 
wound  healing  and  osteogenic  properties.  However,  direct  injection  of  FGF-2  into 
skeletal  defects  results  in  inconsistent  stimulation  of  bone  repair  (Zellin  and  Linde 
2000) This may be due to difficulties of growth factor delivery and release, rather than a 
lack  of  action  of  FGF  itself,  and  research  to  refine  carrier  systems  to  improve 
bioavailability is continuing, with mixed results (Manferdini et al. 2010). 
 
1.7.2.4.3 PDGF is a potent osteoblastic mitogen, enhancing proliferation, chemotaxis 
and collagen activity (Devescovi et al. 2008). Furthermore, PDGF receptors are highly 
expressed within newly-formed osteoid in fracture healing, and recombinant PDGF in 
combination with IGF-1 have shown enhanced periodontal bone formation in humans 
(Hollinger et al. 2008). 
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1.7.2.4.4 VEGF is a term applied to four homologous homodimeric glycoprotein family 
members that play an integral role in angiogenesis, osteogenesis and skeletal repair 
(Carano and Filvaroff 2003). VEGF is key in inducing endochondral development and 
its interaction with VEGF receptors regulates vascularisation, chondrocyte apoptosis, 
SSC recruitment and growth plate ossification (Gerber et al. 1999, Mayr-Wohlfart et al. 
2002,  Wang  et  al.  2007).  Furthermore,  the  activities  of  BMPs  and  VEGF  are 
intrinsically linked, aiding the coordination of vascularisation with skeletal development 
(Deckers et al. 2002). Several studies have incorporated active VEGF with SSCs into 
engineered constructs to enhance the regeneration of bone defects in rabbit radius and 
mouse  femoral  defect  models  (Geiger  et  al.  2005,  Kanzcler  et  al.  2008).  The 
osteogenic-angiogenic  interplay  between  VEGF  and  BMPs  has  also  more  recently 
been  exploited  in  such  models,  with  newer  generations  of  scaffold  that  have  been 
engineered to release these angiogenic and osteogenic growth factors in a temporally-
controlled manner (Patel et al. 2008, Kanzcler et al. 2010, Kempen et al. 2009). Other 
strategies to ensure the accurate delivery of growth factors to the site of regeneration 
include gene therapy with various viral and non-viral vectors, which maintain high local 
concentrations by continuous expression of the appropriate genes (Southwood et al. 
2004). 
 
 
 
1.7.3 Growth factors in tendon and ligament healing 
 
The role of growth factors in tendon and ligament healing is only now being elucidated: 
TGF-β1 enhances cell proliferation and migration, and stimulates their production of 
collagen and proteoglycans, and PDGF may accelerate tendon and ligament healing 
by increasing ECM synthesis (Yin et al. 2010). Growth Differentiation Factor (GDF, a 
member of the BMP family) stimulates tendon and ligament formation in vivo in rats, 
and  can  improve  healing  following  injury  (Hoffmann  et  al.  2006).  This  action  is 
orchestrated through the Smad8 signalling pathway, inducing fibroblastic proliferation 
and increasing their expression of collagen type I, scleraxis, and tenomodulin (Mendias 
et al. 2008). 
 
Development of strategies to generate a functional vasculature at an early stage of 
tissue  healing  will  facilitate  the  recruitment,  proliferation  and  differentiation  of  cells 
involved in the repair of these tissues as well as providing the essential growth factors, 
nutrients and gaseous exchange for regeneration and homeostasis. 28 
 
1.7.4  Platelet-rich plasma (PRP) 
 
The first uses of PRP in skeletal reconstructive therapy were in maxillofacial surgery for 
the treatment of mandibular and periodontal defects (Alsousou et al. 2009). Since then 
its  uses  have  been  widened  to  orthopaedic  approaches  to  enhance  fracture  union 
(Kitoh et al. 2007b)
 and spinal fusion (Hartmann et al. 2010, Initini 2009). The healing 
effects of PRP are mediated through the activation of the coagulation cascade, which 
releases growth factors from the α-granules of platelets (Cenni  et  al. 2010). These 
growth factors include VEGF, TGF-β, IGF, PDGF and Epidermal Growth Factor (EGF).  
 
The combination of PRP with SSCs has been used with considerable success in the 
maxillofacial  field:  Culture  expanded  autologous  SSCs  and  PRP  were  applied  to  a 
titanium mesh scaffold as a tissue engineered construct that demonstrated enduring 
and functional reconstruction of a congenital cleft lip and alveolus in a young girl (Hibi 
et al. 2006). The combination of autologous SSCs, PRP and Hydroxyapatite (HA) have 
also shown promise as grafting materials for maxillary sinus floor augmentation in 20 
patients (Ueda et al. 2005). However, clinical analyses of constructs containing PRP 
are generally confined to case studies or small series, and many strategies also involve 
concurrent SSC therapy, obscuring the potential effects of PRP. Controversy therefore 
remains over the additional therapeutic effects provided by the growth factors within 
PRP, many of which only have a brief duration of action. 29 
 
1.8  Scaffolds – osteoconduction and osteoinduction 
 
Emerging  strategies  strive  towards  the  ultimate  therapeutic  objective:  to  replace 
damaged  skeletal tissues  with  appropriate  autogenous  components that  have  been 
harvested  without  significant  morbidity  and  presented  within  a  suitable  matrix  for 
cellular  conduction  and  induction.  Although  biological  scaffolds  have  been  used 
clinically with success, their disadvantages can have serious implications. Research 
activity has therefore been centred upon approaches that couple material science with 
autogenous SSCs as true tissue engineering constructs. The ideal scaffold would be 
biocompatible  and  have  structural  integrity,  yet  be  bio-resorbable,  thus  acting  as  a 
temporary framework until new tissue is generated (Cancedda et al. 2007). Research 
behind scaffolds and cell-based tissue engineering has culminated in their application 
to a number of human cases (Table 1.6). 
 
Scaffolds for orthopaedic regeneration require particular functions and characteristics 
for success. In the case of load-bearing tissues, the scaffold must provide sufficient 
temporary  mechanical  support  to  withstand  in  vivo  loading  and  stresses,  ideally 
matching  the  mechanical  properties  of  the  host  tissue  (Hutmacher  et  al.  2000). 
Furthermore, the material must degrade at such a rate as to allow the strength of the 
scaffold to be maintained until the host tissue can assume its structural role (Rose and 
Oreffo  2002).  These  conditions  can  only  be  met  if  the  construct  stimulates  and 
modulates exogenous or existing cells to produce the appropriate tissue types. This in 
turn requires early and sufficient angiogenesis to allow metabolic processes to proceed 
and for regeneration to take place (Bouhadir and Mooney 2001, Rivron et al. 2008). 
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Table 1.6  Clinical translation of cell-based tissue engineering approaches to skeletal 
regeneration 
Tissue engineering strategy  Site/ Indication  Reference 
HA scaffold seeded with culture-expanded 
autologous periosteum-derived cells 
Right thumb distal 
phalanx sub-amputation 
Vacanti et al. 2001 
 
HA scaffold seeded with culture-expanded 
autologous marrow-derived cells 
Long bone segmental 
defects following trauma 
Quarto et al. 2001 
Marcacci et al. 2007 
Polymer fleece impregnated with culture-
expanded mandibular periosteal cells 
Maxillary sinus floor 
augmentation 
Schimming et al. 
2004 
Alumina-ceramic prosthesis seeded with 
culture-expanded autologous SSCs 
Ankle osteoarthritis  Ohgushi et al. 2005 
HA scaffold seeded with culture-expanded 
autologous SSCs 
Knee osteochondral 
defect 
Adachi et al. 2005 
HA scaffold seeded with autologous SSCs 
and PRP 
Reduced maxillary 
crestal height 
Ueda et al. 2005 
HA and titanium scaffold seeded with 
autologous bone marrow 
Mandibular defect 
following ablative 
tumour surgery 
Warnke et al. 2004 
Warnke et al. 2006 
Percutaneous injection of autologous 
concentrated BMA 
Tibial non-union 
Hernigou et al. 
2005a and b 
HA seeded with culture-expanded 
autologous SSCs 
Benign long bone 
tumours 
Morishita et al. 2006 
Titanium mesh plate seeded with culture-
expanded SSCs and PRP 
Alveolar cleft 
osteoplasty 
Hibi et al. 2006 
Percutaneous injection of autologous 
concentrated BMA 
Femoral head avascular 
necrosis 
Hernigou et al. 2009 
PRP 
Fracture non-union, 
spinal fusion 
Alsousou et al. 2009 
IBG of allograft seeded with autologous 
concentrated BMA 
Femoral head avascular 
necrosis 
Bolland et al. 2006 
Tilley et al. 2006 
DBM seeded with concentrated 
autologous SSCs 
Unicameral bone cysts, 
various locations 
Di Bella et al. 2010 
HA  =  Hydroxyapatite,  BMA  =  Bone  Marrow  Aspirate,  SSCs  =  Skeletal  stem  cells,  PRP  = 
Platelet  rich  plasma,  IBG  =  Impaction  bone  grafting,  DBM  =  Demineralised  bone  matrix. 
Adapted from Smith et al. 2011 
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1.8.1  Biological scaffolds 
 
1.8.1.1 Autogenous biological scaffolds 
 
1.8.1.1.1  Cancellous  autograft  –  Autologous  cancellous  bone  represents  the 
clinical gold standard for enhancing bone healing in spinal fusion, treating bone defects 
and for fracture repair (Marino and Ziran 2010, Burwell 1964, Burwell 1966, Kanakaris 
et  al.  2007).  Cancellous  autograft  bone  provides  an  osteoconductive  3D  matrix  of 
collagen,  mineral  and  matrix  proteins,  with  osteoinductive  proteins,  whilst  retaining 
native SSCs (Delloye et al. 2007). Cancellous autograft can be harvested from various 
sites and implanted during the same procedure, without provoking an immunogenic 
reaction. However, it is only considered osteogenic if implanted immediately (Delloye et 
al. 2007) and associated donor site morbidity and pain limit its use to smaller defects 
(Ahlmann et al. 2002). Indeed, the risk of donor site complications, such as cutaneous 
nerve  damage,  chronic  donor  site  pain,  vascular  injury,  infection  and  fracture,  is 
reported to be approximately 10% (Younger et al. 1989). 
 
1.8.1.1.2  Cortical autograft – Autologous cortical bone has superior mechanical 
strength to cancellous bone, however full incorporation into surrounding tissue can take 
considerably longer because it contains fewer SSCs and has a lower porosity, which 
inhibits  vascular  ingress  (Delloye  et  al.  2007).  Vascularised  cortical  bone  grafts 
(implanted with or without surrounding soft tissues) can transport an immediate blood 
supply to the wound, and these are used in limb salvage and reconstruction scenarios 
following  trauma,  ablative  tumour  surgery  or  debridement  of  infection  (Taylor  et  al. 
1975,  Warnke  et  al.  2004).  However,  significant  donor  site  morbidity  restricts 
harvesting to just a few options, such as fibula, scapula, iliac crest, and rib transplant. 
These bones function mainly as an attachment for muscles, and consequent functional 
reduction following full or partial excision can often be tolerated to improve function 
elsewhere  (Muramatsu  et  al.  2004).  In  one  study,  surgically-induced  long  bone 
segmental  defects following  tumour resection  were  treated  with  vascularised fibular 
grafts  in  30  patients,  resulting  in  primary  union  in  23  patients  within  a  mean  of  6 
months. However, over half of these had complications and 40% required re-operation 
for non-union, graft fracture or infection (Eward et al. 2010). Attempts have been made 
to improve the outcomes following this technique by placing the fibular autograft within 
the intramedullary canal of a cortical allograft shell (Innocenti et al. 2009). Although this 
provides initial structural support and promotes the biology and regeneration of host 
bone, the procedure is technically more challenging and high complication rates remain 32 
 
(Abed et al. 2009). Consequently, despite significant biological, economic and practical 
disadvantages to its use, allograft is generally used in isolation, for the treatment of 
expansive defects (Emms et al. 2009). 
 
 
1.8.1.1.3  Autogenous cartilage graft – Articular cartilage defects that are too 
large for microfracture treatment can be treated using mosaicplasty: Several circular (4-
8 mm) autogenous grafts are harvested from non weight-bearing articular regions and 
then transplanted in a mosaic conformation to fill the osteochondral defect. This has 
yielded good results, but with the drawback of donor site morbidity (Gudas et al. 2006). 
Cartilage transplantation  involves  a  smaller  biopsy  of  a  non  weight-bearing  area of 
cartilage,  so  is  less  invasive  than  mosaicplasty  and  causes  less  morbidity  at  the 
harvest site. Chondrocytes are isolated and cultured ex vivo prior to re-implantation 
during a subsequent operation, either directly into subchondral bone or onto a matrix, 
which is implanted into the bone (Matrix induced Autologous Chondrocyte Implantation 
(MACI)). These procedures are currently expensive, they require two operations to the 
injured joint, and the results are limited in comparison to those of mosaicplasty, both in 
terms of symptomatic relief and quality of cartilage regeneration (Horas et al. 2003). 
 
1.8.1.1.4  Autogenous tendon/ligament – Tendons and ligaments have a poor 
intrinsic  repair  capability  and  injury  of  these  tissues  often  requires  therapeutic 
intervention. Fortunately autogenous tendon may be harvested with little morbidity from 
several donor sites with ‘expendable’ muscle-tendon units and can be used to repair or 
replace tendon and ligamentous structures (Yin et al. 2010). However, some reports of 
donor site morbidity do exist (Getgood and Bollen 2010) and the transplanted tissue 
may have poorer tensile strength than its native substitute, particularly if a tendon is 
used to replace ligamentous tissue (as in anterior cruciate ligament reconstruction of 
the knee using hamstring tendon) (Menetrey et al. 2008). Despite this, the orthopaedic 
literature contains abundant examples of tendon transfers and ligament reconstruction 
using  autogenous  material  in  a  wide  variety  of  conditions,  with  generally  good 
outcomes (Sammer and Chung 2009). 
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1.8.1.2 Allogeneic biological scaffolds 
 
1.8.1.2.1 Allogeneic bone (allograft) 
Allograft is obtained from cadaveric donation or from live donors. Most frequently, the 
femoral head is salvaged in patients undergoing total hip replacement surgery and the 
donated  bone  is  processed  and  stored  in  regional  bone  banks  for  future  use.  The 
porous,  collagen-rich  matrix  of  allograft  bone  contains  multiple  sites  for  SSC  and 
endothelial  cell  attachment  and  multiple  embedded  growth  factors  which  can  be 
liberated  by  osteoclastic  resorption  (Fleming  et  al.  2000).  These  growth  factors, 
including  IGF,  TGF-β,  PDGF,  FGFs  and  BMPs  give  allograft  its  osteoinductive 
properties, inducing cells from surrounding soft tissue to produce new bone at the host-
graft interface, which then progresses into the graft material (Delloye et al. 2007). This 
process requires a contiguous vascular supply and sufficient mechanical stability to 
permit angiogenesis and eventual bone remodelling (Hernigou et al. 2005b, Stevenson 
et al. 1996) – conditions that are often absent, particularly in traumatic defects, where 
there is frequently surrounding soft tissue disruption and instability. However, where 
the conditions are appropriate for bone healing, the allograft matrix is fully resorbable 
through normal metabolic pathways with no reactive by-products or debris (Fleming et 
al. 2000). 
 
1.8.1.2.1.1  Allograft processing – The technique of graft milling and impaction has 
been used clinically in revision hip arthroplasty surgery for over 30 years. The impacted 
allograft provides a mechanically solid foundation and acts as a ‘void filler’ to support 
the prosthesis in the context of poor bone stock (Slooff et al. 1984). Relatively small 
acetabular and femoral defects have been treated with favourable outcomes at 10 and 
20 years (99% (Halliday et al. 2003) and 87% (Schreurs et al. 2009) respectively). 
However, such surgery can be technically demanding and operator-dependent. Thus, 
poorer results are often reported outside specialist centres or in the treatment of larger 
defects, such as those encountered during revision total hip arthroplasty (Eldridge et al. 
1997, van Haaren et al. 2007). Alternatively, structural allograft can be used to restore 
bone stock in the presence of large uncontained defects. However, structural allograft 
shows little remodelling or incorporation into the host bone, particularly at the host-graft 
interface. Furthermore, its bone mineral density decreases following implantation, and 
progressive microfracture accumulation results in a 50% reduction in strength at 10 
years (McNamara IR 2010). 
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1.8.1.2.1.2  Enhancement  of  allograft  properties  –  There  has  been  significant 
interest in the addition of SSCs to Impaction Bone Grafting (IBG) constructs to restore 
the osteoinductive properties lost during processing and storage of allograft (Fig. 1.8). 
Recent studies have demonstrated SSC survival following the impaction process and 
confirm enhancement in the shear strength of the graft following culture with SSCs 
(Bolland et al. 2006, Smith et al. 2011). 
 
 
Fig. 1.8  In vitro culture of human SSCs seeded onto allograft, stained with CellTracker
™ 
Green  after  7  days  culture.  Adherence  of  allograft  fragments  by  cellular  interaction  is 
demonstrated. Scale bar: 200 µm 
 
Regenerative  efficacy  has  been  demonstrated  following  clinical  translation  for  the 
treatment of bone defects in two patients (due to a benign non-ossifying fibroma and 
AVN, both in the proximal femur) (Tilley et al. 2006). Despite recurrence of the cyst in 
the first case, this provided an opportunity for ex vivo analysis of the retrieved tissue-
engineered bone, and confirmed remodelling of trabecular bone in the treated region 
(Aarvold  et  al.  2011).  Increasing  the  concentration  of  SSCs  applied  may  improve 
results in future cases, as further in vitro studies indicate a correlation between cell 
seeding  density  and  the  shear  strength  of  the  construct,  reaching  a  significant 
difference at 2x10
5 cells/ml, with a 16% increase in shear strength over allograft alone 
(Jones et al. 2009). The IBG technique to treat patients with early femoral head AVN 
(Ficat stage 1 and 2) has given encouraging clinical  results at three year follow-up 35 
 
(Jones et al. 2010). The procedure involves initial removal of necrotic bone by drilling 
and curettage from the avascular region, followed by impaction of allograft seeded with 
concentrated autologous SSCs (Fig. 1.9). The approach aims to augment mechanical 
support  to  the  overlying  cartilage  and  also  improves  angiogenesis  and  new  bone 
formation through enhanced biology. 
 
 
Fig. 1.9 Impaction bone grafting technique to treat early femoral head avascular necrosis. 
A. Pre-operative MRI in a patient with bilateral femoral head avascular necrosis (AVN) in the 
subchondral bone (arrows). B. Allograft from a donor femoral head is milled. C. The addition of 
concentrated  BMA  containing  SSCs.  D.  Donor  allograft  in  combination  with  concentrated 
aspirate.  E.  Intra-operative  radiograph  of  a  12  mm diameter  impactor  in  the  drilled  channel 
within the left femoral head. The SSC-seeded allograft is impacted into the necrotic segment of 
subchondral bone (radio-dense zone). F. Post-operative pelvic AP radiograph demonstrating 
maintenance  of  the  architecture  of  left  femoral  head.  The  right  total  hip  replacement  was 
performed following collapse of the femoral head as a result of progressive AVN. 
 
Despite these positive findings, several caveats to the use of allograft remain: given the 
concerns  of  potential  pathogen  transmission  by  allograft,  regional  ‘bone  banks’  are 
required to screen and store freeze-dried, fresh-frozen or irradiated allograft for future 
use  and  provide  quality  assurance  (Mallick  et  al.  2011).  These facilities  are  strictly 
regulated in the UK under the Human Tissue Act 2004 and in the US by the American 
Association of Tissue Banks, with robust legislation to ensure traceability of allograft. 
This  system  has  the  advantage  of  providing  a  ready  supply  of  screened  and 
quarantined bone; however the mechanical, biological and immunological properties of 36 
 
allograft may be affected differently by varying processing and storage arrangements at 
each facility (Schreurs et al. 2004). This can result in undesirable variation in clinical 
performance over and above the donor-to-donor variation in graft quality (Garbuz et al. 
1998). Although it can act as an osteoconductive scaffold, the requirement to process 
allograft for safe storage and to reduce its immunogenic reactivity, removes much of its 
inherent  osteoinductive  properties.  Nevertheless,  despite  stringent  processing  and 
donor  screening  there  remains  the  possibility  of  carriage  of  bacteria,  viruses  and 
prions,  some  of  which  may  not  yet  have  been  discovered.  Indeed,  many  allograft 
recipients  develop  antibodies  to  donor  antigens  despite  screening  and  processing, 
indicating the stimulation of an immune response (Mankin et al. 1987). Studies have 
reported bacterial infection rates of 0-12%, the incidence varying with donor selection 
criteria, processing technique and quarantine protocol  (Costain  and Crawford  2009, 
Sutherland  et  al.  1997,  Lord  et  al.  1988,  Kappe  et  al.  2010).  The  risk  of  Human 
Immunodeficiency Virus (HIV) transmission from screened donors has been estimated 
at just 1 in 1.6 million procedures (Tomford 1995), with no new reported cases since 
1985 (Costain and Crawford 2009, Simonds et al. 1992), although the risk of Hepatitis 
C Virus (HCV) transmission is probably much greater: four cases of HCV infection were 
attributed  to  transplanted  skeletal  tissue  harvested  from  a  single  antibody-negative 
donor in 2000 (Cieslak et al. 2003). 
 
To minimise the risks of infection transmission, the Medicines and Healthcare products 
Regulatory  Agency  (MHRA)  in  the  UK,  and  the  US  Food  and  Drug  Administration 
(FDA)  implemented  new  directives  and  legislations  in  2004  and  2005  respectively 
(Mallick et al. 2011). Such legislations ensure traceability of allograft and provide a 
framework  to  coordinate  recalls  of  potentially  infected  allograft  (Mroz  et  al.  2009). 
However,  these  regulations  complicate  the  logistics  of  acquisition,  transport  and 
storage of allograft, increasing its cost and reducing availability, and as requirements 
increase, supply will soon be outstripped by demand (Delloye et al. 2007). 
 
 
1.8.1.2.1.3  Demineralised  Bone  Matrix  (DBM)  –  DBM  is  cortical  cadaveric 
allograft that has been decalcified and additionally treated to reduce immunological and 
potential  pathogen  transmission.  Strict  donor  selection  and  testing  procedures  are 
observed  (as  above),  before  aseptic  recovery  of  allograft.  Processing  involves  the 
following  steps:  exposure  to  low-dose  gamma  irradiation;  high-pressure  lavage  in 
antibacterial  solution;  mechanical  dissection,  crushing  or  pulverisation;  ultrasonic 
decontamination in alcohol; demineralisation in hydrochloric acid, and copious washing 37 
 
in purified water (Dinopoulos and Giannoudis 2006). The final product is supplied either 
pure or incorporated with a carrier (such as lecithin, calcium sulphate, hyaluronic acid, 
collagen or glycerol) to facilitate handling and graft containment as a gel, malleable 
putty, mouldable paste, injectable paste or in flexible strips (Giannoudis et al. 2005). 
The process of demineralisation removes many biologically active factors and results in 
a  trabecular  collagenous  scaffold  with  little  structural  strength.  However,  some 
osteoinductivity is imparted by internal growth factors (including BMPs, osteocalcin and 
osteopontin)  which  are  rendered  more  bio-available  by  the  removal  of  the  mineral 
phase.  Thus,  DBM  can  be  more  osteoinductive  than  standard  mineralised  allograft 
(Fleming et al. 2000). 
 
DBM is widely used for filling bone defects and cavities in orthopaedic, neurosurgical 
and  dental  practice.  It  is  used  either  alone  or  in  combination  with  other  materials 
(particularly autologous bone marrow) as a ‘bone graft extender’, however studies of 
efficacy  show  mixed  clinical  results  and  there  are  few  prospective,  randomised 
controlled trials (Dinopoulos and Giannoudis 2006). The paucity of robust large-scale 
studies  reflects  the  wide  range  of  clinical  applications  for  which  DBM  is  used. 
Moreover, its efficacy is determined not only by clinical factors, but may vary between 
manufacturers depending on the specific preparation and carrier material. Furthermore, 
although no report of disease transmission through DBM exists, the theoretical risk of 
infection or  contamination  from  allogeneic material  remains.  Despite these  caveats, 
DBM remains a useful product for the treatment of specific bone defects. 
 
The combination of DBM with concentrated  BMA has been used to stimulate bone 
healing in the treatment of paediatric unicameral bone cysts. (Di Bella  et  al.  2010) 
When  compared  to  the  standard  treatment  of  multiple  steroid  injections  (n  =  143), 
healing improved after a single intralesional injection of BMA and DBM (n = 41) from 
38% to 71%. The results of this series confirm the utility of DBM composites in the 
clinical scenario. 
 
1.8.1.2.2  Cartilage and composite allogeneic grafts 
As an alternative to autogenous cartilage transplantation, allogeneic articular cartilage 
may be obtained from a cadaveric donor, most commonly as an osteochondral allograft 
(Gortz and Bugbee 2006). The intact cartilage with underlying subchondral bone can 
be implanted en bloc into a defect with the advantage of immediate viable cartilage 
restoration and no donor site morbidity to the recipient (Getgood and Bollen 2010). 38 
 
Given cartilage is avascular and thus relatively immunoprivileged, transmission of viral 
disease  has  not  been  reported  following  cartilage  transplantation  alone  (Tomford 
1995),  however  the  risks  of  bacterial  infection  and  transmission  from  the  osseous 
portion of grafts remain, particularly as the use of screened fresh osteochondral grafts 
is routine to avoid chondrocyte damage by storage and processing techniques (Gortz 
and Bugbee 2006). Immunological incompatibility is also an issue, and bone must be 
thoroughly washed with pulsatile lavage before implantation to reduce its antigenic load 
(Getgood  and  Bollen  2010).  Despite  these  shortcomings,  several  large  trials  have 
reported successful medium-term outcomes of osteochondral allograft transplantation 
in  72  to  88%  of  patients  with  corresponding  radiological  incorporation  (Gortz  and 
Bugbee  2006,  Bedi  et  al.  2010).  This  technique  is  expensive  however,  and  the 
procedure requires significant skill and logistical support. Furthermore, the procedure is 
dependent upon a reliable supply of screened cadaveric material with the inherent risks 
of disease transmission therein. 
 
Commercial  allograft  composites  (such  as  Osteocel
®  and  Trinity™)  containing 
allogeneic  skeletal  stem  cells  (SSCs)  have  recently  become  available  (Rush  2010, 
Rush et al. 2009, McAllister et al. 2009). These composites employ a combination of 
immuno-depleted cellular cortical allograft with particulate demineralised bone matrix, 
which  have  been  cryopreserved  to  retain  cell  viability  and  multipotency,  thus 
demonstrating osteoinduction, osteoconduction and osteogenesis. Encouraging case 
series  confirm  therapeutic  utility  of  these  products  in  maxillofacial  reconstruction 
(McAllister et al. 2009) and revision foot and ankle surgery (Rush 2010, Rush et al. 
2009) as an alternative to autogenous bone, although the caveats of using allogeneic 
material remain. 
 
1.8.1.2.3  Allogeneic tendon and ligament 
The use of cadaveric tendon allograft has increased markedly over the last 20 years 
(McDermott  et  al.  2006).  It  is  mainly  used  for  the  treatment  of  knee  and  shoulder 
pathology,  particularly  in  cases  requiring  multiple  ligamentous  reconstruction  or  in 
revision surgery, where the most appropriate autogenous candidate has already been 
harvested (Getgood and Bollen 2010). Allograft has the advantage of eliminating donor 
site morbidity, whilst allowing shorter operation times and smaller scars. Furthermore, 
some  studies  have  demonstrated  superior  implant  strength  and  better  clinical 
outcomes  compared  to  tendon  autograft  (Krych  et  al.  2008).  However,  the  risks  of 39 
 
immunogenic reaction, disease transmission, delayed graft incorporation, high cost and 
restricted availability, limit its use for routine cases (Getgood and Bollen 2010). 
Cadaveric human skin can also be processed into acellular dermal matrix, which is 
commercially available for tendon and ligament repair as Graftjacket
® (Wright Medical 
Technology  Ltd)  (Longo  et  al.  2010).  Following  processing  and  freeze-drying,  the 
acellular graft is mainly composed of Collagen I, III, IV and VII, elastin, chondroitin 
sulphate,  proteoglycans  and  fibroblast  growth  factor,  and  because  the  basement 
membrane  and  vascular  channels  remain  intact,  rapid  revascularisation  and  graft 
incorporation  are  claimed  (Derwin  et  al.  2006).  This  product  is  licensed  for  tendon 
repairs,  ligament  reconstructions,  capsular  reinforcement  and  periosteal  covering 
(Coons  and  Alan  2006).  A  study  using Graftjacket
®  to  repair  chronic  tendo-achilles 
ruptures  in  nine  patients  confirmed  no  re-ruptures  or  chronic  pain  in  any  patient 
followed up beyond two years (Lee MS 2004). 
 
 
1.8.1.3 Xenogeneic scaffolds 
 
Xenogeneic  scaffolds  have  found  widespread  orthopaedic  acceptance  in  soft-tissue 
reconstructive strategies, but are rarely used for skeletal reconstruction per se.  The 
most  frequent  sources  are  porcine  (e.g.  Cuffpatch
®  (Arthrotek,  IN  USA),  Restore™ 
(DePuy, IN USA), bovine (e.g. Bio-Blanket
® (Kensey Nash, PA, USA)) or equine (e.g. 
OrthADAPT
®  (Pegasus  Biologic  Inc,  CA,  USA))  (Longo  et  al.  2010).  Tissue  is 
harvested from sites such as small intestinal submucosa, pericardium, renal capsule or 
dermis. The ECM is processed, denuded and combined with chemically cross-linked 
collagen. Initially limited to rotator cuff repair, these products have now been shown to 
be effective for the reconstruction of many different tendons and ligaments, including 
tendo-achilles,  biceps  and  triceps  tendons  and  the  posterior  hip  capsule.  Retrieval 
analyses  confirm  well-integrated  tissues  with  organised  bundles  of  tissue  and 
resolution  of  fibrous  scar  tissue;  however  the  significant  disadvantages  of  using 
xenogeneic tissues will still exist until a solution has been found for problems such as 
immunological reactions and disease transmission (Badylak 2004). 
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1.8.2  Synthetic scaffolds 
 
As a consequence of the disadvantages of using autograft and allograft bone, there 
has been a significant drive for the development of bio-resorbable synthetic scaffold 
materials which aim to mimic the beneficial characteristics of biological material whilst 
avoiding their drawbacks. Hydrogels and collagen are particularly favoured as scaffold 
materials because they occur naturally, although other promising candidates include 
polylactic acid, a synthetic polymer, and the minerals hydroxyapatite (HA) and beta-
tricalcium phosphate (TCP) (Hutmacher et al. 2007). These scaffolds can be fabricated 
to  possess  desirable  osteoconductive  properties  and  the  constituent  materials  are 
readily available subject to manufacturing processes. Work is ongoing to improve their 
structural and osteoinductive properties and to ensure their degradation within the body 
is  safe,  predictable  and  complete.  The  distinction  between  biological  and  synthetic 
materials is rather arbitrary in this context as the majority of the following scaffolds are 
initially  derived  from  natural  biological  sources,  albeit  with  significant  chemical 
manipulation during manufacture and processing. Materials that are natural in origin 
have the distinct advantage of reduced toxicity and inflammatory reactions and they are 
more rapidly degraded by enzymes, however they may suffer from natural structural 
variability (Hutmacher et al. 2007). 
 
 
1.8.2.1 Hydrogels 
 
Hydrogels, such as gelatin, agar, collagen, hyaluronan or fibrin, form 3D networks of 
hydrophilic polymers that absorb large quantities of water and biological fluids. Their 
high water-content, elasticity, biocompatibility and ability to permit diffusion of nutrients 
and  bioactive  molecules  make  them  well-suited  to  cartilage  tissue  engineering 
strategies, but their strength and structural characteristics render them unsuitable for 
structural roles (Kessler and Grande 2008). Fibrin glue has been used to encapsulate 
chondrocytes in articular cartilage restoration techniques, but the resulting gel is weak 
with  little  spatial  control  over  matrix  formation  (Elisseeff  et  al.  2005).  Alginate  and 
agarose gels have also been used in craniofacial cartilage regeneration applications, 
but  the  problems  of  cell  encapsulation  and  regulation  of  final  scaffold  shape  after 
polymerisation remain (Rowley et al. 1999, Elisseeff et al. 2005). 
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The properties of clay gels such as laponite have recently been harnessed for their 
ability to deliver cells, angiogenic and osteogenic factors for a regenerative medicine 
strategy (Dawson et al. 2011) (Fig. 1.10). 
 
Collagen, the main component of the ECM functions poorly as a graft material by itself 
(Drury and Mooney 2003). However, it has shown efficacy as a delivery system for 
ceramic granules, BMPs and SSCs in animal models and a composite of collagen gel 
with granules of HA and TCP has been marketed for  bone regeneration strategies 
(Collagraft
®) (Fleming et al. 2000). 
 
 
Fig. 1.10  Laponite forms a thixotropic hydrogel when added to water, allowing it to be 
dispensed onto allograft bone through a hypodermic needle before re-establishment of a gel 
network. Scale bar: 250 µm. Image courtesy of Dr JI Dawson. 
 
The application of these hydrogels with autologous cells, growth factors and even pre-
vascularised composite systems is likely to be a productive avenue for the treatment of 
certain  musculoskeletal  conditions  (Rath  et  al.  2012);  however  the  absence  of 
structural  integrity  of  hydrogels  in  themselves  restricts them to  limited load  bearing 
applications. 
 
 
1.8.2.2 Ceramics 
 
Calcium  phosphate  ceramics,  such  as  hydroxyapatite  (HA)  and  tricalcium 
phosphate (TCP) have been used extensively in clinical orthopaedic practice. Several 
formulations  with varying viscosities  are available  for different applications,  allowing 42 
 
either rapid or slow absorption, or use as an injectable cement (Fleming et al. 2000). In 
addition, HA can be used as a coating on metal implants to reduce the rate of aseptic 
loosening in applications such as hip arthroplasty and reconstructions following tumour 
resection (Trikha et al. 2005, Spiegelberg et al. 2009). 
 
Porous TCP has been in clinical use for several years, however because the porosity 
of bulk TCP is only around 35% and pore interconnections are incomplete, only modest 
bone in-growth is permitted before re-absorption of the TCP matrix. Therefore TCP is 
normally supplied as granules to increase the bioavailable surface, but at the cost of 
short-term strength. 
 
Natural coral (calcium carbonate (CaCO3)) exists in a variety of porous conformations 
with highly reproducible pore sizes and interconnecting fenestrations depending upon 
the genus, with structures similar to human cortical or cancellous bone (Chiroff et al. 
1975).  Despite  its  favourable  microstructural  composition,  which  facilitates  the  in-
growth of host fibrovascular tissue and bone, its high dissolution rate, poor longevity 
and stability renders it unsuitable for weight-bearing implants (Hutmacher et al. 2007). 
However,  a  simple  hydrothermal  exchange  process  converts  delicate  coral  into 
mechanically  superior  HA  [Ca10(PO4)6(OH)2]  without  altering  its  structure.  These 
scaffolds are biocompatible and readily invaded by fibrovascular tissue, which is later 
converted  to  mature  lamellar  bone  nearly  identical  to  autogenous  bone,  which 
undergoes active remodelling and resorption (Chapman et al. 1997). However, host 
bone in-growth relies on rigid stability and rapid opposition, which is inhibited by the 
lack of completely interconnected pores and slow resorption. Furthermore, its inherent 
brittleness  and  susceptibility  to  fracture  in  compressive  loading  prevent  the  use  of 
scaffolds with more open porosity, and limit its translation to clinical application. 
 
Despite these drawbacks, the application of tissue engineering strategies to ceramic 
scaffolds  has  been  successful.  Following  ovine  trials,  (Kon  et  al.  2000)  autologous 
SSCs from three patients were culture-expanded ex vivo and seeded onto HA scaffolds 
to treat extensive segmental long bone defects (between 4 and 7 cm). Radiological 
osseointegration  and  surrounding  callus  was  observed  after  just  two  months,  with 
subsequent functional recovery (Quarto et al. 2001) and ongoing clinical success at 6-7 
year follow-up (Marcacci et al. 2007). The radiographic signs of bone healing presented 
in  this  study  should  be  interpreted  with  caution  however:  the  layer  of  new  bone 
surrounding each of the scaffolds remains limited, even at several years’ follow-up and 
additional evidence of bone formation and integration within the pores of the scaffold 43 
 
would be required for clinical confidence. The presence of such ossification within the 
implant  is  difficult  to  assess,  even  from  the  Computed  Tomography  (CT)  sections 
presented, not least because the implanted porous HA scaffold is radio-opaque and 
non-absorbable,  and  no  immediate  post-operative  comparative  CT  scans  are 
presented.  Nevertheless,  despite  these  limitations,  these  were  clearly  challenging 
cases, and it is important to note the patients reached good clinical outcomes with no 
subsequent fractures reported to date. 
 
A porous HA scaffold, inoculated with autologous culture-expanded cells derived from 
periosteum,  has  also  been  used  to  re-create  a  human  distal  phalanx  following 
traumatic amputation (Vacanti et al. 2001). Although the resultant construct was limited 
in function with significant dorsal subluxation and no active range of movement at the 
interphalangeal joint, the resultant thumb was sufficiently functional for the patient to 
return to work within three months and the case may be regarded as ‘proof of concept’ 
to create new bone using in essence, tissue engineering principles. 
 
Ceramics have also been used as part of a tissue engineering strategy in the treatment 
of benign bone tumours: an aneurysmal bone cyst of the proximal tibia, a giant cell 
tumour of the proximal tibia and fibrous dysplasia of the proximal femur were treated by 
implanting autologous culture-expanded SSCs seeded onto a HA scaffolds (Morishita 
et al. 2006). Early mechanical strength was achieved and all three patients were able 
to bear weight within 3 weeks with no adverse clinical or radiological sequelae. The 
same  group  successfully  applied  a  tissue  engineering  approach  to  prevent  aseptic 
loosening following ankle arthroplasty in three patients with osteoarthritis (Ohgushi et 
al. 2005). The authors culture-expanded autologous SSCs, then applied these to the 
bone-ceramic interfaces of the prostheses, culturing ex vivo for a further two weeks 
before  implanting the  constructs. The  authors emphasise  several  drawbacks  of  the 
study, including lack of a control group, a small cohort with short patient follow-up and 
the need for an additional procedure to harvest the bone marrow. Nevertheless, this 
highlights an exciting new technique to enhance the integration at the prosthesis-bone 
interface. 
 
In  a  recent  preliminary  study,  22  patients  were  treated  for  femoral  head  AVN  with 
porous calcium-HA implants seeded with autologous concentrated bone marrow SSCs. 
Radiological and clinical improvements were apparent in the majority of patients in the 
treatment group, with only three patients showing disease progression at two years 
follow up, compared to severe femoral head collapse in six of the eight control patients 44 
 
(calcium-HA  implant  alone)  (Yamasaki  et  al.  2010).  The  authors  point  out  several 
weaknesses of their study, including the lack of a true negative control group, however 
this pilot study provides encouraging results for future trials. 
 
 
1.8.2.3 Bioactive glasses 
 
Commercial bioactive glasses (e.g. Bioglass
®) with selected compositions of silicate 
and phosphate have been in clinical use for over 20 years (Yang et al. 2006). These 
glasses  react  with  physiological  fluids  and  form  strong  bonds  with  tissues  through 
cellular activity, and biodegrade safely within a physiological environment. Most recent 
research activity surrounding bioactive glasses has been in combining them with other 
synthetic scaffold types to  enhance their mechanical competence, impart bioactivity 
and modulate degradation (Hutmacher et al. 2007). 
 
 
1.8.2.4 Osteoconductive metals 
 
Metal implants have long been used in orthopaedic surgery for the reconstruction of 
bone  defects  or  as  a  supportive  mesh  for  reconstructive  strategies,  although  the 
structural  modification  of  the  bulk  material  itself  to  enhance  osseointegration  and 
stimulate bone regeneration in its own right has only relatively recently been realised 
(Navarro  et  al.  2008).  The  main  advantage  of  metal  implants  is  their  excellent 
mechanical properties, although the low rate  of degradation results in the need for 
either permanent implantation with the associated risks of metal toxicity, or a further 
surgical procedure for implant removal (Karageorgiou and Kaplan 2005). 
 
The  osteoconductive  properties  of  Tantalum  Trabecular  Metal  (TTM)  are  already 
exploited in several orthopaedic applications, such as hip and knee arthroplasty, spinal 
fusion,  for  the  treatment  of  AVN  and  for  reconstruction  following  skeletal  tumour 
excision (Findlay et al. 2004). In a recent series to evaluate trabecular tantalum for the 
management  of  severe  acetabular  bone  defects  in  revision  hip  arthroplasty, 
mechanical integrity was maintained in all 23 patients at 35 months follow-up (Flecher 
et  al.  2008).  The  treatment  of  femoral  head  AVN  using  TTM  rods  represents  a 
pragmatic alternative to vascularised fibular grafting, and has potential advantages of 
immediate  construct  stability,  expediting  safe  weight-bearing  and  return  to  function. 
The procedure can be performed using a minimally-invasive technique and without the 45 
 
disadvantage  of  donor  site  morbidity,  however  in  cases  where  subchondral  bone 
collapse does occur, the implant can become prominent, causing pain and acetabular 
degeneration.  In  addition,  on  eventual  removal  of  the  metal  implant  to  allow  joint 
reconstruction, the result is a sizeable defect that ultimately requires further grafting. 
 
The combination of TTM with human SSCs has also previously been reported in vitro 
(Findlay et al. 2004, Matsuno et al. 2001, Sagomonyants et al. 2011, Stiehler et al. 
2007,  Welldon  et  al.  2008,  Smith  et  al.  2012).  These  studies  show  excellent 
osteoconductive properties of TTM and pave the way for new clinical approaches that 
extend its current applications. 
 
Titanium  has  also  been  recognised  as  a  bioactive  metal,  with  bone  induction  first 
reported in 2004 after manufacture of macroporous titanium using a plasma spraying 
technique (Fujibayashi et al. 2004). More recently, an open-porous titanium foam has 
been  fabricated  that  supports  and  encourages  the  growth  of  SSCs  throughout  the 
scaffold in vitro (Muller et al. 2006). Electron Beam Melting technology has also been 
applied to titanium to create a trabecular conformation with various different pore sizes 
to  enhance  cellular  infiltration  (Marin  et  al.  2010).  In  comparative  studies,  adipose-
tissue  derived  stem  cells  grown  on  trabecular  titanium  in  osteogenic  conditions 
produced significantly more calcified ECM than comparable polymer scaffolds (Asti et 
al. 2010, Gastaldi et al. 2010). 
 
Osteoconductive metals possess some important disadvantages that limit their use in 
skeletal tissue engineering: metals in isolation lack osteoinductive capacity and as such 
may  not  be  appropriate  for  use  in  large  unsupported  defects.  In  a  goat  femoral 
diaphyseal defect model for example, the use of trabecular tantalum cylinders required 
the preservation of native periosteum in order to achieve bony union (Bullens et al. 
2009).  This  indicates  potential  limitations  in  the  application  of  tantalum  to 
reconstruction following trauma, infection or tumour excision, because periosteum is 
often  deficient  in  such  scenarios.  Furthermore,  metals  are  not  biodegradable  and 
removal  can  cause  considerable  collateral  damage  to  surrounding  bone  should 
subsequent revision be required. 
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1.8.2.5 Synthetic polymers 
 
Chemically synthesised polymers are versatile and enable the fabrication of scaffolds 
with appropriate characteristics to suit a variety of different applications (Table 1.7). 
 
Table 1.7   Synthetic polymers investigated for use in tissue engineering scaffolds for 
orthopaedic applications 
Polymer  Abbreviation  Examples 
Poly(lactide) or Poly(lactic acid) or 
Poly(L)lactic acid 
PLA or PLLA 
Freed et al. 1993, Kanczler et 
al. 2010 
Poly(DL-lactide)  PDLLA  Wildemann et al. 2005 
Poly(glycolic) acid  PGA  Freed et al. 1993 
Poly (L) lactic acid poly(glycolide)  PLA/PLGA  Bostman et al. 1989 
Poly(L-lactide-co-D,L-lactide)  PLDLLA  Coe et al. 2004 
Poly(lactide-co-glycolide)  PLGA 
Goldstein et al. 1999, Borden et 
al. 2003 
Poly(lactide-co-glycolide)/poly(ethylene 
glycol) 
PLGA/PEG 
King et al. 2000, Schaefer et al. 
2000 
Poly(lactide-co-glycolide)/ polyvinyl 
alcohol 
PLGA/PVA  Oh et al. 2003 
Polyethylene terephthalate  PET  Takahashi et al. 2004 
Poly(propylene glycol-co-fumaric acid)  PPF  Hile et al. 2003 
Poly(desaminotyrosyl-tyrosine ethyl ester 
carbonate) 
PDTE 
carbonate 
Simon et al. 2003 
Polyethylene glycol  PEG  Terella et al. 2010 
Polycaprolactone  PCL 
Yoshimoto et al. 2003, Schantz 
et al. 2006 
Polymethyl methacrylate  PMMA  Shimko and Nauman 2007 
Polyhydroxyalkanoates  PHAs  Chen and Wu 2005 
Poly(poly(ethylene oxide) terephthalate-
co-(butylene) terephthalate 
P(P)EO/PBT  Bulstra et al. 1996 
Poly (L) lactic acid/ Poly (ethylene oxide)  PLLA/PEO  Coraca et al.  2008 
Poly (L) lactic acid/ Polycaprolactone  PLLA/PCL  Khan et al.  2010 
Adapted from Zippel et al. 2010, Karageorgiou and Kaplan 2005 
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Well-defined  changes  in  variables  such  as  solvent  type,  precipitation  temperature, 
chemical formulation and pressure allow the precise manipulation of the scaffold, thus 
tailoring its overall shape, pore interconnectivity and size, degradation rate, molecular 
weight,  mechanical  properties  and  handling  properties  (Karageorgiou  and  Kaplan 
2005). 
 
However, synthetic materials are more likely than natural scaffolds to have undesirable 
effects within the body, so care is needed to ensure the scaffold is fabricated from a 
highly biocompatible material that has no potential to elicit an immunological or foreign 
body reaction (Muschler et al. 2004). Furthermore, suitable polymers should be chosen 
for the intended application not only to support sufficient load, but also to degrade and 
resorb at an appropriate rate, and release non-toxic degradation products (Hutmacher 
2001). Most synthetic polymers in trials and in clinical use undergo bulk degradation to 
lactic  and/or  glycolic  acid  (Hutmacher  2000).  Substantial  local  concentrations  of 
degradation products produced either by a large quickly resorbing scaffold, or through 
poor elimination capacity of local tissues, can lead to a reduced local pH and increased 
osmotic pressure (Bostman et al. 1989, Bostman et al. 1990). This hostile environment 
can damage the local cells, potentially negating the regenerative effects of the strategy 
and  further,  the  local  acidification  can  increase  the  rate  of  polymer  breakdown, 
exacerbating the problem and leading to further inflammation, giant cell activation and 
cytotoxicity (Hutmacher 2000). 
 
The design of synthetic polymers for orthopaedic regenerative applications requires a 
trade-off between desirable properties that contribute to the strength of the construct 
and properties that allow consistent degradation (Fig. 1.11). A cardinal requirement for 
successful synthetic polymer scaffolds is an open, interconnecting porous architecture 
(Karageorgiou and Kaplan 2005). Porosity is defined as the percentage of void space 
within  a  solid,  and  is  necessary  for  migration  and  proliferation  of  progenitor  and 
vascular cells and also for diffusion of nutrients into and waste products away from the 
construct.  Surface  porosity  also  increases  the  stability  of  the  scaffold  by  providing 
mechanical interlocking at the interface with surrounding tissue. Optimal pore size has 
not been fully established, but for bone formation, most strategies aim for pores of 100-
500  μm  diameter  to  allow  adequate  blood  vessel  ingress  (Zippel  et  al.  2010, 
Hutmacher 2000). 
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Fig. 1.11  ‘Balancing  act’  demonstrating  the  trade-off  between  contradictory  desirable 
attributes of a polymer scaffold 
 
 
1.8.2.5.1 Polymer scaffold fabrication techniques 
Techniques to fabricate porous 3D scaffolds have evolved over the last two decades 
(Table 1.8). Modern strategies tend to be automated and are capable of producing 
larger quantities of scaffold with more complex designs over a shorter timeframe, with 
high  fidelity  to  the  intended  architecture.  Newer  methods  are  also  capable  of 
incorporating more materials in spatially  defined configurations to encourage robust 
regeneration  throughout  the  entire  volume.  However,  not  all  fabrication  techniques 
work for every polymer, so the choice of scaffold for an intended application and the 
properties that are induced by its various fabrication options must be identified at an 
early stage. 
 
Initial  techniques  for  scaffold  fabrication  involved  dissolving  the  polymer  in  organic 
solvents  such  as  chloroform,  before  casting  the  polymer  into  the  desired  shape. 
Porosity was induced by including salt microspheres or gelatin in the solution which 
were  then  leached  out  following  evaporation  of  the  solvent  (Mikos  et  al.  1993a, 
Thomson et al. 1995). These constructs only produce thin sheets or membranes with 
reliable porosity and attempts to create thicker 3D scaffolds result in residual solvent 
encapsulation,  which is cytotoxic and  reduces porosity.  Furthermore,  the product  is 
brittle  and  therefore  unsuitable  for  soft  tissue  applications.  A  modification  of  this 49 
 
technique, which included lamination of multiple layers of this construct with a solvent 
binder,  was  demonstrated  to  produce  3D  scaffolds,  but  the  problem  of  residual 
chloroform  remained  and  pore  interconnectivity  was  not  consistent  (Mikos  et  al. 
1993b).  Alternatively,  the  solvent-casting  and  particulate-leaching  approach  can  be 
followed by an extrusion step where the composite is heated and extruded as a tube 
through a nozzle at high pressure. After cooling, the scaffold is leached as before, prior 
to  vacuum  drying.  This  allows  good  control  over  pore  size  and  number,  although 
thermal degradation of the polymer is a risk (Widmer et al. 1998). 
 
Another early technique to produce 3D scaffolds made use of technology from the 
textile industry. Fleeces or meshes can be manufactured by laying fibres side by side 
with the next layer laid in a perpendicular conformation. Bonding at the cross-links can 
be achieved through heating or local application of solvent (Hutmacher 2001). Despite 
having a large surface area to volume ratio necessary for successful cell infiltration, 
these  scaffolds  lack  structural  stability  for  use  in  weight-bearing  orthopaedic 
applications and are prone to contractile deformation (Hutmacher et al. 2007). 
 
Phase  separation  allows  the  incorporation  of  biologically  active  molecules  into  the 
biodegradable polymer. The polymer  is dissolved with a solvent such as phenol or 
naphthalene before addition of the bioactive molecules. However, subsequent removal 
of  the  solvent  during  sublimation  is  often  incomplete,  with  potentially  harmful 
consequences when incorporated into the body. Furthermore, the technique gives a 
scaffold with low porosity, and incorporation of larger proteins and drugs reduces their 
activity (Sachlos and Czernuszka 2003). 
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Table 1.8  Porous 3D polymer scaffolds – evolution of scaffold fabrication techniques  
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Porosity can also be induced in a solid block of polymer by emulsion freeze-drying. The 
polymer is dissolved in a solvent before adding to water. The two immiscible layers are 
then  homogenised  to  form  an  emulsion,  which  is  subsequently  quenched  in  liquid 
nitrogen and freeze-dried to produce a porous structure. This has the advantage of 
producing large 3D scaffolds with multiple interconnected pores. However, mechanical 
strength is low and exact conformation is operator-dependent (Whang et al. 1995). 
 
All the above techniques make use of solvents (chloroform, methylene chloride, phenol 
or naphthalene) in order to solubilise the polymer and allow its manipulation. The exact 
solvent depends on the technique and polymer involved, but residual solvent has been 
identified in these methods despite attempts to remove them through thorough washing 
and  evaporation  techniques.  The  risks  of  toxicity,  inflammation  and  potential 
carcinogenicity must therefore be taken into consideration (Sachlos and Czernuszka 
2003). 
 
Techniques to produce a 3D polymer without using solvent include melt-moulding and 
gelatin-leaching. Here, the polymer is melted rather than solubilised by heating above 
its  glass-transition  temperature,  and  the  addition  of  gelatin  microspheres  induces 
porosity on their subsequent dissolution (Thomson et al. 1995). This process allows 
tight control of porosity by varying the size and number of gelatin microspheres, but the 
high temperatures can alter the mechanical properties of the polymer and denature or 
inactivate  any  added  drugs  or  growth  factors.  Alternatives  to  thermal  or  solvent 
techniques include the use of high pressure gasses: In gas foaming, polymer pellets 
are compressed into custom made moulds, then saturated with high pressure carbon 
dioxide (CO2) gas. As the pressure is reduced, the solubility of gas in the polymer is 
decreased,  leaving  nucleation  and  growth  of  gas  cells  of  100-500  μm  diameter 
(Mooney et al. 1996). In order to produce an interconnected open pore morphology, 
this  method  has  been  combined  with  particulate-leaching  (Harris  et  al.  1998). 
Supercritical fluid processing also makes use of high pressure gas (either CO2 or N2), 
which plasticises polymer granules and creates air cells, which reduces the viscosity 
and allows the incorporation of heat sensitive pharmaceuticals or biological agents. 
The  resultant  pores  are  only  on  average  10-30%  interconnected,  although  the 
combination of this technique with particulate-leaching produces a controllable highly-
interconnected porosity. The resultant scaffolds have been used with incorporation of 
growth factors with success in vivo (Mathieu et al. 2006, Harris et al. 1998). 
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Although  the  latter  techniques  dispense  with  the  requirement  for  solvents  in  their 
fabrication, several limitations still exist. These techniques are not capable of precisely 
controlling pore size, their geometry, spatial distribution and interconnectivity. This has 
a negative impact on cellular migration and infiltration into the scaffold and restricts 
diffusion  of  nutrients  and  oxygen  and  removal  of  waste  products.  Furthermore, 
scaffolds  produced  by  casting  tend  to  form  a  thin  external  coating  or  ‘skin’  which 
requires removal before use (Sachlos and Czernuszka 2003). 
 
As  a  result  of  the  disadvantages  of  scaffolds  produced  by  these  techniques,  the 
technology  transfer  of  Solid  Freeform  Fabrication  (SFF,  also  known  as  rapid 
prototyping or advanced manufacturing technologies) to tissue engineering has led to 
great  advances.  This  involves  building  3D  objects  using  layered  manufacturing 
strategies  and  allows  scaffolds  to  be  designed  and  manufactured  with  customised 
external  shapes  and  pre-defined,  reproducible  internal  morphology.  The  process 
makes  use  of  Computer-Aided  Design  and  Manufacture  (CAD-CAM),  whereby  a 
conceptual  3D  model  (which  could  be  derived  clinically  from  CT  or  Magnetic 
Resonance Imaging (MRI) images of the defect region) is expressed as a series of 
cross-sectional layers. Repetitive deposition and processing of these physical layers is 
then accurately controlled through an entirely computerised and mechanised process 
to  produce  an  accurate  and  reproducible  3D  construct.  This  has  the  potential 
advantage  of  providing  a  custom-built  implant  for  any  specific  clinical  scenario, 
although  all  techniques  currently  in  use  involve  considerable  time-consumption  in 
manufacture (Hutmacher 2001, Sachlos and Czernuszka 2003). 
 
Several techniques have been developed for final deposition of the layered construct: 
in Three-Dimensional Printing (3DP) the powdered polymer  is first spread  in a thin 
layer over the surface of the powder bed. A jet head with x- and y-axis control moves 
over  the  powder  and  ejects  a  binder  material  in  accordance  with  Computer-Aided 
Design (CAD) cross-sectional data onto the polymer surface, which locally dissolves 
the  polymer,  allowing  adherence  to  subsequent  layers.  The  chamber  is  lowered 
following each pass of the jet head to allow incremental build-up of bound layers. The 
whole process can be achieved at room temperature, and water-based binders can be 
used; however the unbound powder must be completely removed following component 
completion  (Hutmacher  2000).  Stereolithography  uses  similar  co-ordinated  control 
systems, but makes use of an ultraviolet laser beam to selectively polymerise a liquid 
photocurable monomer as it is lowered into the monomer liquid-filled vat. In Fused 
Deposition  Modelling  (FDM),  a  fibre  of  thermoplastic  polymer  is  extruded  from  a 53 
 
moving  nozzle  in  semi-liquid  state,  and  deposited  layer-by-layer.  As  the  material 
solidifies,  it  laminates  to  the  preceding  layer.  This  process  requires  heating  of  the 
polymer  (up  to  120°C),  which  eliminates  the  possibility  of  incorporating  biological 
molecules.  However  it,  results  in  a  highly  accurate,  reproducible  product  with  high 
porosity and strength (Hutmacher 2001). 
 
Polymers have also been fabricated for tendon and ligament reconstruction. Synthetic 
scaffolds  manufactured  for  clinical  use  are  made  of  polyester,  polypropylene, 
polyarylamide,  polyethylene  terephthalate,  carbon  and  nylon  (Chen  et  al.  2009). 
Despite having superior mechanical properties as compared to biological scaffolds for 
tendon/ligament reconstruction, they are designed as permanent replacements for the 
native tissue, rather than as true tissue engineering constructs. Consequently, these 
materials often have poor biological compatibility and major longer-term complications 
have  been  reported  for  some  scaffolds  (e.g.  polytetrafluoroethylene  (PTFE)). 
Inflammatory  reactions  are  common  and  may  extend  to  synovitis,  osteolysis  and 
foreign body rejection, resulting in failure of the construct and further collateral damage. 
Given these concerns, current developments are focusing on improving the biological 
compatibility  of  future  scaffolds  and  applying  tissue  engineering  principles  to  their 
design to improve the healing process at the enthesis (Longo et al. 2010). Fibroblasts 
cultured on cross-linked collagen, silk and PLGA scaffolds have shown encouraging 
results in vitro and in small animal studies, particularly with the addition of exogenous 
growth  factors,  such  as  TGF,  EGF,  IGF  and  PDGF  (Rahaman  and  Mao  2005). 
However,  challenges  in  culturing  fibroblasts  and  limitations  of  the  properties  of 
bioresorbable scaffolds mean that no tissue engineering strategy to date has shown 
resilient  neo-tendon  formation  with  sufficient  tensile  strength  for  potential  clinical 
application. 
 
 
1.8.2.6 Composite scaffolds 
 
The use of single scaffolds to replace skeletal tissues in tissue engineering strategies is 
unlikely to achieve adequate functional results in the clinical scenario because each 
skeletal  tissue  is  in  itself  a  composite  material  in  many  senses.  The  mechanical 
properties of bone, for example depend on its local structure with respect to porosity 
and lamellar architecture and also its composition of collagen-rich organic matrix and 
mineral  hydroxyapatite  (Hutmacher  et  al.  2007).  In  addition,  the  composition  and 
mechanical  characteristics  of  bone  change  with  age,  activity,  nutritional  state  and 54 
 
disease  status,  adding  to  the  challenge  of  fabricating  an  appropriate  scaffold  for 
individual requirements (Karageorgiou and Kaplan 2005). Clearly then, a successful 
tissue engineering scaffold will have to take account of this complex of properties to act 
as a functional surrogate for native tissue until regeneration is complete. 
 
Collagen  has  been  demonstrated to  encourage  osteogenesis,  but  provides  minimal 
structural support, so in isolation it functions poorly as a graft material (Mizuno and 
Kuboki  2001).  Once  coupled  with  SSCs,  growth  factors,  or  scaffold  materials,  its 
properties  can  be  enhanced  considerably  (Giannoudis  et  al.  2005).  A  composite 
strategy, using collagen type I pre-coated onto allograft, has been shown to enhance 
osteogenic  differentiation  of  SSCs  in  basal  culture,  augmenting  the  mechanical 
properties of the allograft (Jones et al. 2009).  
 
HA  has  been  combined  with  chitosan  to  form  a  bioactive  scaffold  for  bone  tissue 
engineering  (Venkatesan  and  Kim  2010).  Chitosan  is  produced  from  chitin,  an 
abundant natural polysaccharide found in marine crustacean shells. Alone, it is highly 
biocompatible,  biodegradable,  antibacterial,  and can be moulded into  various forms 
with a porous structure (Di Martino et al. 2005). However, it is flexible, with poor loading 
characteristics and is not, in itself, osteoconductive. The combination of chitosan with 
HA vastly improves osteoconductivity and to some extent also its mechanical strength, 
so that the composite closely mimics both the organic and inorganic portions of natural 
bone. Several in vitro studies have been performed that confirm its osteogenic utility; 
however  translation  has  been  prevented  because  its  compressive  strength  is  still 
inadequate (Hu et al. 2004, Thein-Han and Misra 2009). The combination of chitosan-
HA composite with carbon nanotubes have been produced, and they possess superior 
mechanical properties, although these scaffolds come at a potential risk of cytotoxicity, 
display poor bioresorption profiles and there have been difficulties ensuring uniform 
dispersion of the carbon skeleton within the scaffold (Venkatesan and Kim 2010). The 
most promising strategy for skeletal tissue regeneration is therefore likely to lie in the 
combination  of  growth  factors  with  enriched  autologous  SSCs  added  to  a  suitable 
composite scaffold. 
 
The  fabrication  of  synthetic  composite  scaffolds  initially  centred  on  achieving  the 
appropriate  scaffold  properties  to  replicate  the  overall  ‘bulk’  properties  of  the  host 
tissue. In addition to the composite of two or more polymers, composites of polymers 
with ceramics or other materials have been trialled with beneficial effects. Not only do 
these  materials  have  the  potential  to  complement  and  enhance  the  structural  and 55 
 
osteoconductive performance of the composite, but biochemical advantages also exist. 
For  example,  when  HA  or  TCP  is  used  in  combination  with  polymers,  the  basic 
resorption products of the ceramic buffer the acidic resorption by-products of polymer 
breakdown  and  help  to  avoid  the formation  of  an  unfavourable  acidic  environment. 
(Agrawal and Athanasiou 1997) Consequently a wide variety of such composites, some 
containing additional biological materials such as collagen, have been investigated for 
use as orthopaedic scaffolds (Zippel et al. 2010). 
 
A further challenge is in the synthesis of tissue-engineered constructs containing a 
single tissue-type, but with a heterogeneous biochemical composition and mechanical 
properties. Replication of the four distinct anatomical and functional regions in native 
human articular cartilage has recently been achieved in vitro (Nguyen et al. 2011). A 
spatially  organised  scaffold  was  formulated  using  distinct  hydrogel  layers,  each 
containing a specific combination of synthetic and natural biomaterials, which was able 
to  direct  appropriate  zone-specific  chondrogenesis  with  corresponding  mechanical 
properties. 
 
An additional requirement for composite scaffolds is in the regeneration of structures at 
the interface of two tissue types. Previous attempts encountered difficulty securing the 
regenerative  scaffold  to  underlying  tissues,  such  as  in  osteochondral  defects  of 
articular cartilage or meniscus (Elisseeff et al. 2005). Success has been achieved by 
the development of a multilayered hydrogel scaffold with different cell types in each 
layer, which were then co-cultured in tandem to produce the appropriate matrix for the 
tissue being engineered, in this case articular cartilage and subchondral bone (Kim et 
al.  2003).  The  production  of  a  bilayered  scaffold  to  re-create  the  tissues  within  a 
temporomandibular joint has also been implemented in a rat model (Alhadlaq et al. 
2004), providing just one example of many where maxillofacial surgery has been at the 
forefront of skeletal tissue engineering research. 
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1.8.2.7 Tissue engineered constructs in maxillofacial surgery 
 
Tissue engineering principles are particularly suited to the field of maxillofacial surgery 
given the region’s high vascularity and because there is limited intra-oral bone suitable 
for grafting as an alternative (Schmelzeisen et al. 2003). Knowledge of the maxillofacial 
progress  is  essential  for  researchers  in  the  field  of  orthopaedics  as  pioneering 
techniques are often first instigated in this arena, and many lessons can be learnt from 
their results before application of the techniques in the orthopaedic field, whilst avoiding 
repetition of work. 
 
In  cases  of  deficient  maxillary  alveolus  bone,  maxillary  sinus  floor  augmentation  is 
required to ensure stability before dental implant insertion. This clinical necessity has 
provided  further  novel  strategies  for  skeletal  regeneration  with  some  larger-scale 
studies. Schimming et al. demonstrated successful maxillary sinus floor augmentation 
at three months in 18 of 27 patients using a polymer fleece with impregnated culture-
expanded mandibular periosteal cells (Schimming et al. 2004). 12 of these patients 
underwent a one-stage procedure, and although one patient from this group sustained 
an early post-operative infection, and the graft was removed, good bone formation was 
demonstrated in all the other patients from this group. 15 patients underwent a two-
stage procedure, where the dental prosthesis was implanted three months following 
augmentation. In eight of these patients the engineered matrix underwent resorption 
and  replacement  with  connective  tissue,  and  they  required  supplementary 
augmentation with autologous bone. One reason cited by the authors for the poorer 
results in the two-stage procedures is the lack of adequate oxygen and nutrient supply 
to cells deep within these larger constructs. Current work to improve the induction of 
vascularisation in such constructs will enhance their application to long bone defects, 
where the extra-osseous blood supply is often significantly impaired (Johnson et al. 
2011). 
 
Tissue engineering principles have also been applied to fabricate an entire mandible de 
novo  using  autologous  bone  marrow  cells  seeded  onto  BMP-7-coated  HA  blocks, 
supported within a titanium mesh scaffold (Warnke et al. 2004). The construct was 
grown  in  the  patient’s  latissimus  dorsi  muscle  before  final  implantation.  Despite 
complications including infection, heterotopic ossification and mesh fracture, a second 
patient has subsequently undergone the procedure (Warnke et al. 2006). Although the 
resulting mandible provides a good cosmetic result, the report detailed limited evidence 57 
 
of  normal function  or  structural  integration  with  the  surrounding  native  tissues.  The 
application of these techniques to weight-bearing bones in an orthopaedic context may 
therefore require significant refinement (Gronthos 2004). 
 
Maxillofacial applications have also been described for the induction of bone formation 
in extra-skeletal sites using growth factors and scaffolds without the requirement for 
exogenous  SSCs.  In  one  report,  a  mandibular  defect  following  surgical  tumour 
resection was reconstructed using an HA implant impregnated with BMP-7 (Heliotis et 
al.  2006).  The  construct  was  implanted  into  a patient’s  pectoralis  major  muscle for 
three months before being harvested and transplanted to the mandibular defect as a 
pedicled ‘myo-osseo-HA’ flap. Unfortunately, despite promising initial integration, the 
graft soon became infected and required excision after five months. 
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1.9  Future directions – scaffolds 
 
The  inherent  disadvantages  of  currently  utilised  reconstructive  strategies  (metal 
implants, cement, autograft and allograft) combined with the ageing population and a 
continuing increase in musculoskeletal pathology and patient expectations, highlight a 
pressing  need  to  augment  or  replace  current  practice  with  osteoregenerative 
techniques.  However,  these  strategies  will  need  to  act  as  a  functionally  and 
physiologically  appropriate  surrogate  for  a  patient’s  lost  or  damaged  skeleton.  In 
addition to the need to reconstruct bone defects, much orthopaedic morbidity is derived 
from cartilage disease and tendon pathology (Khan et al. 2010, Getgood et al. 2009). It 
is  envisaged  that  novel  technologies  to  address  bone  defects  will  also  be  readily 
transferrable to these applications. 
 
The design of biomaterial scaffolds is now focussed on biological stimulation to ensure 
infiltration and regeneration of the appropriate tissue type with coincident promotion of 
angiogenesis (Bouhadir and Mooney 2001). The scaffold can either be functionalised 
on the surface by peptides or growth factors that mimic ECM chemistry, or they can be 
included in the scaffold composition, to allow physical and temporal control of their 
delivery  during  degradation  (Navarro  et  al.  2008).  Due  to  the  high  number  of 
combinations and permutations possible, many studies examining various composites 
of scaffold, cell, and growth factor interaction on skeletal tissue regeneration have been 
published (Yang et al. 2003, Kanczler et al. 2010, Zippel et al. 2010). 
 
Although there is intense interest in augmenting the potential of SSCs by combining 
them with growth factors and biomimetic scaffolds as a self-contained implantable unit, 
some  commentators  believe  the  addition  of  exogenous  SSCs  is  not  necessary  for 
appropriate regeneration (Watt and Driskell 2010). A recent rabbit study has exploited 
the  potential  for  the  contents  and  structure  of  the  scaffold  itself  to  manipulate  the 
surrounding  environment,  hence  stimulating  and  incorporating  the  host’s  own  local 
SSCs and removing the need for ex vivo cell culture and scaffold seeding (Lee CH et 
al. 2010). In the study, the articular surface of the proximal humerus of a group of 
rabbits was completely excised and replaced with an anatomically correct bioscaffold 
spatially  infused  with  TGF-β3-adsorbed  or  TGF-β3-free  collagen  hydrogel.  Four 
months following surgery, the articular surfaces of TGF-β3-adsorbed bioscaffolds were 
entirely covered with hyaline cartilage, whilst TGF-β3-free bioscaffolds supported only 
isolated  cartilage  growth.  Furthermore,  there  was  no  difference  in  shear  and 
compressive characteristics of TGF-β3-mediated articular cartilage, compared to those 59 
 
of native articular cartilage, although these properties were significantly reduced in the 
group  without  TGF-β3.  In  addition,  TGF-β3  delivery  recruited  approximately  130% 
more  cells  in  the  regenerated  articular  cartilage  than  in  the group  without  TGF-β3. 
Clearly the reconstruction of a complex human joint is still some way off, but this study 
demonstrated proof of concept for development of novel scaffolds and carrier materials 
as potential treatments for advanced arthritis. 60 
 
1.10  Considerations for the development of a tissue engineering strategy 
 
The successful development of an emergent tissue engineering approach requires a 
series of tightly coordinated processes to take place within a limited timeframe and 
budget  (Smith  et  al.  2011)  (Fig.  1.12). The  initial  concept  must  be  based  upon  an 
accurate insight into the current clinical needs and a realistic vision of future potential. 
Progression  to  each  subsequent  stage  in  the  development  process  requires  close 
collaboration between multiple agencies with wide-ranging expertise and a high degree 
of discrimination to select the most promising cell, candidate material and protocol. 
Several factors have particular relevance to the development of an effective emergent 
tissue engineering strategy, and without which the process inevitably fails. 
 
 
 
Fig.  1.12  The  collaborative  tissue  engineering  “life  cycle”.  The  process  is  driven  at  all 
stages by informed allocation of funding (denoted by $). The speed of the cycle is not only 
dependent upon the success of scientific research and testing, but also heavily relies on the 
collaboration of multiple agencies (dashed boxes). 
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1.10.1  Funding 
Informed allocation of adequate funding is required at each step, particularly after up-
scaling to pre-clinical studies,  and although this has, to  date, been available,  there 
remains a disparity between early-stage funding and final clinical output (Mason and 
Manzotti 2010, Griffith and Naughton 2002). This contrast may reflect the sources of 
funding:  late-stage  projects  are  often  funded  for  a  specific  product  by  industry  or 
venture capital companies, where given the associated risk, potential losses can be 
high – this restricts funding to only a few selected therapies or approaches. Economic 
modelling has been advocated as a solution to determine the likely cost-benefit of a 
putative  tissue  engineering  construct  before  product  development  is  considered, 
allowing stakeholders to assess convincing data on value and clinical efficacy before 
investing  (Archer  and  Williams  2005).  However,  the  tissue  engineering  ‘life-cycle’ 
remains  an  exhaustive  process,  such  that  even  for  the  successful  strategies  that 
progress  to  sustained  production,  there  is  often  a  significant  lead-time  to  financial 
return. 
 
1.10.2  Regulatory requirements and research governance 
Regulatory hurdles must be overcome at all stages of research. In vivo laboratory work 
must adhere to the principles of replacement, reduction and refinement and is subject 
to licence,  under the Animals (Scientific Procedures)  Act 1986 in the UK, following 
scrutiny of the facilities, research programme and prior assessment of the researchers’ 
training and competence (Kolar 2006). Removal, storage and use of human tissue as 
part of pre-clinical evaluation of strategies involving human cells are regulated in the 
UK  by  the  Human Tissue  Act  2004.  The  conduct  of  any  clinical  trial  requires  prior 
approval by the appropriate ethics committee as part of the quality and accountability 
Research Governance Framework within which research is undertaken in the National 
Health Service (NHS). Before any biomaterial may be used in the clinic, it must comply 
with stringent production and safety standards such as ISO (International Organisation 
for Standardisation), USFDA (United States Food and Drug Administration) and GMP 
(Good Manufacturing Practice) (Reichert  et al. 2010). Even if a particular device or 
material has already been approved for clinical use, such approval may be indication-
specific,  thus  a  novel  application  may  require  further  evaluation  and  approval. 
Furthermore,  the  addition  of  biologically  active  molecules  to  a  previously  approved 
material may change its classification, in certain standardisation systems, to a drug, 
requiring a different or additional evaluation protocol before clinical use is sanctioned. 
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These  regulatory  frameworks  provide  an  important  system  of  governance  which  is 
required to ensure research protocols are necessary, in the interest of the population, 
and produce the maximum impact for any harm caused through the process itself, and 
with minimal unnecessary repetition of established results. However, these regulatory 
processes must in themselves be overseen and regulated to ensure they serve their 
purpose  and  do  not  create  additional  repetition  of  work  through  bureaucratic 
justification by these agencies.  
 
 
1.10.3  Practical factors 
 
1.10.3.1  Scale-up for pre-clinical testing  
Practical obstacles to in vivo scale-up must also be addressed to reliably assess new 
strategies  for  skeletal  tissue  engineering  before  pre-clinical  studies  can  take  place. 
Challenges include the establishment of appropriate large animal models for the clinical 
scenarios to be modelled, the requirement to manufacture larger biomaterials and the 
need  to  culture  cells  on  a  much  greater  scale  than  is  routine  in  most  research 
laboratories (Reichert et al. 2009). Although the bone composition of the dog, sheep, 
goat  and  pig  is  similar  to  those  of  humans,  the  age  and  rate  at  which  osteonal 
remodelling occurs varies between these groups. In addition, cost, local availability, 
temperament and husbandry expertise are important factors (Muschler et al. 2010). For 
bone  regeneration  models,  sheep  and  goats  are  particularly  relevant  as  their 
bodyweight is comparable to humans and the dimensions of their long bones allow for 
the use of human implants and fixation techniques (Reichert et al. 2010, Newman et al. 
1995). The  equine knee  is  often  the favoured  model for  cartilage  repair  strategies, 
because the thick hyaline cartilage allows investigation of both partial and full-thickness 
defects (Chu et al. 2010). Furthermore, horses have large joints that permit arthroscopy 
and  they  are  typically  more  compliant  with  post-operative  rehabilitation  protocols 
compared to pigs and ruminants (Sah and Ratcliffe 2010). 
 
The technicalities of large-scale manufacture are often very different to the protocols 
involved  in  producing  small  quantities  of  a  test  substance  for  analysis.  These 
processes  must  not  be  (but  often  are)  neglected  until  a  late  stage  in  product 
development, when modification of manufacturing processes may be costly or require 
regulatory re-approval. The difficulties associated with mass-production of complex bio-
composites  or  cell  production  processes  may  be  overcome  by  incorporating 
commercial interests and production strategies in the initial research and development. 63 
 
This would provide a platform for progression in parallel with translation (Archer and 
Williams 2005). 
 
1.10.3.2  Clinical trials 
Once efficacy has been demonstrated in a large animal model and pre-clinical safety 
approval has been granted, the successful product can then undergo clinical trials prior 
to  commercial  manufacture.  Clinical  trials  present  further  challenges  including  a 
requirement for significant clinician involvement, patient concordance, organisation and 
appropriate clinical facilities to undertake such studies. It is often at this stage that 
important  practical  aspects  of  the  novel  treatment  are  considered.  Routine 
supplementary procedures intrinsic to the patient’s treatment may have unexpected 
effects on the new tissue engineering approach, and these may initially be overlooked. 
Typically,  strategies  that  incorporate  the  use  of  stem  cells  as  part  of  therapeutic 
procedures remain comparable to current surgical protocols, with only modest changes 
advocated  to  accommodate  the  novel  construct.  Without  specific  implementation 
however,  the  efficacy  of  the  new  technique  may  be  adversely  affected  and  there 
remain  a  number  of  factors  in  a  clinical  protocol  whereby  cell  populations  may  be 
compromised. These include temperature changes, infection, wound cleansing (e.g. 
pulsatile lavage) as well as the use of ancillary products such as antibiotic or local 
anaesthetic (LA) agents. It therefore makes sense to assess the impact of each of 
these modifiable factors on the components of a tissue engineering construct before 
clinical translation, so that adverse effects may be minimised and ideal conditions be 
established to ensure optimal therapeutic efficacy. 
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1.11  Major null hypothesis 
 
Enriched skeletal stem cells applied as tissue engineered constructs do not augment 
bone formation. 
 
 
 
 
 
 
1.12  Aims 
 
Following on from this examination of current knowledge surrounding skeletal tissue 
regeneration, the aims of this thesis are to evaluate and refine a clinically appropriate 
stem-cell enrichment strategy, for use within a tissue engineered construct (Chapter II), 
then to apply these concentrated stem cells to putative scaffolds within selected in vitro 
and  in  vivo  models  as  a  precursor  to  clinical  application  (Chapters  III-V).  The 
application  of tissue  engineering  strategies to enhance  the  properties of  a  material 
already in widespread orthopaedic use will be determined (Chapter III), as well as an 
assessment of the appropriate properties of novel scaffold materials (Chapter IV and 
V). As a precursor to clinical evaluation of a further new scaffold, the establishment of a 
large animal in vivo model of skeletal regeneration will also be examined (Chapter V), 
including potential hurdles that must be overcome prior to successful clinical translation 
(Chapter VI). 65 
 
1.13   Objectives 
 
1.  To demonstrate the potential to efficiently concentrate the nucleated fraction of 
BMA, obtained from a clinically relevant elderly cohort, adopting an approach to 
cell filtration applicable within the sterile field of an operating theatre. 
 
2.  To  demonstrate  the  significance  of  cell  enrichment  for  osteogenic  and 
chondrogenic cell differentiation, and seeding efficiency onto allogeneic bone 
graft. 
 
3.  To examine the osteoconductive and inductive capacity of Tantalum Trabecular 
Metal (TTM) in relation to allograft and autograft 
 
4.  To determine the potential of TTM with the addition of human skeletal stem 
cells in tissue engineering applications as an alternative to the current accepted 
standard treatments for loss of skeletal tissues. 
 
5.  To perform in vitro and in vivo analyses for skeletal regeneration applications of 
candidate  polymer  scaffolds  selected  by  a  High  Throughput  (HT)  screening 
approach. 
 
6.  To establish a consistent and reproducible technique for stabilisation of a 35 
mm tibial critical defect in sheep, for subsequent trialling of tissue regeneration 
strategies. 
 
7.  To  demonstrate  a  living  cell  composite  using  cultured  skeletal  stem  cells  on 
synthetic scaffold to augment bone formation in a large animal segmental defect 
model. 
 
8.  To  investigate  the  effects  of  three  local  anaesthetic  agents,  in  routine  use  in 
orthopaedic practice, on skeletal stem cell function and survival and instruct the 
implementation of appropriate analgesia during the application of skeletal tissue 
engineering strategies. 66 
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Chapter II 
 
Development of an intra-operative strategy to enrich 
skeletal stem cells from bone marrow for orthopaedic 
application 
 
 
This study was performed with Dr Jonathan Dawson and Mr Alexander Aarvold. I gratefully 
acknowledge their support, in addition to Mr Andrew Jones for obtaining ethical approval and Mr 
Doug Dunlop and Mr David Higgs for provision of aspirated bone marrow. Initial development 
and testing of the device was performed by Dr Jonathan Ridgway and Dr Steven Curran at the 
Smith  &  Nephew  Product  Development  Centre  in  York,  prior  to  the  work  described  in  this 
chapter and has been published separately. Initial steps in the development of the aspiration 
and filtration technique have already been documented in Mr Aarvold’s thesis. All experimental 
and analytical components presented in this chapter were conducted jointly by Dr Dawson and 
me. This work was funded by the Technology Strategy Board (AG280K) and Engineering and 
Physical Sciences Research Council (TS/G001650/1) 
 
 
 
A  paper  detailing  this  study  has  recently  been  published  in  Cytotherapy  under  joint  first 
authorship 
 
The  collaboration  between  clinician,  scientist  and  industry  in  developing  and  evaluating  this 
novel technique was recognised nationally by ‘The Engineer’ Technology & Innovation Awards 
2010, winning both the ‘Medical and Healthcare’ category and the overall ‘Grand Prix’ 
 
A presentation based on this study received the Pfizer Award for best conference poster at the 
UK National Stem Cell Network, York, 2011 68 
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2.1  Introduction 
 
2.1.1  The clinical requirement for cell enrichment strategies 
 
Tissue engineering strategies seek to harness the regenerative potential of stem or 
progenitor  cells  to  replace  tissue  lost  or  damaged  through  injury  or  disease.  With 
respect to skeletal tissues, aspirated bone marrow possesses considerable potential in 
such  applications  as  an  autologous  source  of  SSCs  able  to  regenerate  bone  and 
cartilage tissue. While connective tissue progenitors are resident in many tissues, bone 
marrow serves as the richest and most readily available repository of  SSCs (Block 
2005). Indeed, much of the osteogenic capacity of autologous bone graft derives from 
the bone marrow component (Nade and Burwell 1977). Despite some notable isolated 
successes  however,  where the  regenerative  capacity  of  autologous  BMA  has  been 
successfully applied in the treatment of chronic wounds (Badiavas and Falanga 2003), 
or in combination with DBM for the treatment of aneurysmal (Docquier and Delloye 
2005) and unicameral (Rougraff and Kling 2002) bone cysts, variable results obtained 
with aspirated cells suggest that concentration of BMA for SSCs is required to sustain 
robust skeletal regeneration  (Warnke  et  al.  2004,  Connolly  et  al.  1991, Tilley  et  al. 
2006). The proportion of SSCs present in bone marrow is typically only 0.005% of total 
nucleated cells. These numbers are variable and dependent on sampling technique, 
volume, and site (Muschler and Midura 2002). Although this low cell concentration is 
sufficient when transplanting bulk autograft bone, where cells are translocated within 
their  existing  osteoinductive  environment,  robust  skeletal  regeneration  using  BMA 
appears likely to require pre-emptive cellular enrichment (Hernigou et al. 2005a and b, 
Jäger et al. 2011, Quarto et al. 2001). 
 
Key  clinical  and  pre-clinical  studies  have  established  the  importance  of  SSC 
concentration  and  number  on  bone  repair.  Early  clinical  and  pre-clinical  studies  by 
Connolly et al. indicated that the nucleated cell concentration of BMA was significant 
for  bone  formation  and  repair  (Connolly  et  al.  1989,  Connolly  et  al.  1991).  More 
recently,  Hernigou  and  colleagues  successfully  treated  53  out  of  60  patients  with 
femoral  head  AVN  or  fracture  non-unions  using  percutaneous  injection  of  BMA 
concentrated for SSCs (Hernigou et al. 2005b). Retrospective analysis of SSC number 
(by  Colony  Forming  Unit-Fibroblastic  (CFU-F)  analysis)  revealed  that  the  seven 
atrophic non-unions that failed to heal had significantly lower number and concentration 
of SSCs (reviewed in detail in Chapter I, section 1.7). 
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2.1.2 Sources of BMA for enrichment 
 
Several sites for BMA harvesting have been described (Table 2.1). Each aspiration site 
has  its  particular  advantages,  disadvantages  and  technique  of  acquisition.  Most 
commonly a proprietary sterile aspiration kit consisting of a needle with introducing 
trocar is used, although novel methods include collection from the intramedullary canal 
using  a  reamer-irrigator  (Cox  et  al.  2011).  For  clinical  application,  certain  sampling 
procedures  can  be  performed  under  local  anaesthesia,  or  in  conjunction  with  the 
principal  operation,  although  frequently  a  separate  anaesthetic  is  required.  These 
factors should be considered for each case to maximise sample size and quality but 
minimise associated morbidity. 
 
Table 2.1  Sources of BMA for human therapeutic clinical application 
Source  Application  Example 
Iliac crest (anterior 
or posterior) 
Most common approach, minimally invasive 
Brodano et al. 2012 
Smith et al. 2011 
Kitchel et al. 2005 
Mandible  Maxillofacial surgical reconstruction  Lee BK et al. 2011 
Supra-acetabular 
sulcus 
Facile approach during total hip arthroplasty  Fennema et al. 2009 
Vertebral body 
Facile approach during preparation for 
pedicle screw insertion in spinal fusion 
Kitchel et al. 2005 
McLain et al. 2005 
Intramedullary 
canal 
By-product of using the ‘Reamer-Irrigator 
Aspirator’ to prevent fat embolism during 
arthroplasty/ intramedullary surgery 
Porter et al. 2009 
Cox et al. 2011 
Distal femur  Performed during arthroscopic knee surgery  Beitzel et al. 2012 
Proximal humerus 
Performed during arthroscopic rotator cuff 
repair 
Mazzocca et al. 2010 
Sternum 
BMA implanted into myocardium during 
coronary artery bypass grafting 
Holinski et al. 2011 
BMA = Bone Marrow Aspirate 
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2.1.3  Cell enrichment strategies 
 
In response to the critical requirement for the operative delivery of stem cells into a 
tissue engineering construct, several cell enrichment strategies have been developed. 
Many of these systems are already in clinical use in the orthopaedic field, although 
each has its own advantages and disadvantages and therefore a pragmatic approach 
is required to evaluate each option for its suitability before undertaking a procedure 
using one of these strategies. 
 
2.1.3.1 Culture expansion 
For this technique, autologous BMA is acquired from a patient often several weeks 
prior  to  the  planned  implantation  of  the  tissue  engineered  construct.  The  BMA  is 
transported  under  sterile  conditions  to  the  laboratory  for  processing  and  culture  to 
selectively expand the required cell fraction in vitro. Expanded cells are released from 
culture and seeded onto a suitable scaffold either immediately prior to implantation, or 
cultured  with  the  scaffold  in  vitro  for  several  days  to  establish  confluence  prior  to 
implantation. This technique has been used successfully to treat various osteochondral 
and  osseous  defects  (Vacanti  et  al.  2001,  Quarto  et  al.  2001,  Schimming  and 
Schmelzeisen 2004, Ohgushi et al. 2005, Adachi et al. 2005, Morishita et al. 2006, Hibi 
et  al.  2006,  Marcacci  et  al.  2007)  (see  Chapter  I,  Table  1.6).  Although  culture 
expansion  reliably  provides  a  high  concentration  of  required  stem  cells,  several 
inherent disadvantages to this technique exist (Table 2.2). 
 
Table 2.2  Disadvantages  of  using  culture  expansion  techniques  for  clinical  tissue 
engineering purposes 
Requirement  Potential consequences 
Interval operative procedures – for 
aspiration and subsequent implantation 
Increased anaesthetic and surgical risk 
Delay in treatment 
Removal of cells from the operating theatre 
for culture expansion 
Infection, contamination or donor cross-
contamination 
Artificial culture conditions, potential use of 
animal-derived culture media 
Altered cellular phenotype, contamination, 
disease transmission 
Laboratory expertise, accreditation and 
licensing, personnel, specialist equipment 
Considerable capital expense 
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Attempts to overcome some of these hurdles include the development of bioreactors, 
which allow continuous culture perfusion and increase mass transport to mitigate the 
diffusion limitation during the cultivation of clinically-sized tissue engineering constructs 
(Koller et al. 1993). Serum-free bioreactor models have demonstrated some efficacy, 
but non-homogenous distribution of cells on scaffolds and cellular ‘wash-out’ due to 
turbulent  flow  of  media  has  hindered  clinical  application  (Zhang  et  al.  2012). 
Consequently  attempts  have  been  made  to  identify  alternative  cell  concentration 
strategies. 
 
 
Fig. 2.1  Biaxial bioreactor used for bone tissue engineering. It is designed to rotate around 
two perpendicular axes simultaneously, with continuous media perfusion occurring between the 
culture vessel and a medium reservoir. From Zhang et al. 2012. 
 
 
2.1.3.2 Centrifugation 
Density gradient centrifuge-based devices are the most commonly used systems that 
rapidly and effectively concentrate the nucleated cell content of BMA for operative use 
(Jäger et al. 2011, Hernigou et al. 2005b, Hernigou et al. 2006, Hernigou et al. 2009). 
Following  concentration,  cells  are  either  applied  directly  to  the  operative  site,  or 
infiltrated  into  a  scaffold.  Current  products  include  the  Res-Q™  Bone  Marrow 
Concentration (BMC) System (Thermogenesis, Rancho Cordova, USA), Marrowstim™ 
(Biomet Biologics Inc, Indiana, USA) and Bone Marrow Aspirate Concentrate (BMAC) 
SmartPrep2™ (Harvest Technologies Corp., Plymouth, USA), which have been used 
for  a  wide  range  of  orthopaedic,  maxillofacial,  soft  tissue  and  cardiovascular 
applications (Hernigou et al. 2005b, Badiavas et al. 2003, Rougraff and Kling 2002). 73 
 
 
Although  cellular  enrichment  can  be  achieved  within  the  time-constraints  of  most 
operations, it involves the removal of aspirated marrow from the sterile operative field 
for  processing, significant  capital equipment expenditure and a risk of donor cross-
contamination (Ridgway et al. 2010). 
 
 
 
Fig. 2.2  Commercially available density-gradient centrifugation devices for enrichment 
of BMA. a) Biomet Marrowstim™ centrifugation unit, b) Disposable Marrowstim™ concentration 
tube  following  centrifugation,  demonstrating  layers  of  cell  poor  plasma  (top),  nucleated  cell 
concentrate (middle), erythrocytes (bottom), c) Harvest BMAC SmartPrep2™ centrifugation unit, 
d) Thermogenesis Res-Q™ BMC module. Images a) and b) from www.biomet.co.uk, c) from 
www.harvesttech.com and d) from www.thermogenesis.com. 
 
 
2.1.3.3 Gradient separation 
Gradient separation techniques are frequently employed to isolate cells for diagnostic 
purposes and require addition of a graded density solution such as Ficoll or sucrose 
(Hunter et al. 1987). Although this technique has been shown to separate cells with 
reasonable sensitivity and specificity, the process is time consuming and addition of 
graded solutions is likely to interfere with clinical use. 
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2.1.3.4 Field-assisted separation 
Cells,  bio-macromolecules  and  micro-organisms  have  been  successfully  separated 
using  various  field-assisted  techniques,  including  electric,  magnetic  and  acoustic 
phenomena (Karumanchi et al. 2002). These processes have largely been limited to 
laboratory use as they are complex, rely on constant adjustment and tuning to maintain 
effectiveness  and  tend  to  operate  on  a  small-volume  scale.  Consequently,  direct 
transference  of  these  techniques  to  large-scale  clinical  application  has  not  been 
forthcoming. 
 
 
2.1.3.5 Selective cell retention 
Several animal studies have successfully used selective cell retention as a method of 
seeding  scaffolds  with  enriched  BMA  prior  to  implantation  (Muschler  et  al.  2005, 
Brodke  et  al.  2006). The technique relies on the principles of an affinity column to 
populate a porous matrix with a high proportion of SSCs found in bone marrow by 
establishing  a  controlled  flow  of  aspirate  through  the  scaffold.  The  nucleated  cells 
attach  to  the  matrix  while  haematopoietic  cells  pass  through,  resulting  in  a  graft 
material that contains an increased concentration of SSCs. Although studies report a 
higher  union  rate  in  animal  models  using  this  technique,  the  fold  enrichment  of 
nucleated cells produced (up to 3-fold) is unlikely to have therapeutic benefit in the 
human clinical scenario. 
 
 
2.1.3.6 Filtration 
Various filtration techniques have been successfully used to separate mammalian cells 
including spin filters, vibrating and rotating disc filters, cross-flow micro-filter devices 
and controlled shear filtration (Ridgway et al. 2010). In this study, a combination of 
negative pressure-assisted filtration and acoustic vibration has been evaluated, as a 
technique  to  separate  cells  by  size  to  provide  therapeutic  enrichment  of  the  SSC 
fraction of human BMA. 75 
 
2.2  Aims 
 
The aim of this study was to demonstrate the potential to efficiently concentrate the 
nucleated fraction of BMA, obtained from a clinically relevant elderly cohort, adopting 
an approach to cell filtration applicable within the sterile field of an operating theatre 
(Ridgway  et  al.  2010).  A  further  aim  was  to  demonstrate  the  significance  of  cell 
enrichment for osteogenic and chondrogenic cell differentiation, and seeding efficiency 
onto allogeneic bone graft. 
 
 
 
2.3  Null hypotheses 
 
1.  Negative  pressure-assisted  filtration  does  not  significantly  enhance  the 
concentration of SSCs in human BMA. 
 
2.  Enrichment  of  SSCs  in  human  BMA  by  negative  pressure-assisted  filtration 
does not enhance osteogenic and chondrogenic cell differentiation and seeding 
efficiency onto allogeneic bone graft. 
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2.4  Materials and methods 
 
2.4.1  Patient selection 
 
Volunteers were selected from haematologically normal patients undergoing primary 
Total Hip Replacement (THR). Exclusion criteria were pre-existing conditions that may 
have  confounding  effects  on  cellular  activity:  a  history  of  Paget’s  disease  of  bone; 
malignancy; infection; clotting disorders; osteogenesis imperfecta; rheumatoid arthritis; 
avascular necrosis of the femoral head; long term bisphosphonate or glucocorticoid 
therapy, and known transmissible disease (e.g. hepatitis, HIV, malaria) or sickle cell 
disease. Patients provided fully informed consent after receiving a lay summary of the 
trial,  together  with  a  verbal  explanation  and  an  opportunity  for  questioning.  Ethical 
approval of the study was obtained locally (LREC194/99/1) and regionally (Research 
Ethics Committee 09/H0505/5). Medicines and Healthcare products Regulatory Agency 
(MHRA) registration was unnecessary at this stage as the device was not being used 
for direct therapeutic intervention. 
 
 
2.4.2  Bone marrow harvest from the femoral canal 
 
BMA for in vitro experimentation was harvested as waste tissue from the femoral canal 
during THR surgery (Fig. 2.3A). Prior to aspiration of bone marrow, a 20 ml Luer lock 
syringe containing 5000 IU heparin in 5 ml normal saline was prepared and the needle 
was flushed with heparin. Bone marrow was aspirated from a location proximal to the 
pending  neck  osteotomy  into  the  heparinised  syringe,  then  transferred  to  a  sterile 
universal container for transport from operating theatre to laboratory for filtration. 
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Fig. 2.3  SSC enrichment strategy schematic. (A) Bone marrow aspiration from the femoral 
canal during a total hip replacement (top) and from iliac crest (bottom). (B) BMA enrichment 
process  (projected  to  occur  immediately  following  aspiration  and  within  the  sterile  field  for 
clinical application) (i), BMA is injected into the unit (ii). After passing through a pre-filter to 
remove debris the BMA is applied to a secondary filter (iii) and an acoustic wave applied to 
agitate the sample and ensure an even cell suspension. Negative pressure draws erythrocytes 
and platelets through the filter retaining nucleated cell fraction via size exclusion. (iv) Enriched 
nucleated cells, retained above the filter, are removed for analysis (projected use for therapeutic 
application). (C) Concentrated bone marrow being applied to allogeneic bone graft (allograft) 
prior to bone grafting in the clinical scenario. 
 
 
2.4.3  Operation of the device  
BMA was concentrated via a vacuum assisted filtration approach facilitated by acoustic 
agitation (Figs. 2.3 - 2.5). Filters were manufactured from 23 µm thick polyethylene 
terephthalate (PET) to achieve a range of uniform pore sizes (between 1.2 and 4.1 µm 
diameter) and porosities (between 150,000 and 1.5 million pores/ cm
2) using a track 
etching process (it4ip, Seneffe, Belgium). Acoustic vibration was applied using a voice-
coil  (model  RM-ETNC0033K19C-2KOI,  NXT  Technology,  Cambridge,  UK).  Vacuum 
pressure  was  produced  with  a  6  V  miniature  diaphragm  pump (Kage  KPV14A-GA, 
Taiwan).  78 
 
 
 
Fig. 2.4  Initial  concept  designs  for  the  acoustic  negative-pressure  filtration  product. 
Courtesy of Smith & Nephew 
 
 
Following straining through a 70 μm pore-size pre-filter (Fig. 2.3B ii), BMA samples 
were  applied  to  a  size-exclusion  filter  positioned  above  a  reservoir  of  Phosphate 
Buffered Saline (PBS) (Fig. 2.3B iii). A resonant frequency wave was passed through 
the PBS reservoir, agitating the filter and BMA above it. This produced a geometric 
standing waveform pattern on the aspirate fluid surface. The frequency was manually 
adjusted  as  the  remaining  unconcentrated  volume  reduced,  in  order  to  maintain  a 
standing wave and the resultant stable cell suspension. A negative pressure (25 psi) 
was  applied  from  below  the  filter,  to  preferentially  filter  out  the  smaller  cells 
(erythrocytes (diameter 5-8 μm) and platelets (1-3 μm)), whilst retaining the nucleated 
cell fraction above the filter.  
 
Following filtration, the volume of aspirate remaining above the filter was recovered as 
concentrated BMA for analysis (Fig. 2.3B iv). 2-5 ml of fresh heparinised BMA was set 
aside prior to filtration as unconcentrated control BMA. 79 
 
 
Fig. 2.5  Laboratory  prototype  acoustic  filtration  device  used  to  process  all  BMA 
samples for this study. Final product concept is a single self-contained automated unit.  
 
 
 2.4.4  Filtration time 
 
Filtration was continued to achieve either a minimum 4.0-fold volume reduction, or until 
flow through the filter became laborious. Start and end time-points, starting volume and 
final volume were recorded for each sample filtered.  
 
 
2.4.5  Nucleated cell count and cell viability analysis 
 
Nucleated cell counts of unconcentrated and concentrated BMA were determined on 
15 samples using Guava Easycyte (Millipore Corp., Billerica, USA) flow cytometry and 
confirmed by manual count on a haemocytometer. Guava Viacount Reagent was used 
to differentiate live and  dead cells, and the viable cell count  value  was used in all 
calculations.  Statistical  analysis  was  performed  using  Microsoft  Excel  and  SPSS 
Ver.18 (SPSS Inc, Chicago, IL, USA). 
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2.4.6  CFU-F analysis 
CFU-F assay was used as an indicator of SSC number present in the aspirate pre- and 
post-  filtration  through  the  device,  and  was  performed  on  15  samples.  Following 
determination  of  viable  nucleated  cell  count  using  Guava  Easycyte  flow  cytometry, 
unconcentrated  and  concentrated  BMA  was  seeded  into  T25  culture  flasks  (n=3) 
according to the Friedenstein protocol for density independent growth (Bianco et al. 
2006).  Briefly,  aspirates  were  diluted  in  basal  medium  (αMEM  (Minimum  Essential 
Medium Eagle, Alpha Modification) containing 10% Fetal Calf Serum (FCS)) to achieve 
clonal seeding densities of 1x10
4 and 1x10
5 nucleated cells/ml, strained to ensure a 
single cell suspension, and seeded at 0.2 ml/cm
2. After three hours at 37˚C and 5% 
CO2, plates were washed twice with PBS to remove non-adherent cells and incubated 
at 37˚C and 5% CO2 in basal medium for 14 days. Following fixation in 95% ethanol, 
and staining for Alkaline Phosphatase (ALP) activity against Gill’s haematoxylin nuclear 
counter-stain, colony number was counted and the CFU-F/ml value for each aspirate 
was calculated taking into account the dilution factor required to achieve clonal seeding 
densities. Parallel assays of like-for-like volumes of unconcentrated and concentrated 
BMA were also performed to illustrate differences in CFU-F concentration. 
 
 
2.4.7  Flow cytometric analysis of stem cell markers  
 
Unconcentrated and concentrated BMA were washed in PBS with 1% Bovine Serum 
Albumin (BSA) before being incubated in blocking buffer (PBS, 1% BSA, 10% human 
serum, 5% FCS) at room temperature for 30 minutes. Cells were then immuno-labelled 
with  antibodies  against  STRO-1  (undiluted  culture  supernatant  from  the  STRO-1 
hybridoma  provided  by  Dr  J.  Beresford,  University  of  Bath),  CD146  (1:50,  mouse 
monoclonal  [P1H12],  BD  Pharmingen,  Oxford,  UK)  and  CD105  (1:50,  chicken 
polyclonal,  Abcam,  Cambridge,  UK)  for  60  minutes  at  room  temperature  and  then 
washed  and  incubated  with  fluorescently  labelled  secondary  antibodies  (1:100). 
Labelled populations from each sample were quantified against the relevant isotype 
control using Guava Easycyte flow cytometry. 
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2.4.8  Multi-lineage differentiation of concentrated and unconcentrated cells 
 
Following filtration, equal volumes of unconcentrated and concentrated aspirate were 
seeded across culture vessels and culture expanded for 12 days. After expansion, cells 
(which were at less than 80% confluence) were released with trypsin, counted and 
reseeded,  at  densities  consistent  with  the  fold  difference  in  cell  number  (2.54-fold) 
obtained from expanded concentrated vs. unconcentrated samples, into 12-well plates 
for  osteogenic,  adipogenic  and  chondrogenic  differentiation.  Control  cultures  were 
refreshed with basal medium every 3 days. 
 
Osteogenic culture: After a further 14 days in basal conditions, monolayer cultures of 
concentrated and unconcentrated BMA were transferred to osteogenic media (αMEM 
with  10%  FCS,  100  μM  ascorbate  (ascorbic  acid  2-phosphate)  and  10  nM 
dexamethasone) for 14 days. Media were refreshed every 2-3 days. 
 
Adipogenic culture: After a further 14 days in basal conditions, monolayer cultures of 
concentrated  and  unconcentrated  BMA  were  transferred  to  adipogenic  media 
consisting of basal cell culture media containing additional 2 g/L D-glucose and 0.5 mM 
3-isobutyl-1-methylxanthine,  1  μM  dexamethasone,  1%  ITS  ( Insulin,  human 
Transferrin and sodium Selenite) solution (equal to 10 μg/ml insulin (Sigma-Aldrich, 
Gillingham, UK)), and 100 μM indomethacin, for three days followed by 1 day in basal 
cell culture medium containing 1% ITS solution. Both cycles were repeated for 28 days. 
 
Chondrogenic  culture:  Monolayer  expanded  cells  were  seeded  at  high  density 
(unconcentrated BMA 1.475x10
6 cells/ml; concentrated BMA 3.75x10
6 cells/ml) in 20 µl 
volumes at the centre of each well and following 30 minutes incubation to allow cell-
adhesion, cultured in chondrogenic medium (serum-free αMEM supplemented with 10 
ng/ml TGF-β3, 10 nM dexamethasone, 100 μM ascorbate, and 10 μl/ml 100 × ITS 
Solution) for 21 days. Media were refreshed every 2-3 days. 
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2.4.9  Histological staining and quantification of differentiated cultures   
 
Osteogenic  differentiation  was  determined  using  ALP  histochemical  staining, 
demonstrated with naphthol AS-MX phosphate and Fast Violet B Salts. Relative ALP 
staining  intensity  was  quantified  using  Cell  Profiler  image  analysis  software 
(www.cellprofiler.org). 
 
Adipogenic differentiation was identified by adipocyte accumulation of lipid droplets 
observed under light microscopy using a Zeiss microscope and following staining for 
lipid with Oil Red O histochemistry. In brief, cells were fixed in Baker's formal calcium, 
rinsed  in  60%  isopropanol,  and  stained  using  double-filtered  Oil  Red  O  solution. 
Following imaging, Oil Red O staining was leached from the cells in 100% isopropanol, 
and absorbance measured via spectrophotometry. 
 
Chondrogenic differentiation was determined by staining for proteoglycan with Alcian 
blue. Following imaging, Alcian blue staining was leached using 0.5% Triton X-100 and 
absorbance measured via spectrophotometry. 
 
 
2.4.10  Cell seeding onto decellularised human bone graft 
 
For this part of the study, BMA was filtered through the device to achieve a 7.4-fold 
reduction in volume and a corresponding increase in the concentration of nucleated 
cells was confirmed via flow cytometry. Equal volumes of unconcentrated BMA and 
concentrated BMA were applied to bone graft to assess the affect of concentration of 
BMA on seeding. Two further preparations were applied to bone as controls: 1) a 7.4-
fold reduced volume of  concentrated BMA to  normalise to unconcentrated BMA by 
nucleated  cell  number, and  2)  a  7.4-fold  reduced  volume  of  concentrated  BMA  re-
diluted in PBS to normalise to unconcentrated BMA by both volume and nucleated cell 
number.  Aspirates  were  applied  so  as  to  immerse  approximately  5  mm
3  pieces  of 
decellularised  human  trabecular  bone.  After  incubation  for  18  hours  under  gentle 
agitation, excess BMA was removed and samples were washed twice with PBS before 
being re-immersed in αMEM with 10% FCS. Samples were cultured for a further 48 
hours before cell quantification and viability analysis. 
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2.4.11 WST-1 assay for relative quantification of cell seeding 
 
Following seeding and a 48 hour culture period the extent of cell seeding and growth 
on decellularised human trabecular bone matrix was assessed using the colorimetric 
WST-1  (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium)  assay 
for metabolic activity (Roche, Burgess Hill, UK). Seeded matrices were washed twice 
with PBS, re-immersed in 9% WST-1 reagent and transferred to an incubator. After 2 
hours the absorbance was read at 450 nm on an ELx800 microplate reader (BioTek 
Instruments, Potton, UK). 
 
 
2.4.12  Cell viability and imaging 
 
Prior to fixation, cell cultures were incubated for 45 minutes (37°C and 5% CO2) in the 
presence  of  αMEM  containing  10  µg/ml  CellTracker
™  Green  (CTG,  5-
chloromethylfluorescein diacetate (CMFDA)) and 5 µg/ml Ethidium Homodimer-1 (EH-
1) to label viable and necrotic cells respectively. Cells were then incubated in fresh 
αMEM for a further 45 minutes before fixing in 95% ethanol for 15 minutes. Fluorescent 
imaging was conducted on a Zeiss Axiovert 200 inverted microscope equipped with an 
AxioCam MRm monochrome camera and an X-Cite 120 fluorescence light source. 
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2.5  Results 
 
2.5.1  BMA concentration and SSC enrichment 
 
Femoral BMA sampled from 15 patients from an elderly cohort was concentrated up to 
4-fold with a corresponding enrichment of SSCs (Table 2.3). 
 
Table 2.3  Nucleated cell counts and CFU-F concentrations pre- and post- filtration 
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Pre-filtration  Post-filtration 
Viable NC 
conc. 
(x10
6 cells/ml) 
CFU-F conc. 
(per ml BMA) 
Viable NC 
conc. 
(x10
6 
cells/ml) 
CFU-F conc. 
(per ml BMA) 
F  77  20  2.4  8  6.6  71  13.2  141 
M  75  40  4.7  10  6.1  29  23.8  143 
F  91  18  2.7  29  6.8  89  14.9  198 
F  70  40  4.0  16  27.8  115  89.3  357 
M  70  19  5.2  21  12.5  158  43.7  554 
F  82  20  4.0  15  19.6  116  41.0  611 
F  78  20  4.0  8  16.9  202  78.1  703 
F  75  40  5.5  25  44.8  131  195.8  703 
F  71  40  4.0  20  17.7  215  59.2  977 
F  69  20  4.0  20  14.2  426  52.3  1152 
M  55  40  4.0  20  12.1  317  40.3  1379 
F  89  20  6.0  25  32.4  330  126.0  1418 
M  52  20  4.0  15  18.5  368  61.6  1493 
F  78  40  4.3  15  37.7  2108  95.4  3955 
M  68  20  4.0  25  70.2  1032  234.1  4003 
Mean  27.8  4.2  18.1  22.9  380.3  77.9  1185.8 
SD  10.3  0.9  6.5  17.4  536.9  64.0  1220.9 
Concentrations corrected for BMA dilution with heparin at time of harvest. Samples below the 
double  line  displayed  post-filtration  CFU-F  concentrations  above  the  critical  therapeutic 
threshold of 1000 CFU-F/ml suggested by Hernigou and colleagues (Hernigou et al. 2005a and 
b). M = Male, F = Female, Conc. = concentration, CFU-F = Colony Forming Unit (Fibroblastic), 
BMA = Bone Marrow Aspirate, NC = Nucleated Cell 
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Samples were obtained from five male and ten female patients, with a mean age of 73 
years (range 52-91, SD 10.3). All samples were analysed for nucleated cell number 
and viability, and cultured for CFU-F analysis. No significant difference in filtration time 
or initial nucleated cell count was observed between the sexes or across the age range 
of this elderly cohort. 
 
The 15 freshly obtained samples of BMA were filtered to achieve between a 2- and 6-
fold reduction in volume (mean = 4.2) with an average filtration time of 18.1 minutes. 
Eight samples were filtered to achieve the target 4-fold volume reduction and a further 
five samples were filtered to achieve a volume reduction in excess of 4-fold. 
 
Counts of viable cells following a 2-fold and then 4-fold reduction in volume revealed a 
corresponding  increase  in  the  concentration  of  nucleated  cells  in  the  concentrated 
aspirate relative to both volume and erythrocyte concentration (Fig. 2.6). 
 
 
Fig. 2.6  SSC  enrichment  of  BMA  following  filtration  to  achieve  2-  and  4-fold  volume 
reductions, a corresponding concentration of total NCs relative to erythrocytes/red blood cells 
(RBCs) was observed. Error bars: +/- SD of replicates.   
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An increase in the concentration of CFU-F was also observed (Fig. 2.7). 
 
 
Fig. 2.7  CFU-F  analysis.  Equal  volumes  of  unconcentrated  and  concentrated  BMA  were 
cultured for 14 days and colonies were counted after staining for ALP. In this case, a 3.7-fold 
increase in CFU-F number was observed. 
 
Flow cytometry analysis of commonly used markers for SSCs (STRO-1, CD105 and 
CD146) revealed enrichment of these cells in the concentrated BMA volume (Fig. 2.8) 
 
 
 
Fig. 2.8  Flow  cytometric  analysis  of  BMA,  immuno-labelled  for  markers  associated  with 
SSCs  revealed  a  corresponding  enrichment  in  concentrated  samples.  Error  bars:  +/-  SD  of 
replicates. 
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A viable nucleated cell concentration of mean 3.65 (+/-0.52) was observed following 4-
fold  volume  reduction  (Fig.  2.9A)  indicating  88%  (+/-12.83)  of  nucleated  cells  were 
recovered subsequent to filtration (Fig. 2.9B). An equivalent CFU-F concentration of 
3.88 (+/-1.17) was observed (Fig. 2.9C). When BMA was filtered to achieve >4-fold 
volume reduction a drop in nucleated cell recovery (mean =  68.3% +/-  10.47) was 
observed (Figure 2.9B). 
 
 
 
Fig. 2.9  Analysis  of  cellular  concentration,  viability  and  CFU-F  concentration  with 
respect  to  BMA  concentration  by  volume.  (A)  Across  the  15  samples  a  corresponding 
enrichment of total NCs was observed in relation to the volume filtered. (B) While cell viability 
was maintained during filtration, a reduction in the percentage retention of NCs was observed 
when  samples  were  filtered  to  achieve  >4-fold  reduction  in  volume.  (C)  A  corresponding 
enrichment of CFU-F relative to the aspirate volume filtered was observed.  
 
 
 
2.5.2  Multi-lineage differentiation of concentrated and unconcentrated cells 
 
Following a 2.54-fold concentration of nucleated cells via acoustic-mediated filtration, 
aspirates were seeded at equal volumes and cells expanded before being transferred 
to differentiation conditions to assess the effect of cell concentration on the response to 
multi-lineage induction. After 14 days, cells from concentrated BMA seeded onto tissue 
culture plastic at an equal volume to unconcentrated BMA displayed significantly higher 
ALP activity (P<0.05) in both osteogenic and basal conditions (Fig. 2.10A). 
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Fig. 2.10  Multilineage  induction  of  human  bone  marrow  stromal  cell  cultures  derived 
from concentrated vs. unconcentrated BMA. Following a 2.54-fold concentration, aspirates 
were seeded at equal volumes and cells expanded before being transferred to differentiation 
conditions.  Enhanced  osteogenesis  (A);  ALP  activity;  p<0.05  (*))  and  chondrogenesis  (B); 
proteoglycan; p<0.001 (***)), but reduced adipogenesis (C); lipid; p<0.001 (***)) was observed 
in concentrated samples relative to unconcentrated samples (abs = absorbance). Scale bars: 
100 µm, except upper panel of B (500 µm) and upper panel of C (200 µm). 
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Furthermore,  when cells obtained from concentrated  vs.  unconcentrated BMA  were 
seeded  at  equivalent  cell  concentrations  into  chondrogenic  high-density  culture 
conditions,  significantly  higher  proteoglycan  synthesis  (p<0.001)  was  observed  in 
concentrated  samples  with  negligible  Alcian  blue  staining  for  proteoglycan  being 
observed  in  cultures  derived  from,  and  seeded  at  densities  equivalent  to, 
unconcentrated  BMA  (Fig.  2.10B).  In contrast, under  adipogenic  conditions,  higher-
density seeding facilitated by BMA concentration was observed to significantly reduce 
(p<0.001) the response to adipogenic induction compared with unconcentrated BMA 
(Fig. 2.10C).  
 
 
2.5.3 Cell seeding onto decellularised human trabecular bone graft 
 
To assess the effect of concentration of BMA on the seeding efficiency of adherent 
cells  onto  allogeneic  bone  graft,  25  ml  of  freshly  obtained  aspirate  was  filtered  to 
achieve a 7.4-fold reduction in volume. Total nucleated cell counts revealed a 7.2-fold 
concentration  of  nucleated  cells  with  97.8%  viability  corresponding  to  95.1%  viable 
nucleated  cell  retention  efficiency.  Equal  volumes  of  concentrated  (Conc.vol.)  and 
unconcentrated  (Unconc.)  BMA  were  seeded  onto  decellularised  human  trabecular 
bone  and,  following  culture,  assessed for  relative  seeding  efficiency  via  imaging of 
viable cells and an assay for relative metabolic activity (Fig. 2.11A). To control for the 
various possible factors affecting seeding efficiency, two further control samples were 
prepared: concentrated BMA was added at 7.2-fold reduced volume to normalise for 
cell number and assess for the effect of concentration alone (Conc.cell), and a 7.2-fold 
reduced volume of concentrated BMA was re-diluted in PBS to normalise for volume 
and cell number and assess for the effect of nucleated cell concentration relative to 
erythrocytes  alone  (Conc.cell+vol.).  In  all  cases,  concentrated  BMA  demonstrated 
significantly higher seeding efficiency than the unconcentrated control (Fig. 2.11B and 
C).  Conc.vol.  resulted  in  the  highest  seeding  reflecting  the  increased  number  of 
nucleated  cells  present  in  these  samples,  however  concentration  resulted  in 
significantly  higher  seeding  even  when  normalised  for  cell  number  (Conc.cell  and 
Conc.cell+vol.). That the increase in seeding efficiency was not lost when concentrated 
BMA was re-diluted (Conc.cell+vol.) indicates that the enhanced seeding observed in the 
samples normalised to the control by cell number can be attributed to concentration of 
nucleated cell number relative to erythrocytes.  
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Fig. 2.11  Enhanced cell seeding efficiency via BMA enrichment. BMA was concentrated 
and seeded, at equal volumes, onto allograft (Conc.vol.) to compare seeding efficiency relative to 
unconcentrated  controls  (Unconc.).  In  addition,  concentrated  BMA  was  normalised  to  the 
control  by  NC  number  (Conc.cell)  or  normalised  by  cell  number  and  volume  by  re-dilution 
(Conc.cell+vol.) to assess the effect of concentration apart from cell number and concentration 
relative to erythrocytes respectively (A). In all cases seeding efficiency is significantly higher 
(p<0.001 (***)) when BMA is concentrated, as observed via WST-1 assays for gross metabolic 
activity (B) and CTG staining (C). Scale bars: 200 μm, abs = absorbance. 91 
 
2.6  Discussion 
 
In the current study we assessed the potential of an acoustic-wave facilitated filtration 
technique  to  enrich  BMA  from  an  elderly  patient  cohort  for  the  nucleated  cell 
population,  and  tested  the  hypothesis  that  such  cell  enrichment  enhances  the 
regenerative efficacy of BMA.  
 
This study demonstrated effective volume reduction in BMA from the femoral canal of a 
cohort of elderly patients. Following filtration to achieve a 4-fold reduction in volume, a 
corresponding 3.4-fold enrichment of viable nucleated cells and a 3.9-fold enrichment 
of CFU-Fs was observed (difference not significant), demonstrating this device to be 
effective  for  the  intended  function  of  SSC  enrichment.  Furthermore,  the  average 
filtration  time  of  18  minutes  proved  the  viability  and  practicality  for  intra-operative 
clinical application of the device. 
 
There was a wide variation of CFU-F/ml from the aspirated marrow of this cohort of 
patients (29-2108 CFU-F/ml), though interestingly, a wide range was also seen in a 
young cohort previously tested (710-1440 CFU-F/ml) (unpublished observations:  JN 
Ridgway  and  SJ  Curran,  Smith  &  Nephew  Ltd.,  2010).  These  values  are  also 
consistent with a recent study comparing CFU-F numbers obtained from the iliac crest 
and the femoral canal (Cox et al. 2012). Furthermore dilution of marrow with peripheral 
blood during sampling is also likely to account for some variability (Horn et al. 2008, 
Cuthbert et al. 2012). This may explain the variable outcomes seen in clinical practice, 
and may account for the low CFU-F counts following concentration by centrifugation in 
the seven cases of non-union in Hernigou’s series (Hernigou et al. 2005b). BMA from 
our cohort of elderly patients had a mean of 380 CFU-F/ml, significantly lower than the 
therapeutic threshold of 1000 CFU-F/ml suggested by Hernigou and colleagues.  
 
A phenomenon of age-related decline in CFU-F number has been suggested by some 
authors  (Muschler  et  al.  2001,  Stolzing  et  al.  2008),  although  other  studies  have 
demonstrated  maintenance  of  SSC  number  and  function  with  ageing,  including  in 
osteoarthritic  and  osteoporotic  bone  (D’Ippolito  et  al.  1999,  Stenderup  et  al.  2001, 
Oreffo et al. 1998). Nevertheless, the clinical indication for bone  tissue engineering 
technology is most applicable to the elderly population, and the low CFU-F number 
found in this cohort of elderly patients highlights the pressing need for cell enrichment 
strategies in clinical practice. Enrichment of CFU-F by 3.7-fold over all samples filtered 
increased the mean value in concentrated aspirate to 1185 CFU-F/ml. There was a 92 
 
close correspondence between volume reduction and concentration of viable nucleated 
cell  count  relative  to  both  total  volume  and  erythrocyte  number  indicating  good 
specificity  of  filtration.  Additionally,  enriched  aspirate  contained  significantly  higher 
concentrations per ml aspirate of cells expressing three widely used SSC markers. 
 
Following  on  from  significant  previous  clinical  and  preclinical  studies  indicating  the 
importance of SSC concentration for bone repair (Connolly et al. 1989, Connolly et al. 
1991, Hernigou et al. 2005a and Hernigou et al. 2005b, Jäger et al. 2011, Pittenger et 
al. 1999), we designed two in vitro experiments to probe the regenerative significance 
of  BMA  cell  concentration  by  assessing  the  effect  of  cell  concentration  on  skeletal 
differentiation and seeding efficiency.  
 
Following  culture  in  osteo-,  chondro-  and  adipogenic  differentiation  conditions,  an 
enhanced  osteogenic  and  chondrogenic  response,  but  reduced  adipogenic 
differentiation was observed in concentrated populations compared with populations 
derived from unconcentrated BMA. Interestingly, these significant differences, which 
reflect  differences of initial cell-seeding density between treatments, were observed 
despite a relatively low small fold-difference in cell number (2.54) after the initial phase 
of expansion. These results thus underline the importance of cell concentration for the 
outcome of skeletal regeneration strategies. The importance of higher cell density for 
chondrogenic differentiation is well established, and provides the rationale for micro-
mass  culture  approaches  to  chondrogenic  differentiation  (Pittenger  et  al.  1999, 
Johnstone et al. 1998). The influence of initial cell seeding density on osteogenic and 
adipogenic  differentiation,  however,  remains  controversial  (Jaiswal  et  al.  1997, 
McBeath et al. 2004, Lu et al. 2009, Holy et al. 2000, Lode et al. 2008). The reduced 
adipogenic responsiveness observed in this study may be a function of the increased 
levels  of  ALP  activity,  indicating  early  osteogenesis,  observed  in  basal  cultures  of 
concentrated BMA.  
 
The seeding of cells onto 3D scaffolds and matrices is an important step in many tissue 
engineering approaches. Several recent studies have made use of allograft or allograft 
substitute materials seeded with BMA (Tilley et al. 2006, Jäger et al. 2011, Bolland et 
al. 2006), so the demonstration that cells enriched by the acoustic filtration method 
adhere in greater numbers onto allograft following enrichment is highly significant. In 
the  current  study  we  have  demonstrated  a  significant  enhancement  of  seeding 
efficiency in concentrated BMA over unconcentrated BMA.  Furthermore the current 
studies show that the effect is not only a function of higher nucleated cell number within 93 
 
a given plasma volume (though this is itself an important observation in a technique 
where volume is often a limiting factor), but that seeding efficacy is improved critically 
as  a  function  of  reduced  erythrocytes.  This  is  consistent  with  a  previous  study 
demonstrating the  positive  effect  of  erythrocyte  lysis  on  CFU-F  growth  (Horn  et  al. 
2008) and indicates that even in a situation where cell number is limiting, filtration of 
erythrocytes  is  itself  of  benefit  for  tissue  engineering  strategies  utilising  BMA.  The 
negative impact of erythrocyte number on seeding efficiency may offer an insight into 
why concentration of SSCs is of regenerative significance independent of total number 
of SSCs delivered. 
 
The current study provides evidence for the importance of BMA NC concentration for 
cell  differentiation  and  seeding  of  scaffolds  using  an  approach  designed  to  be 
applicable intra-operatively. There of course remains substantial heterogeneity within 
this  fraction  with  the  CFU-F  population  constituting,  in  this  cohort,  a  mean  of  only 
0.012% (+/-0.013%) of total nucleated cells. Furthermore, well-documented functional 
heterogeneity  exists  within  the  CFU-F  fraction  itself  (Sengers  et  al.  2010,  Phinney 
2012). There is thus considerable scope for further enrichment of SSCs and a large 
body of research is devoted to developing approaches to achieving this. It should be 
noted however that while this and previous studies (Connolly et al. 1989, Connolly et 
al.  1991,  Hernigou  et  al.  2005a  and  b,  Horn  et  al.  2008,  Jäger  et  al.  2011)  have 
indicated  the  importance  of  CFU-F  concentration  for  regenerative  outcome,  the 
increments  of  benefit  derived  from  further  enrichment  steps  are  yet  to  be  defined 
experimentally  in  the  current  context  of  bone  grafting  and  the  relationship  of 
concentration  and  efficacy  is  not  necessarily  straightforward  (Cuomo  et  al.  2009, 
Jayakumar  and  Di  Silvio  2010).  Further  work  is  therefore  required  to  confirm  the 
benefits of further enrichment in balance with the risks inherent in increasingly involved 
processes. 
 
 
In conclusion, the null hypotheses that: ‘negative pressure-assisted filtration does 
not  significantly  enhance  the  concentration  of  SSCs  in  human  BMA’  and 
‘enrichment of SSCs in human BMA by negative pressure-assisted filtration does 
not  enhance  osteogenic  and  chondrogenic  cell  differentiation  and  seeding 
efficiency onto allogeneic bone graft’ can both be rejected. 
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This  study  provides  evidence  for  the  importance  of  BMA  concentration  for  cell 
differentiation and seeding. We have presented an efficient and inexpensive alternative 
to the current clinical intra-operative strategies for administration of concentrated BMA. 
This  solution  to  cell  enrichment  is  amenable for  development  towards  a  single-use 
device  that  can  be  applied  intra-operatively  within  the  sterile  field,  thus  offering 
considerable potential for clinical benefit. 95 
 
 
 
Chapter III 
 
Tantalum Trabecular Metal – Addition of human skeletal 
cells to an established orthopaedic implant to enhance 
bone-implant interface strength and clinical application 
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3.1  Introduction 
 
 
3.1.1 Current clinical strategies for bone stock replacement  
 
Autograft  bone  represents  the  current  favoured  standard  clinical  therapy  for 
replacement  of  lost  or  damaged  bone  stock  in  a  diverse  range  of  musculoskeletal 
pathologies. However, despite excellent osteoconductive and inductive properties, the 
application of autograft is severely restricted due to pragmatic factors associated with 
donor site morbidity and dysfunction, thus only small defects can usually be treated 
(Giannoudis et al. 2005). As a result, allograft has been used as a substitute for over 
30 years despite its reduced osteoinductivity – a consequence of processing to remove 
potential antigenicity. This results in a reparative structure that often heals by fibrosis 
and granulation, and is therefore frequently regarded as a ‘void filler’ rather than a true 
living construct (Ling et al. 1993; van der Donk et al. 2002; van Haaren et al. 2007). 
More recently, the addition of SSC populations to allograft has been demonstrated to 
improve the osteogenic and mechanical properties of allograft  (Bolland  et  al.  2006; 
Bolland et al. 2007; Tilley et al. 2006), with in vivo incorporation and remodelling into 
the existing bone (Aarvold et al. 2011). However, there are major caveats to the use of 
allograft, including: i) cost, ii) structural variability, iii) potential for disease transmission, 
and iv) limited supply, driving the search for synthetic alternatives (Delloye et al. 2007). 
 
 
3.1.2  The rationale for extending the clinical application of tantalum 
 
Despite its current high cost, the clinical use of tantalum in orthopaedic implants has 
recently  undergone  an  expansion,  with  increasing  component  options  and 
configurations for widening applications (Bobyn et al. 2004, Levine et al. 2006, Patil et 
al. 2009). Tantalum, a transition metal element (symbol Ta, atomic number 73) is the 
49
th most abundant element on earth, making up around 1.7 ppm by weight (Singh 
2009). (Fig. 3.1) Currently, it is mined primarily for the electronics industry, and the 
orthopaedic  market  makes  up  only  a  small  percentage  of  tantalum  consumption 
(Maccauro et al. 2009, Buckman 2000). Its main use today is in capacitors and high-
fidelity electronic components, but its ductility, resistance to corrosion and inert nature 
are attractive in a variety of other applications. As such, it has been used safely in 
medical devices and implants for several years, and once it gains more routine clinical 98 
 
use and is mined for the healthcare industry in its own right, the wholesale price of 
tantalum for orthopaedic components is only likely to decrease. 
 
 
 
Fig. 3.1  Elemental tantalum a) after extraction from ore b) following isolation and purification. 
Scale  bars:  10  mm.  Images  from:  a)  http://images-of-elements.com/tantalum.php,  b) 
http://michael5000.blogspot.co.uk/2010/01/januarys-element-of-month-tantalum.html 
 
 
Tantalum  possesses  characteristics  that  confer  great  advantages  over  traditional 
implant materials: it is chemically stable and biocompatible and can be manufactured to 
form  a  trabecular  consistency  similar  to  bone.  The  technology  of  chemical  vapour 
infiltration  and  foam  deposition  onto  a  carbon  skeleton,  has  allowed  Tantalum 
Trabecular  Metal (TTM)  to be manufactured in a  variety of different geometric net-
shapes with a range of pore sizes to suit different applications (Bobyn et al. 1999a, 
Balla et al. 2010a) (Fig. 3.2). Furthermore, despite its high density, in a trabecular form 
tantalum possesses a favourable strength to weight ratio and has superior ductility to 
many  alternative  materials  (Aubry  et  al.  2009,  Shimko  et  al.  2005).  These 
characteristics place it in an excellent position to combine it with regenerative medicine 
techniques for orthopaedic application.  
 
The mechanical properties and established clinical safety of TTM already define this 
material as a useful orthopaedic implant particularly suited to scenarios where local 
bone  density  is  low,  or  in  applications  where  poor  implant  integration  would  be 
envisaged  with  non-porous  alternative  implants  (Flecher  et  al.  2008,  Gross  and 
Goodman  2005,  Lachiewicz  and  Soileau  2010).  Excellent  bone  in-growth 
characteristics have been demonstrated in human and animal models (Bobyn et al. 99 
 
1999b, Boscainos et al. 2007, Nehme et al. 2004) and it does not display some of the 
major  disadvantages  of  allograft.  However,  current  TTM  implants  rely  on  an 
interference fit into stable bone, and are not indicated to provide an immediate stable 
construct  when  bone  stock  is  inadequate  (Bobyn  et  al.  2004,  Patil  et  al.  2009).  In 
applications  where  there  is  poor  initial  implant  stability,  or  when  TTM  is  used  in 
conjunction with bone grafting, loading may need to be limited until sound integration 
has occurred. Such scenarios will become increasingly common, particularly as the 
cohort of patients requiring revision or subsequent re-revision operations of hip and 
knee arthroplasty surgery is destined to increase dramatically over the coming years 
(McNamara  IR  2010).  Although  TTM,  which  is  neither  degradable  nor  capable  of 
remodelling, is not the consummate  substitute for  lost  bone stock, it does possess 
several  advantages  over  allograft  that  justify  the  use  of  pragmatic  techniques  to 
enhance its therapeutic properties. Development of enhanced bone-implant integration 
strategies  will  improve  patient  outcomes,  dramatically  extending  the  clinical 
applications of TTM as a substitute for allograft, particularly in elderly patients who 
have a limited biological reserve and need to be able to weight bear early. 
 
 
 
Fig. 3.2 Trabecular tantalum as supplied by manufacturer a) tibial augments for treating 
bone loss during revision total knee arthroplasty b) magnified image of cut surface of trabecular 
tantalum, demonstrating trabecular conformation and significant porosity. Scale bars: a) 10 mm, 
b) 1 mm. Image a) from http://zimmer.com. 
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3.2  Objectives 
 
Although the interaction of tantalum with human SSCs has previously been reported 
(Findlay et al. 2004, Matsuno et al. 2001, Sagomonyants et al. 2011, Stiehler et al. 
2008),  a  direct  comparison  of  cell  interaction  between  tantalum  in  trabecular 
conformation and current gold standards for skeletal tissue engineering, autograft and 
allograft, has never been undertaken. 
 
This study examines the osteoconductive and inductive capacity of TTM in relation to 
allograft and autograft, to determine the potential of TTM with the addition of human 
skeletal stem cells in tissue engineering applications as an alternative to the current 
accepted standard treatments for loss of skeletal tissues. 
 
 
 
3.3  Null hypothesis 
 
1.  TTM  does  not  support  skeletal  cell  growth  and  osteogenic  differentiation 
comparable to allograft and autograft. 
 
2.  The addition of skeletal stem cells to TTM in vitro does not enhance early bone-
TTM interface strength. 
 
 101 
 
3.4   Materials and methods 
 
3.4.1  Materials 
 
Tissue culture reagents and all staining agents were purchased from Sigma, Aldrich, 
UK unless otherwise stated. CTG and EH-1 were purchased from Molecular Probes, 
Leiden, Netherlands. TTM was kindly donated by Zimmer Ltd., Swindon, UK. 
 
 
3.4.2  Cell culture 
 
Skeletal cell populations (primary passage) were obtained from the bone marrow of 
haematologically  normal  patients  undergoing  primary  total  hip  replacement  at 
University  Hospital  Southampton  with  the  approval  of  the  Local  Research  Ethics 
Committee (LREC 194/99) following informed patient consent, as previously described 
(Bolland et al. 2006). In brief, SSCs were harvested by repeatedly washing the marrow 
in αMEM and removing the washed cell population prior to centrifugation at 1100 rpm 
for 5 minutes at 4ºC. The cell pellet was re-suspended in 10 ml αMEM and passed 
through  a  70  μm  filter.  The  cell  fraction  was  plated  into  tissue  culture  flasks  and 
incubated  in  basal  medium  (αMEM  with  10%  FCS)  at  37ºC  in  5%  CO2.  Cells 
immunoselected using the STRO-1 antibody were isolated by Magnetically Activated 
Cell Sorting (MACS) as described previously (Howard et al. 2002; Stewart et al. 1999). 
Cells  were  washed  in  sterile  phosphate  buffered  saline  (PBS)  and  media  changes 
repeated every 3-4 days. Upon confluence the cells were released using 10% trypsin 
(Lonza, Wokingham, UK), centrifuged and re-suspended in basal medium, and the total 
cell count was determined using a haemocytometer. Specified cell concentrations were 
then seeded onto TTM, allograft or autograft constructs (as described in sections 3.4.6 
and  3.4.8)  and  incubated  in  either  basal  (10%  FCS)  or  osteogenic  (basal  medium 
supplemented  with  100  μM  ascorbate-2-phosphate  and  10  nM  dexamethasone) 
conditions. Control samples were incubated without cells in basal medium. 
 
 
3.4.3  Tantalum preparation 
 
TTM with a porosity of 75-85% was cut with a Buehler IsoMet Low Speed saw using a 
Series 15LC Diamond Wafering Blade (Buehler, Düsseldorf, Germany). Samples were 
then sterilised in 70% ethanol for 2 hours and washed in sterile PBS prior to use. 102 
 
3.4.4  Allograft preparation 
 
Allograft was cut into the specified size and shape from the calcar region of a single 
femoral head, removed during total hip arthroplasty for osteoarthritis. Samples were 
defatted in 2% hydrogen peroxide and washed five times consecutively in sterile PBS. 
 
 
3.4.5  Autograft preparation 
 
Autograft was taken from the calcar region of a second femoral head, removed during 
total hip arthroplasty for osteoarthritis. Samples were kept sterile, and were otherwise 
untreated. 
 
 
3.4.6 Analysis of skeletal cell penetration and viability 
 
Tantalum,  allograft  and  autograft  were  cut  into  3x2x2  mm  cuboids  and  sizes  were 
verified  to  +/-  0.03  mm  using  a  digital  calliper  (RS  Components  Ltd,  Corby,  UK). 
Cuboids  of  each  material  were  cultured  in  pairs  (in  either  basal  or  osteogenic 
conditions) for 28 days on non-tissue culture plastic. Each culture group was seeded 
with either: 5x10
5 unselected SSCs derived from the same patient as the autograft 
samples; 5x10
5 STRO-1 positive cells in osteogenic conditions, from a third patient, or 
no cells (negative controls). After 28 days in culture, cuboids were taken from each 
group  for  live/dead  immunostaining,  cell  proliferation  assays,  deoxyribonucleic  acid 
(DNA) and ALP expression, and for molecular profiling. 
 
 
3.4.6.1 Live/dead immunostaining 
CTG was used to label viable cells (after 14, 28 and 63 days incubation) and EH-1 for 
necrotic  cell  nuclei.  The  samples  were  washed  in  PBS  and  then  incubated  for  90 
minutes  in  1  ml  of  standard  CTG/  EH-1  solution  (10  µg/ml  CTG,  5  µg/ml  EH-1). 
Samples were fixed in ethanol and stored in PBS prior to fluorescence microscopy 
using  a  standard  fluorescein  isothiocyanate  (FITC)  filter  or  for  confocal  microscopy 
using  a  Leica  SP5  Laser  Scanning  Confocal  Microscope  and  software  (Leica 
Microsystems, Wetzlar, Germany). 
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3.4.6.2 Collagen type I and Bone Sialoprotein immunostaining 
Following  incubation,  samples  of  TTM  were  fixed  in  4%  paraformaldehyde  and 
immunostained  with  the  anti-type  I  collagen  (LF-67,  rabbit  polyclonal,  1:300  dil.) 
antibody provided by Dr L Fisher or anti-bone sialoprotein antibody (rabbit polyclonal, 
1:100 dil.) antibody provided by Dr J Sodek. Following incubation with species-specific 
Alexa  Fluor  594-labelled  secondary  antibodies  and  4’,6-diamidino-2-phenylindole 
(DAPI)  nuclear  counterstain,  samples  were  visualised  using  a  Zeiss  Axiovert  200 
inverted microscope (Carl Zeiss Ltd. Welwyn Garden City, UK). Negative controls (i.e. 
omission of the primary antibodies) were included in all immunostaining protocols. 
 
 
3.4.6.3 WST-1 assay 
Cell number and viability were quantified for 3 pairs of cuboids from each culture group 
using the WST-1 assay.  After removal of the incubation medium and washing in PBS, 
750 μl of 1:10 dilution WST-1 substrate (Roche Ltd, Welwyn Garden City, UK) was 
added to each pair. At 4 hours, three 100 µl aliquots of substrate were removed from 
each  well  and  read  in  triplicate  using  a  BioTek  ELx-800  universal  microplate 
spectrophotometer (BioTek, Potton, UK) at a wavelength of 450 nm. An increase in 
absorbance value (i.e. increase in optical density of the substrate) indicated increased 
cell number and viability. Mean and standard deviation were calculated for the optical 
densities of each group and compared to controls. 
 
 
3.4.6.4 DNA assay 
Cell number was determined using a standard DNA PicoGreen
® assay, as previously 
described (Bolland et al., 2006). In brief, scaffolds were washed in PBS and cells were 
released from the scaffold by incubation in collagenase IV (1 mg/ 5 ml medium) for 15 
minutes,  then  10%  trypsin  for  10  minutes,  followed  by  repeated  agitation  and 
centrifugation at 1500 rpm for 10 minutes. After removal of supernatant, the material 
was fixed in 85% ethanol prior to air-drying.  The cells were then rewashed in PBS and 
lysed in 1 ml of 0.5% Triton X-100 before undergoing three freeze-thaw cycles and 
mechanical  lysis.  Cell  lysate  was  measured  for  DNA  content  using  PicoGreen
® 
(Molecular Probes, Paisley, UK) according to routine manufacturer protocol. 10 µl of 
lysate  was  run  in  triplicate  for  each  well  on  a  plate  against  calibrated  standards, 
analysed using a BioTek FLx-800 microplate fluorescent reader. 
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3.4.6.5 Alkaline Phosphatase assay 
ALP activity within the cell lysate was measured using p-nitrophenyl phosphate as the 
substrate in 2-amino-2-methyl-1-propanol alkaline buffer solution (Sigma, Poole, UK) 
according to manufacturer protocol. 10 µl of cell lysate was run in triplicate for each 
well  on  a  plate  against  calibrated  standards,  analysed  using  a  BioTek  ELx-800 
microplate reader. 
 
 
3.4.6.6 Preparation for molecular analysis 
Following incubation, samples were washed, incubated with collagenase, then trypsin 
and total RNA was extracted using Gibco’s method with TRIzol reagent (Invitrogen, 
UK) for molecular analysis. Extracted RNA was subjected to DNase treatment (DNA-
free  RNA  kit,  Zymo  Research,  UK)  and  reverse-transcribed  using  the  Super-Script 
First-strand system for RT-PCR (Reverse Transcription Polymerase Chain Reaction). 
Quantitative  real-time  RT-PCR  (qRT-PCR)  was  performed  using  a  96-well  optical 
reaction  plate  and  a  7500  Real-Time  PCR  system  (Applied  Biosystems,  Carlsbad, 
USA).  Following complementary DNA (cDNA) synthesis, each sample underwent RT-
PCR against a panel of osteogenic gene primers (Table 3.1). Values were calculated 
using  the  comparative  threshold  cycle  (Ct)  method  and  normalised  to  β-actin 
expression. Values were expressed as the mean ± SD and expression was recorded 
relative to unselected SSCs incubated on allograft bone in basal medium. 
 
Table 3.1  Osteogenic gene primer sequences used for RT-PCR 
Primer  Sequence 
Beta actin (housekeeping gene)  β-actin 
F: 5’-GGCATCCTCACCCTGAAGTA  
R: 5’-AGGTGTGGTGCCAGATTTTC 
Alkaline Phosphatase  ALP 
F: 5’-GGAACTCCTGACCCTTGACC  
R: 5’-TCCTGTTCAGCTCGTACTGC 
Collagen type I alpha I  Col1A1 
F: 5’-GAGTGCTGTCCCGTCTGC  
R: 5’-TTTCTTGTTCGGTGGGTG  
Runt-related transcription factor 2  RUNX-2 
F: 5’-GTAGATGGACCTCGGGAACC 
R: 5’-GAGCTGGTCAGAACAAAC 
Sex determining region Y, box 9  SOX-9 
F: 5’-CCCCAACAGATCGCCTACAG 
R: 5’-GAGTTCTGGTCGGTGTAGTC 
F = Forward, R = Reverse. Courtesy of Dr R. Tare, Bone and Joint Research Group, University 
of Southampton 
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3.4.7  Analysis of cellular morphology and penetration 
 
3.4.7.1 Scanning Electron Microscopy 
20x10x10 mm cuboids of TTM were cultured with or without 5x10
5 SSCs for 21 days in 
osteogenic conditions, with regular medium changes. Following incubation, samples 
were fixed whole in 3% glutaraldehyde and 4% formaldehyde in 0.1M PIPES buffer 
(1,4-Piperazinediethanesulfonic acid) at pH 7.2. A post-fixative of 1% osmium tetroxide 
was  applied  before  dehydrating  in  graded  ethanols.  Over  24  hours,  the  specimens 
were embedded in TAAB resin (TAAB Laboratories, Aldermaston, UK) after graded 
acetonitrile-resin steps and polymerised at 60°C. The embedded specimens were then 
sectioned using a Buehler 15LC Diamond Wafering Blade with copious irrigation (Fig. 
3.3). Following dissolution of the resin with sodium ethoxide and 100% ethanol, the cut 
surface  was  silver-coated  and  visualised  with  a  Quanta  200  Scanning  Electron 
Microscope (SEM, FEI, Oregon, USA), to demonstrate the penetration of cells within 
the TTM. 
 
 
Fig. 3.3  Preparation of TTM for Scanning Electron Microscopy, a) following embedding in 
TAAB resin, b) during sectioning with a diamond wafering blade 
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3.4.8 Analysis of mechanical ‘pull-apart’ strength 
 
Multiple  (10x12x1  mm)  sections  of  TTM  and  allograft  were  prepared  and  their 
dimensions  verified  as  described,  before  sterilisation.  Constructs  of  TTM/TTM, 
TTM/allograft or  allograft/allograft were fabricated by sandwiching the two materials 
together in perpendicular directions with a custom-made polyethylene clip, to ensure a 
contact overlap area of precisely 10x10 mm. Test constructs were each seeded with 
5x10
5  SSCs  (passage  2,  from  the  same  patient)  and  incubated  for  9  weeks  in 
osteogenic conditions before removing the clip and performing direct tensile ‘pull-apart’ 
strength  assessment  using  a  Bose  EnduraTEC  ELF3220  mechanical  tester  (Bose, 
Eden Prairie,  Minnesota, USA), with a custom-made jig.  Data were analysed using 
WinTest 2.58 data acquisition software and Matlab v 7.9.0 (Mathworks, Cambridge, 
UK). 
 
 
3.4.9 Statistics  
 
All experiments were run at least three times, with six replicates for mechanical tests, 
statistical analysis was performed using SPSS Ver. 18.0. Statistical comparison was 
made  using  Student’s  unpaired  t-test  with  a  p  value  less  than  0.05  taken  to  be 
significant. 
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3.5  Results 
 
 
3.5.1 Cellular proliferation, viability and immunostaining 
 
Following culture of SSCs on TTM, adherent matrix was readily visible macroscopically 
within 14 days (Fig. 3.4 a) There was no substantial macroscopic difference in cell 
number or adherence between the two media types, and live-dead staining with CTG 
and  EH-1  confirmed  excellent  adherence  of  viable  cells  throughout  the  trabecular 
matrix from an early stage of incubation, with cellular matrix coating the entire surface 
of tantalum (Fig. 3.4 b and c). 
 
 
 
Fig. 3.4  Cellular  proliferation  and  viability  following  culture  with  TTM:  a)  Macroscopic 
appearance of trabecular tantalum after culture with SSCs, abundant cellular matrix is visible 
adhering to the tantalum structure, b) and c) Live–dead staining after culture of: b) unselected 
SSCs in basal medium for 14 days; c) STRO-1 positive cells in osteogenic medium for 14 days; 
note the altered morphology of cells after incubation under osteogenic conditions. Scale bars: a) 
5 mm, b) and c) 200 µm. 
 
 
Cells maintained a flattened fibroblastic phenotype following culture in basal medium, 
however  cells  grown  in  osteogenic  conditions  displayed  an  enhanced  osteoblastic 
morphology, with a pronounced cuboidal appearance (Fig. 3.5). 
 108 
 
 
Fig. 3.5 Live/dead analysis of unselected SSCs grown on TTM: in basal (a) and b)) and 
osteogenic  conditions  (c)  and  d));  cells  grown  in  basal  conditions  retained  a  fibroblastic 
phenotype, whereas osteogenic conditions stimulated phenotypic changes of SSCs to a more 
cuboidal osteoblastic morphology on TTM. Scale bars: a) and c) 200 µm, b) and d) 500 µm. 
 
Confocal  microscopy  following  extended  culture  periods  demonstrated  live  SSCs 
surrounding  a  few  dead  cells  (Fig.  3.6  a).  Cross-sectional  imaging  achieved  by 
confocal microscopy confirmed deep cellular in-growth between trabecula (Fig. 3.6 b). 
 
 
Fig. 3.6  Confocal  microscopy  of  TTM  cultured  with  SSCs  in  osteogenic  medium: 
demonstrating live (green) and dead (red) cell staining; a) just superficial to the tantalum surface 
– the tantalum lattice is visible as a ‘shadow’ in the image; b) deeper within the trabecula of 
tantalum – the cut ‘skeleton’ surface is visible as bright yellow. Note the monopolar direction of 
the cells. Scale bars: 100 µm. 109 
 
Cells within the superficial layer, outside of the trabecular structure of tantalum were 
arranged in a haphazard fashion, but in deeper regions within the trabecula, cells were 
observed to be closely aligned (Fig. 3.7 a-c). 
 
 
Fig. 3.7  Sequential  ‘slices’  of  SSCs  growing  on  TTM:  a)  superficial  to  c)  deep;  b) 
demonstrates the cross-sectional profile of cellular growth on TTM to a depth of approximately 
100 µm, centred upon the cross-hairs; there was deep penetration of live cells into the structure 
with a consistent cytoplasmic alignment. Scale bars: 100 µm 
 
Immunostaining with collagen type I and BSP confirmed abundant ECM adherent to 
the surface and significantly, deep within the trabecular conformation, displaying high 
levels of collagen fibre organisation (Fig. 3.8). 
 
 
Fig. 3.8 Immunocytochemistry of cells cultured on TTM for 63 days: a) and b) Collagen type 
I, d) and e) BSP, c) and f) respective negative controls. Abundant ECM adherent to the surface 
fluoresces with Alexa Fluor 594 (red) and deep within the trabecular conformation, with high 
levels  of  collagen  fibre  organisation.  Multiple  cells  are  demonstrated  by  DAPI  nuclear 
counterstain (blue) throughout the constructs. Scale bars: a, c, d and f = 200 µm, b = 50 µm, e = 
100 µm. 
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Live/dead analysis was also performed following culture of cells on allograft, TTM or 
autograft  after  28  days  in  basal,  osteogenic  or  selected  STRO-1  positive  cells  in 
osteogenic conditions, to obtain a direct comparison between scaffolds (Fig. 3.9). In 
basal medium, cells were almost confluent on allograft (Fig. 3.9 b) but appeared fully 
confluent  throughout  both  TTM  and  autograft  (Fig.  3.9  f  and  j).  When  cultured  in 
osteogenic conditions, fewer cells were visible on allograft compared to either TTM or 
autograft  (Fig.  3.9  c,  g  and  k).  In  addition,  cells  on  allograft  retained  a  fibroblastic 
morphology even when cultured in osteogenic conditions, whereas cells cultured with 
TTM  or  autograft  had  a  cuboidal  morphology.  STRO-1  positive  cells  produced 
abundant ECM, particularly when cultured on TTM in osteogenic conditions (Fig. 3.9 d, 
h and l). 
 
Fig. 3.9  Comparison of live/dead SSCs grown on allograft, TTM or autograft after 28 days 
in basal, osteogenic or selected STRO-1 positive cells under osteogenic conditions. Note that 
there  were  confluent  cells  on  the  control  autograft  (i),  due  to  intrinsic  cellular  activity  and 
proliferation over the culture period (in basal medium), but no live cells on control allograft (a) or 
TTM (e). In basal medium, cells were less dense on allograft (b) but appear entirely confluent 
throughout both TTM (f) and autograft (j). When cultured under osteogenic conditions, there 
were fewer cells visible on allograft (c) compared to the other constructs (g, k); in addition, cells 
on allograft retained a fibroblastic morphology under osteogenic conditions. STRO-1 positive 
cells produced abundant ECM, particularly when cultured on TTM (h). Scale bars: 200 µm 
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3.5.2  Analysis of cell proliferation 
 
Following 28 days culture in basal or osteogenic conditions, proliferation of cells on 
TTM was compared with current clinical standard bone stock replacements, allograft 
and autograft using the WST-1 cell proliferation assay (Fig. 3.10). The autograft control 
showed  relatively  high  proliferation  in  the  absence  of  exogenous  cells,  given  the 
intrinsic cellular activity of untreated autograft, confirmed also by live/dead images (Fig. 
3.9  i).  TTM  supported  an  enhanced  number  of  proliferating  cells  in  comparison  to 
allograft  (p<0.001),  and  similar  numbers  to  autograft  irrespective  of  the  culture 
conditions (p>0.05). In contrast, selected STRO-1 positive cells displayed significantly 
greater  proliferation  within  TTM  than  either  allograft  or  autograft  in  osteogenic 
conditions (p<0.001). 
 
 
Fig. 3.10  Graph comparing cellular activity on allograft, TTM and autograft under basal 
and  osteogenic  conditions  as  measured  by  WST-1  cell  proliferation  assay.  Control 
samples were cultured without additional cells in basal medium. High activity was present in 
control autograft due to intrinsic cellular activity. Error bars are SD, ***p<0.001. 
 
 
3.5.3  Analysis of DNA, ALP and specific ALP Activity 
 
Control autograft displayed significant intrinsic DNA activity, although ALP expression 
in this group was low suggesting minimal osteoinductive stimulus following incubation 
in basal medium (Fig. 3.11 and 3.12). When cultured with unselected SSCs in basal 112 
 
medium, TTM demonstrated significantly greater DNA expression to allograft (p<0.05) 
but no significant difference to autograft (p>0.05). ALP activity on TTM was significantly 
lower than both allograft (p<0.01) and autograft (p<0.001) in these culture conditions, a 
trend reflected in specific ALP activity (Fig. 3.13). Following incubation with unselected 
SSCs in osteogenic conditions, there was no significant difference between allograft 
and TTM for DNA and ALP expression, however the clinical gold standard, autograft 
performed significantly better (p<0.001), supporting enhanced DNA and ALP activity. 
Consequently, specific cellular activity was similar for all groups cultured in osteogenic 
conditions (Fig. 3.13). Furthermore, when selected STRO-1 positive cells were cultured 
with each scaffold in osteogenic conditions, although the trends for DNA activity with 
unselected SSCs were replicated (Fig. 3.11), ALP activity was significantly higher on 
TTM  than  allograft  (p<0.001)  (Fig.  3.12),  confirming  that  TTM  specifically  supports 
selected skeletal progenitor cell proliferation. In addition, STRO-1 positive cells cultured 
in osteogenic conditions displayed significantly enhanced specific ALP activity in the 
TTM group compared with both allograft (p<0.01) and autograft (p<0.05) (Fig. 3.13). 
 
 
 
Fig. 3.11  Graph comparing cellular DNA activity on allograft, TTM and autograft under 
basal and osteogenic conditions. Control samples were cultured without additional cells in 
basal medium, although some activity was present in control allograft, due to residual cellular 
material following washing, and high activity was present in control autograft due to intrinsic 
cellular activity. Error bars are SD, *p < 0.05, ***p < 0.001. 
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Fig. 3.12 Graph  comparing  cellular  ALP  activity  on  allograft,  TTM  and  autograft  under 
basal and osteogenic conditions. Control samples were cultured without additional cells in 
basal medium, although some activity was present in control allograft, due to residual cellular 
material following washing, and high activity was present in control  autograft due to intrinsic 
cellular activity. Error bars are SD, **p < 0.01, ***p < 0.001. 
 
 
 
Fig. 3.13  Graph comparing specific cellular ALP activity on allograft, TTM and autograft 
under  basal  and  osteogenic  conditions.  STRO-1  positive  cells  cultured  in  osteogenic 
conditions,  displayed  significantly  enhanced  specific  ALP  activity  in  the  TTM  group  to  both 
allograft (p<0.01) and autograft (p<0.05). Error bars are SD, *p < 0.05, **p < 0.01. 114 
 
3.5.4  Molecular analysis 
 
Molecular expression of allograft, autograft and TTM were compared for a panel of 
osteogenic genes following culture in basal and osteogenic conditions (Fig. 3.14). 
 
Fig. 3.14  Molecular expression of a panel of osteogenic genes of interest. All values are 
expressed relative to β-actin expression of unselected SSCs incubated on allograft in basal 
medium: a) ALP expression was highest in STRO-positive and unselected cells grown under 
osteogenic conditions on autograft. Although there was minimal ALP expression on both TTM 
and  autograft  in  basal  conditions,  after  osteogenic  stimulation,  TTM  supported  similar  ALP 
expression to allograft; b) Col1A1 expression of unselected cells in TTM was similar to allograft 
and  autograft  in  both  basal  and  osteogenic  conditions,  although  when  cultured  with  STRO-
positive  cells,  expression  of  Col1A1  on  TTM  was  significantly  higher  than  allograft  and  not 
significantly different to autograft. There was no significant difference in expression of RUNX-2 
(c) or SOX-9 (d) on any scaffold under osteogenic conditions with either cell type; however, 
there  was  a  trend  under  osteogenic  conditions  for  TTM  to  support  higher  osteogenic  gene 
expression than allograft. Error bars are SD, *p < 0.05, **p < 0.01, ***p < 0.001 
 
ALP  expression  was  highest  in  STRO-1  positive  and  unselected  cells  grown  in 
osteogenic conditions on autograft. Although there was minimal ALP expression on 
both  TTM  and  autograft  in  basal  conditions,  following  osteogenic  stimulation,  TTM 
supported  similar  ALP  expression  to  allograft  (Fig.  3.14  a).  Col1A1  expression  of 115 
 
unselected cells in TTM was comparable to allograft and autograft in both basal and 
osteogenic  conditions,  although  following  culture  with  STRO-1  positive  cells, 
expression  of  Col1A1  on  TTM  was  significantly  higher  than  allograft,  and  not 
significantly different to autograft. There was no significant difference in expression of 
RUNX-2  or  SOX-9  on  any  scaffold  in  osteogenic  conditions  with  either  cell  type. 
Interestingly, there was a trend, in osteogenic culture conditions, for TTM to support 
higher osteogenic gene expression than allograft. 
 
 
3.5.5 Analysis of cellular morphology and penetration 
 
SEM  of  control  (cultured  in  osteogenic  media,  processed  and  embedded  but  not 
seeded with cells) TTM revealed a regular trabecular structure (Fig. 3.15). The carbon 
framework was visible within the cut end-on trabecula, and high magnification revealed 
a crystalline deposition of tantalum (Fig. 3.15 c). 
 
 
Fig. 3.15  SEM images of control TTM section, showing a) cut surface with intact trabecular 
structure,  b)  Magnified  view  of  boxed  area,  c)  Further  magnified  view  (boxed  area  in  b) 
demonstrating crystalline surface of tantalum. Scale bars: a) 500 µm, b) 100 µm, c) 2 µm. 
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Following culture for three weeks, SSCs were observed tightly adherent to the TTM 
surfaces,  with  projecting  cell  membranes  and  early  matrix  deposition  (Fig.  3.16  a). 
SSCs were observed throughout the TTM, indicating sufficient nutrient delivery and 
osteogenic stimulation (Fig. 3.16 b and c). Furthermore, the cuboidal phenotype of cells 
was retained, even at depths of 1 cm (Fig. 3.16 c). 
 
 
Fig. 3.16 SEM image of TTM cultured with SSCs for 3 weeks: a) demonstrates a section 5 
mm deep,  with multiple cells and matrix almost obscuring the underlying  tantalum; b in the 
deeper zones (approximately 750 µm), there are fewer cells, but they maintain interconnecting 
projections;  c)  The  cuboidal  morphology  of  cells  was  maintained  even  at  1  cm  depth, 
suggesting adequate nutrient delivery and osteogenic stimuli. 
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3.5.6  Mechanical ‘pull-apart’ strength 
 
The three different acellular control constructs all displayed low tensile properties, and 
they did not differ significantly (maximum pull-apart stress of less than 0.02 N/m
2). All 
constructs cultured with cells for 9 weeks displayed a significantly greater ‘pull-apart’ 
strength  than  acellular  controls  (p<0.05,  4.91x10
3  N/m
2  for  allograft/allograft  (SD 
1.79x10
3),  7.52x10
3  N/m
2  for  TTM/allograft  (SD  4.00x10
3)  and  1.02x10
4  N/m
2  for 
TTM/TTM (SD 5.32x10
3)). Although there was no significant difference between cellular 
allograft or TTM constructs, there was a trend to greater strength with TTM (an effect 
over and above any surface friction effects) (Fig. 3.17). 
 
 
 
 
Fig. 3.17  Maximum mechanical ‘pull-apart’ stress for the different cellular constructs, 
cultured in osteogenic conditions for 9 weeks, in comparison to acellular controls. There is a 
significant increase in pull-apart strength for all cellular constructs (p<0.01) when compared to 
acellular controls. Although there is a trend towards increasing pull-apart strength in constructs 
containing TTM, this was not statistically significant. Error bars are SD, **p < 0.01. 
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3.6  Discussion 
 
Recent research into skeletal tissue regeneration has centred upon the application of a 
structural, osteoconductive material combined with factors to enhance osteoinductive 
properties (Smith et al. 2011). However, the quest for suitable alternatives to biological 
materials  for  skeletal  reconstruction  has  been  complicated  by  the  requirement  for 
regulatory approval of any putative novel material before clinical implantation. 
 
Following encouraging biocompatibility and osteogenesis assessments, the clinical use 
of tantalum in orthopaedic implants has recently undergone an expansion (Bobyn et al. 
2004,  Levine  et  al.  2006,  Patil  et  al.  2009).  Despite  the  high  cost  of  tantalum, 
increasing component options and configurations are becoming available for widening 
applications. Particular advantages are conferred by the technology of chemical vapour 
infiltration and foam deposition onto a carbon skeleton, which has allowed TTM to be 
manufactured in a variety of different geometric net-shapes with a range of pore sizes 
to suit different applications (Balla et al. 2010; Bobyn et al. 1999a). The porosity of TTM 
used in this study was 75-85%, consistent with that of human cancellous bone (Shimko 
et  al.  2005).  Consequently,  normalisation  of  each  experimental  group  to  volume 
resulted in approximately identical surface areas for cellular adherence and growth. 
The physical bulk and composition of TTM make it an attractive alternative to allograft, 
which has poor inherent structural properties amongst other drawbacks. Furthermore, 
tantalum forms a stable surface oxidation layer by self-passivation (Levine et al. 2006). 
 
Our results confirmed excellent adherence and proliferation of SSCs on TTM in basal 
and osteogenic conditions, with deep penetration of viable cells visible on confocal and 
SEM beyond 5 mm depth, indicating the macro-porous three-dimensional structure is 
appropriate  for  cellular  proliferation.  Osteogenic  stimulation  resulted  in  a  cuboidal 
cellular phenotype, consistent with increased expression of ALP both at a molecular 
and  biochemical  level.  The  ordered  arrangement  of  cells  grown  on  TTM,  seen  on 
confocal  microscopy  (Fig.  3.6  and  3.7  b  and  c)  is  not  a  feature  of  cells  grown  on 
allograft or a number of other scaffolds and only cells in close contact with the metal 
surface  exhibited  this  arrangement.  It  is  unclear  whether  the  effect  is  mediated  by 
chemical  signals,  surface  nanotopography  or  macroporous  effects,  however,  the 
presence of the metal in itself appears to act as a co-ordinating marker for cellular 
growth and positioning, and it may be possible in future to modulate the properties of 
TTM to enhance this property (Dalby et al. 2007; McMurray et al. 2011; McNamara LE 
et al. 2010). In addition to cellular proliferation, this study has demonstrated abundant, 119 
 
organised ECM production (Fig. 3.4 a, 3.8, 3.9), which is a prerequisite for early shear 
and tensile strength in the clinical scenario. 
 
Direct comparisons of SSC proliferation on TTM and those cultured on autograft and 
allograft,  confirmed  the  potential  of  TTM  to  support  cellular  proliferation  to  levels 
comparable with allograft in all culture conditions,  similar to autograft in osteogenic 
conditions. Although TTM did not enhance osteogenic differentiation of cells in basal 
conditions,  ALP  assays  and  molecular  profiling  demonstrated  robust  osteogenic 
differentiation when stimulated with osteogenic medium. 
 
Mechanical testing confirmed that the addition of SSCs to TTM constructs significantly 
enhances the interface strength of the construct, and is in keeping with the exuberant 
production of ECM seen in cultured samples. It should be noted that this analysis is 
only a model of the clinical scenario and cannot replicate exactly the processes found 
in vivo. Clinical failure of a TTM component may be due to several factors, including 
different loading modes, such as shear, however we chose to measure only direct ‘pull-
apart’ strength because no account was then needed of the frictional effects of TTM at 
the  metal-bone  interface.  This  provides  an  assessment  of  the  direct  cellular 
contribution to the construct’s strength in the early stages after implantation, allowing a 
direct  comparison  to  allograft.  Moreover,  the  addition  of  appropriate  temporally-
controlled factors to the TTM construct to encourage angiogenesis and mineralisation 
may further enhance these properties. 
 
In 1999, Bobyn et al. showed bone in-growth and enhanced osseointegration of TTM at 
intervals of up to 52 weeks in a transcortical canine model (Bobyn et al. 1999a). The 
authors also reported bone in-growth of 0.2 to 2 mm in canine acetabular tantalum 
components at 6 months (Bobyn et al. 1999b). Primary stability is always necessary in 
clinical orthopaedic use, and if an interference fit is not present at initial operation, 
additional techniques such as the use of cement, autograft or allograft, may be required 
(Flecher et al. 2010, Nabavi and Field 2009). Although the surface consistency of TTM 
displays a high coefficient of friction with bone, and its porosity promotes long-term 
tissue  integration,  any  technique  to  expedite  this  process  will  be  beneficial  to  the 
patient (Deglurkar et al. 2007; Hacking et al. 2000). 
 
In 2004, Findlay et al. found no difference in osteoblast growth rates, gene expression, 
cell  adherence  or  morphology  between  polished  or  textured  tantalum  discs  in  vitro 
versus tissue culture plastic (Findlay et al. 2004). They concluded that tantalum with 120 
 
either  a  smooth  or  a  microtextured  surface  treatment  supports  human  osteoblast 
growth  and  differentiation  in  this  two-dimensional  model.  In  a  further  study, 
immortalised human mesenchymal stem cells cultured on smooth titanium, tantalum 
and chromium surfaces showed the same capacity for proliferation, and osteogenic 
differentiation  (Stiehler  et  al.  2008). Welldon  et  al.  compared  the  growth  of  human 
osteoblasts on three-dimensional TTM with tissue culture plastic, concluding that TTM 
is suitable for osteoblast growth and differentiation and may enhance mineralisation 
(Welldon  et  al.  2008). Further, TTM  was superior  to both tissue-culture plastic and 
titanium  fibre  mesh  in  stimulating  bone  formation  in  human  osteoblast  cultures  of 
elderly  patients,  a  particularly  relevant  finding  in  view  of  the  ageing  demographic 
(Sagomonyants et al. 2011). However, it is not yet understood whether this effect is 
brought  about  by  the  specific  physicochemical  properties  of  the  material,  its  three-
dimensional  structure,  or  both.  The  present  study  takes  account  of  the  three-
dimensional structure of TTM and its high porosity, which are important to encourage 
the appropriate fluid-flow characteristics for cellular infiltration and also provide a direct 
comparison with allograft and autograft (Sengers et al. 2009; Shimko et al. 2005).  
 
In  conclusion,  the  null  hypotheses  that:  ‘TTM  does  not  support  skeletal  cell 
growth and osteogenic differentiation comparable to allograft and autograft’ and 
‘the addition of skeletal stem cells to TTM in vitro does not enhance early bone-
TTM interface strength’, can both be rejected. 
 
This  study  demonstrates  the  capacity  of  TTM  to  support  skeletal  cell  growth  and 
osteogenic differentiation and also the enhancement of the mechanical properties of 
TTM attributable to its interaction with SSCs. 
 
These results support the use of TTM in clinical applications with the addition of SSCs 
as an alternative to allograft for tissue engineering osteo-regenerative strategies in the 
context of lost bone stock. Such clinical scenarios will become increasingly common 
given the ageing demographic, the projected rates of revision arthroplasty requiring 
bone stock replacement and the limitations of allograft. Early stage stability is important 
to reduce excessive implant motion and allow subsequent bone formation to provide 
long term integration (Bragdon et al. 1996), and this direct comparison with allogeneic 
and autogenous bone graft demonstrates that the addition of cells to TTM may extend 
the  therapeutic  options  for  TTM.  Evaluation  in  animal  models  and  preparation  for 
clinical translation are planned. 
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Chapter IV 
 
In  vivo  evaluation  of  novel  ternary  polymer  blend 
scaffolds  for  skeletal  tissue  engineering  strategies 
using a murine model 
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4.1  Introduction 
 
The  current  tissue  engineering  paradigm  relies  on  the  optimal  characteristics  and 
performance  of  several  factors  (cells,  scaffolds  and  growth  factors)  that,  when 
combined, interact to create a new living construct (Smith et al. 2011). Of these factors, 
the most modifiable are the biological and mechanical properties of the scaffold. As 
described  in  Chapter  I  (section  1.8),  multiple  possibilities  of  scaffold  material  exist, 
however  the  ideal  scaffold  for  a  mass-produced  regenerative  strategy  would  be 
synthetic, bioresorbable, with a controlled and highly reproducible resorption profile, 
producing non-toxic by-products, whilst maintaining sufficient structural integrity until 
the newly grown host tissue is able to replace or restore the function of the native 
tissue (Leong et al. 2003, Cancedda et al. 2007). In addition, for osteoregenerative 
applications,  biomaterial  scaffolds  are  required  to  mimic  the  3D  ECM  environment, 
providing  short-term  mechanical  stability  along  with  increased  surface  area  for  cell 
migration, adhesion and differentiation as a prequel to new tissue growth (Schultz et al. 
2000). In an ideal scenario, scaffolds should have a 3D porous interconnected network 
structure, with porosity over 60% (Mastrogiacomo et al. 2006) and individual pore sizes 
ranging from submicron to macroscopic (Ma et al. 2010, Moroni et al. 2008), which 
favours  the  maintenance  of  cellular  activity  (Deng  et  al.  2011),  nutrient  exchange 
(Laurencin  et  al.  1999)
  and  bone  function  (Weiner  and  Traub  1992,  Marotti  1993).  
Surface nanotopography and chemistry characteristics are also thought to be pivotal in 
promoting cellular  attachment,  proliferation  and  mineral  deposition  (McMurray  et  al. 
2011).  These  requirements  place  extremely  challenging  demands  on  the  scaffold 
design  process,  which  aims  to  fulfil  each  criterion  without  compromising  another 
(Oreffo et al. 2005). 
 
Polymeric  biomaterials  are  potential  candidates  for  tissue  engineering 
osteoregenerative  strategies  and  are  already  commercially  available  for  use  in 
healthcare,  in  applications  as  diverse  as  drug  delivery  systems,  sutures  and 
orthopaedic fixation devices (Nair and Laurencin 2006, Gunatillake and Adhikari 2003) 
(Table  4.1).  Certain  specific  polymeric  formulations  have  the  advantage  of  clinical 
approval  (EMA  (European  Medicines  Agency)  in  the  EU,  or  FDA  (Food  and  Drug 
Administration)  in  the  US)  and  a  track-record  of  clinical  efficacy  and  safety. 
Consequently,  these  were  prime  candidates  for  initial  assessments  in  regenerative 
medicine functions. 
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Highly  variable  chemical,  mechanical  and  biological  properties  are  displayed  by 
polymer  blends  composed  of  varying  combinations  of  base  polymers  and  as  the 
techniques of scaffold fabrication and manipulation have improved over recent years, 
the  technology  to  manufacture  and  sample  multiple  formulations  with  only  small 
chemical differences for cellular compatibility has become more commonplace. 
 
Table 4.1  Biodegradable  synthetic  polymers  approved  for  clinical  use.  Adapted  from 
information in Gunatillake et al. 2003, Middleton and Tipton 2000, Zippel et al. 2010 
Group  Polymer  Applications 
Polyesters 
Poly(glycolic) acid 
– PGA 
Suture (e.g Dexon by Covidien) 
Fracture fixation (e.g. PGA Smart Pins by Bionx) 
Poly(L)lactic acid 
– PLLA 
Fracture fixation (e.g. PLLA Smart Pins by Bionx) 
Interference screw (e.g. Bio-Interference by Arthrex) 
Suture anchor (e.g. Panalok by Mitek) 
Meniscus repair (e.g. Clearfix meniscal dart by 
Innovasive Devices) 
Poly(DL)lactide 
– PDLLA 
Pre-prosthetic maxillofacial augmentation (e.g. 
Sonic Pins Rx by Gebruder Martin GmbH)  
Poly(lactide-co- 
glycolide) 
– PLGA 
Suture (e.g. Vicryl by Ethicon) 
Fracture fixation (e.g. LactoSorb Screws and Plates 
by Biomet) 
Meniscus repair (e.g. SDsorb Meniscal staple by 
Surgical Dynamics) 
Poly((DL)lactic-co- 
glycolic acid) 
– PDLLA co PGA 
Interference screw (e.g. Biologically Quiet 
Interference Screw by Instrument Makar) 
Suture anchor (e.g. Biologically Quiet 
Biosphere/Mini-Screw by Instrument Makar) 
ACL reconstruction (e.g. Biologically Quiet Staple by 
Instrument Makar) 
Polylactone 
Poly(caprolactone) 
– PCL 
Suture (e.g. Monocryl by Ethicon) 
Polyether-ester 
Poly(dioxanone) 
– PDO 
Fracture fixation (e.g. Orthosorb pin by Johnson & 
Johnson) 
Suture (e.g. PDS by Ethicon) 
Polyglyconate 
Poly(glycolic)acid-co- 
trimethylene carbonate 
– PGA co TMC 
Suture (e.g. Maxon by US Surgical) 
Interference Screw (e.g. Endo-Fix screw by Smith & 
Nephew) 
Suture anchor (e.g. Suretak by Smith & Nephew) 125 
 
The  exact  mechanisms  through  which  cells  interact  with  polymers  are  incompletely 
understood, so the precise characteristics of each final scaffold cannot be predicted 
prior to manufacture (Shin  et al. 2003). Consequently, the search for practical new 
biomaterials  is  characterised  by  a  time-consuming  iterative  process,  whereby  each 
potential new polymer is studied for myriad desired properties, dictated by factors such 
as  cell  growth  kinetics,  scaffold  degradation  rates  and  rheological  suitability. 
Subsequent structural modifications and re-evaluation are indicated until the desired 
material properties are reached (Oreffo et al. 2005). 
 
One of the most promising techniques to overcome these challenges is the use of High 
Throughput (HT) chemical arrays, which allow rapid synthesis and screening of a large 
number  of  chemically  diverse  polymers  by  modifying  specific  parameters.  These 
libraries  can  be  interrogated  for  specific  attributes  including  cell  attachment, 
immobilisation and toxicity, allowing expedient identification of ‘spotted’ of ‘hit’ polymers 
with  promising  attributes  (Tourniaire  et  al.  2006).  This  significantly  enhances  the 
process of tailoring precise scaffold characteristics for specific applications, facilitating 
further experimental and pre-clinical testing of candidate materials for suitability prior to 
regulatory approval. Similar processes can also be used for diagnostic or cell-sorting 
applications, or identification of polymeric substrates for surface modification of tissue 
engineering scaffolds to enhance skeletal cell growth and differentiation (Tare et al. 
2009). 
 
A  recent  study  within  the  Bone  and  Joint  Research  Group,  Southampton  has 
successfully combined this HT approach with microarray techniques as the basis to 
identify  and  evaluate  multiple  promising  polymers  for  a  tissue  engineering  strategy 
(Khan et al. 2010). Candidate polymer blends were synthesised by combining two of 
seven rudimentary homopolymers in 135 unique permutations. The aim of the study 
was  to  produce  a  ‘binary  blend’  polymer  that  displayed  the  positive  biological  and 
physical attributes of the two dissimilar contributory polymers, whilst suppressing the 
negative properties, resulting in an emergent blend with superior characteristics. In this 
study, the ability to function as a non-toxic matrix for cell attachment and growth was 
evaluated using HT strategies with: bone-marrow derived STRO-1 positive SSCs; fetal 
femur-derived skeletal cells; the early osteoblast-like MG63 cell line, and the mature 
osteoblast-like SaOs cell line. Following HT analysis, the ‘hit’ scaffold was fabricated in 
larger quantities and evaluated for its potential in a skeletal regeneration strategy using 
established in vitro and in vivo techniques (Khan et al. 2010). 
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New  techniques  of  polymer  blending  have  enabled  the  fabrication  of  a  further 
generation of ‘ternary blend’ polymers, which aim to take advantage of the combined 
characteristics of three polymers for regenerative approaches (Grande and Carvalho 
2011).  Using  similar  techniques  to  those  employed  in  the  binary  blend  study,  this 
chapter  details  the  evaluation  of  these  ternary  blend  polymers  for  their  utility  as 
scaffolds for skeletal tissue regeneration. 127 
 
4.2  Aims 
 
The aim of this work was to utilise an HT approach to identify, screen and characterise 
candidate ternary blend polymers, capable of stimulating and/ or modulating stem cell 
activity,  for  their  ability  to  function  as  regenerative  matrices.  We  aimed  to  use  the 
results of this to select candidate polymers for further  in vitro and in vivo analysis, 
following  seeding  of  SSCs,  to  assess  their  suitability  for  skeletal  regeneration 
applications. 
 
 
 
4.3  Null hypotheses 
 
1.  Polymeric  ternary  blend  biomaterials  do  not  facilitate  cell-attachment  and 
lineage-differentiation suitable for skeletal regeneration strategies. 
 
2.  Polymeric ternary blend biomaterials do not function as suitable scaffolds for 
skeletal regeneration strategies. 
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4.4  Materials and methods 
 
Polymeric ternary blends were formulated, fabricated and screened using HT analysis, 
by Dr Ferdous Khan at the University of Edinburgh. 
 
 
4.4.1  Materials 
 
Chitosan (CS), polyethylenimine (PEI), agarose (type 1-B), poly(L)lactic acid) (PLLA) 
and  Silane-Prep™  microscope  slides  were  from  Sigma-Aldrich  (Gillingham,  UK). 
Polycaprolactone (PCL), poly(ethylene oxide) (PEO), poly(vinyl acetate) (PVAc) and 
poly(2-hydroxymethyl methacrylate) (PHEMA) were from Scientific Polymer Products 
(Ontario,  USA).  Analytical  grade  chloroform,  glacial  ethanoic  acid,  N-methyl-2-
pyrrolidinone (NMP) and Hoechst-33342 Fluorescent stain were from Thermo Fisher 
Scientific (Loughborough, UK). 
 
 
4.4.2  Ternary polymer blend microarray fabrication 
 
Solvents were used to synthesise 1% w/v polymer solutions as shown in Table 4.2. 
These  seven  rudimentary  homopolymer  solutions  were  blended  into  35  ternary 
combinations. Characterisation of the phase transition behaviour of these combinations 
isolated 19 polymers which formed stable miscible blends with at least three transition 
temperature phases, distinct from the original homopolymers. Each of these 19 ternary 
polymer blends was then fabricated in three different proportions (20:40:40, 50:25:25, 
80:10:10) which were contact-printed onto the 1.2 μm-thick surface film of agarose-
coated Silane-Prep™ slides using a QArray mini printer (Genetix, New Milton, UK) with 
16 aQu solid pins. The printing conditions comprised of 5 stamps per spot, 200 ms 
inking time and 10 ms stamping time, resulting in a typical spot size of 300-400 μm in 
diameter, with a distance of approximately 750 μm between adjacent spots. Multiple 
slides were printed with identical polymer microarrays using this technique to allow six 
replicates, then the slides were dried for 24 hours under vacuum at 40°C and sterilised 
by UV irradiation for 30 minutes prior to cell seeding. 
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Table 4.2  Rudimentary homopolymers and applicable solvents used as the basis for 
fabrication of ternary polymer blends 
Polymer  Chemical formula 
Molecular 
weight (≈) 
Solvent 
Chitosan 
(CS) 
 
300000  2% C2H4O2 
Polyethylenimine 
(PEI)   
750000  NMP 
Poly(L-lactic acid) 
(PLLA) 
 
152000  CHCl3/NMP 
Polycaprolactone 
(PCL) 
 
120000  CHCl3/NMP 
Poly(ethylene oxide) 
(PEO) 
 
100000  CHCl3/NMP 
Poly(vinyl acetate) 
(PVAc) 
 
260000  CHCl3/NMP 
Poly(2-hydroxymethyl 
methacrylate) 
(PHEMA) 
 
300000  NMP 
C2H4O2 = ethanoic (acetic) acid, NMP = N-methyl-2-pyrrolidinone, CHCl3 = chloroform 
 
 
4.4.3  Cell acquisition and isolation 
 
STRO-1 positive SSCs were isolated, using MACS, from the femoral bone marrow of 
haematologically normal individuals undergoing THR surgery, with the approval of the 
Southampton  and  South  West  Hampshire  Local  Regional  Ethics  Committee 
(LREC194/99) (as described in  Chapter III, section 3.4.2). Human fetal SSCs were 
isolated from fetuses (8-11 weeks post-conception) following termination of pregnancy, 
according to guidelines issued by the Polkinghorne Report and with Local Regional 130 
 
Ethics Committee approval. The cells were expanded prior to harvest by monolayer 
culture in basal medium for nine and 12 days respectively. 
 
 
4.4.4  Selection of candidate ternary polymer blends for 3D fabrication 
 
4.4.4.1 Scanning Electron Microscopy 
A  Philips  XL30CPSEM  Scanning  Electron  Microscope  was  used  to  investigate  the 
surface  morphology  of  the  polymer  microarrays.  The  glass  slides  containing  the 
polymer  arrays  were  attached  to  a  specimen  holder  and  sputter-coated  with  gold 
before image capture at 10 kV in a secondary electron imaging mode (Fig. 4.1). 
 
 
Fig. 4.1  SEM images of the array of ternary polymer blends. From Khan et al. 2012 
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4.4.4.2 Cell culture on polymer microarrays 
Each microarray was sterilised prior to cell seeding under ultraviolet (UV) light for 30 
minutes. 1x10
6 STRO-1 positive or fetal SSCs were labelled with CellTracker
™ Green 
(as described in Chapter 2, section 2.4.12). Cell populations were incubated in 1.5 ml 
basal medium on each selected polymer microarray slide for 18 hours (3 microarray 
slides per cell type) at 37°C, 5% CO2 in humidified atmosphere, followed by washing 
with  PBS,  fixing  and  nuclear  counterstaining  with  Hoechst-33342  fluorescent  stain. 
Quantitative analysis of cell adherence was achieved using an automated microscope 
equipped with Pathfinder™ software (IMSTAR S.A., Paris, France) (Fig. 4.2).  
 
Fig. 4.2  Analysis skeletal cell attachment and growth on ternary blend polymer spots: a) 
STRO-1 positive, b) fetal skeletal cells, evaluated as mean number (+/- SD, n=3 for each spot) 
of cells on each polymer spot. From Khan et al. 2012 132 
 
Cell compatibility and binding was then confirmed for each cell type by counting viable 
cells and cell nuclei bound to each polymer spot using the FITC and DAPI channels on 
a Zeiss Axiovert 200 inverted microscope (Fig. 4.3). 
 
Fig. 4.3  Example  of  affinity  analysis  for  STRO-1  positive  cell  adhesion  (FITC)  and 
nuclear  counterstain  (DAPI)  for  three  ternary  polymer  blends:  CS/PVAc/PEI  (50/25/25), 
CS/PVAc/PLLA (50/25/25) and PEI/PHEMA/PCL (50/25/25), with corresponding SEM images 
(right). From Khan et al. 2012 
 
Using the SEM and the cell adherence data, a shortlist of four ternary blend polymers 
was compiled (in order of preference) with the aim of targeting blends that displayed a 
homogeneous porous consistency with good cellular attachment with both cell types: 
 
1. CS/PVAc/PEI 50/25/25 
2. PEI/PHEMA/PCL 50/25/25 
3. CS/PEI/PLLA 50/25/25 
4. CS/PVAc/PLLA 50/25/25 
 
 
4.4.5  Manufacture of selected 3D polymer blend scaffolds 
 
The chosen scaffolds were fabricated using solutions of the homopolymers, each in its 
appropriate solvent (see Table 4.2), by Dr F Khan at the University of Edinburgh. The 
resulting blends were vortexed for 15 minutes before freezing in liquid nitrogen and 
undergoing a freeze-drying process in glass vials until no solvent remained, yielding 133 
 
scaffold  cylinders  (approximately  23  mm  diameter  x  40  mm  height).  Unfortunately, 
despite modifications to the solvent evaporation technique, blend 2 (PEI/PHEMA/PCL 
50/25/25)  was  not  mechanically  stable  in  a  3D  configuration  and  could  not  be 
synthesised in appropriate quantities to yield a homogeneous polymer scaffold, so only 
blends 1,3 and 4 underwent further analysis in vitro. 
 
 
4.4.6  Assessment of 3D scaffold characteristics 
 
Macroscopic  and  microscopic  analysis  was  undertaken  to  ascertain  the  physical 
properties of each 3D scaffold. Multiple discs (4mm diameter x 1.5mm height) were cut 
from the scaffold cylinders using sterile tissue biopsy punches (NHS Supply Chain, 
Alfreton, UK) and placed into the standard solutions used for processing and analysis 
to ensure insolubility and maintenance of a robust structure following these processes 
(as detailed in section 4.4.8). 
 
 
4.4.7  In vitro pilot culture 
 
Blends  1,  3  and  4  underwent  pilot  cell  culture  for  seven  days  to  validate  the 
experimental  technique,  to  confirm  results  of  the  microarray  analysis  of  initial  cell 
adherence and viability, and to ensure maintenance of appropriate scaffold structural 
properties  following  culture.  Following  sterilisation  overnight  by  exposure  to  UV 
irradiation, two discs of each polymer blend were mounted onto 21 gauge needles and 
seeded with 10
7 STRO-1 positive cells in 2 ml of basal medium and gently agitated for 
12  hours.  Subsequently,  one  disc  of  each  polymer  was  incubated  at  37ºC  in  5% 
humidified  atmosphere  in  either  basal  medium  (supplemented  with  10%  FCS)  or 
osteogenic medium (basal medium supplemented with 100 ng/ml rhBMP-2, 100 µM 
ascorbate-2-phosphate and 10 nM dexamethasone) for 7 days with medium changes 
every third day. 5ml of medium was removed from each sample and pH was tested 
using  a  digital  Bench  pH  meter  (Hanna  Instruments,  Bedfordshire,  UK)  to  detect 
potentially harmful acidic breakdown product from the scaffolds. 
 
4.4.7.1 Characterisation of cell activity following in vitro pilot culture 
Following culture, each polymer scaffold was washed in PBS and processed for cell 
viability analysis and ALP staining (described in Chapter 3, sections 3.4.6.1 and 3.4.6.5 
respectively), to assess early cell survival, proliferation and osteogenic activity. 134 
 
4.4.8 Structural analysis of the chosen scaffold 
 
Following  the  above  assessments,  polymer  blend  4  (CS/PVAc/PLLA  50/25/25)  was 
chosen to be fabricated in larger quantities for further  in vitro and in vivo analysis. 
Structural assessment of overall scaffold porosity, pore size and mechanical properties 
was undertaken by Dr F Khan using liquid displacement, SEM and mechanical testing 
respectively (Table 4.3) 
 
 
Table 4.3  Structural properties of the selected polymer blend scaffold (CS/PVAc/PLLA 
50/25/25) 
Density  
(+/-SD) 
g mm
-3 
Porosity 
(+/-SD) 
% 
Pore diameter 
(range) 
µm 
Maximum 
load 
N 
Tensile 
strength 
Pa 
Elongation 
at failure 
% 
Stiffness 
 
N/mm 
43.8 (1.4)  73.6 (5.7)  50-600  1.65  330  9.68  0.83 
 
 
 
4.4.9  In vitro culture and analysis of single selected scaffold 
 
Sterile discs of the single best-performing polymer blend (as indicated by the results of 
prior experiments described above), were mounted onto 21 gauge needles and seeded 
in batches of 5 discs with 5x10
6 STRO-1 positive cells per ml, as previously described 
(section 4.4.7). For this main in vitro experiment, 20 discs were then incubated in basal 
conditions and 20 discs in osteogenic conditions for 28 days, with medium changes 
every third day. A single disc was removed from each group at day seven and day 28 
for cell viability and ALP analysis. The remaining discs were removed on day 28 and 
were  either  fixed  in  4%  paraformaldehyde  for  immunohistochemical  analysis,  or 
prepared for molecular extraction by rinsing in PBS and placing on ice. 
 
4.4.9.1 Immunohistochemical analysis 
Each fixed disc was cut into quarters and the resulting samples were combined and 
split into five groups for immunohistochemical analysis of osteogenic expression with 
five discrete  markers. Initial attempts to section the samples and mount them onto 
slides proved unreliable as some sections did not adhere to the slides and the micro-
architecture of untreated scaffold was distorted by the sectioning process. Therefore 
the fixed  samples  were  carefully  dissected  into four  approximately  equal  sizes  and 135 
 
immersed directly within aliquots of the appropriate solutions containing the respective 
antibody. Only samples incubated in osteogenic conditions underwent this analysis as 
the basal samples were spoiled during the previous process. 1% BSA in PBS was used 
as  the  blocking  buffer  for  5  minutes,  before  application  of  the  appropriate  primary 
antibody,  diluted  in  1%  BSA  in  PBS:  anti-type  I  collagen  (LF-67,  rabbit  polyclonal, 
1:300  dilution)  and  anti-osteonectin  (LF-8,  rabbit  polyclonal,  1:100  dilution)  were 
provided by Dr L Fisher; anti-bone sialoprotein (rabbit polyclonal 1:100 dilution) was 
provided by Dr J Sodek, and anti-osteopontin (rabbit polyclonal, 1:100 dilution) and 
anti-osteocalcin (mouse monoclonal, 1:100 dilution) were from GeneTex Inc. (Irvine, 
California, USA). Samples were incubated overnight at 4ºC prior to rinsing in running 
water and immersion for 5 minutes in each of three wash buffers containing: Trizma 
wash  (12.1  g  50  mM  tris[hydroxymethyl]aminomethane  (Trizma  base,  Sigma),  1  ml 
0.05% polyoxyethylene-sorbitan monolaurate (Tween 20, Sigma), 2 l H2O) and (a) high 
salt (46.7 g NaCl), (b) low salt (17.4 g NaCl) and (c) double concentration Trizma wash 
(0.1 M), adjusted to pH 8.5. Following complete removal of the final wash buffer, 100 µl 
of  appropriate  Alexa  594  fluorochrome-conjugated  secondary  antibody  (monoclonal 
(anti-mouse) diluted 1:50, polyclonal (anti-rabbit) diluted 1:30 in 1% BSA in PBS) was 
applied at room temperature for one hour, before rinsing and incubating with 300 nM 
DAPI nuclear counterstain (Invitrogen, 1:100 dilution with PBS) for 5 minutes. Samples 
were stored in dark conditions at 4ºC before visualisation with confocal microscopy, 
using  a  Leica  SP5  laser  scanning  confocal  microscope  and  software  (Leica 
Microsystems,  Wetzlar,  Germany).  Negative  controls  (i.e.  omission  of  the  primary 
antibodies) were included in all immunostaining protocols. 
 
4.4.9.2 Preparation for molecular analysis 
The remaining discs from each culture group were prepared for molecular extraction. 
Gibco’s TRIzol method was initially employed: following rinsing in PBS, the samples 
were incubated in dilute collagenase IV (100 U/ml in αMEM) for 30 minutes at 37ºC 
and then released with 10% trypsin for five minutes (Lonza, Wokingham, UK). The fluid 
removed  was  centrifuged  at  1000  rpm  for  10  minutes  and  the  supernatant  was 
vortexed briefly and mechanically lysed with TRIzol reagent before snap-freezing at -
80ºC. During this time, the scaffolds were kept on ice and following addition of TRIzol 
onto the scaffolds, any remaining cells were sonicated directly from the scaffolds using 
a sonicator at 100 J for 30 seconds. These samples were snap-frozen alongside the 
initial samples. An alternative method of RNA extraction was also attempted using the 
Qiagen AllPrep DNA/RNA Micro kit (Qiagen, Crawley, UK) following the manufacturer’s 
protocol. 136 
 
 
Upon  defrosting,  RNA  was  isolated  by  phase  separation  in  chloroform  with 
centrifugation at 13000 rpm. The uppermost layer of isolated RNA was precipitated 
using isopropanol with centrifugation at 12000 rpm before extraction of the pellet and 
washing with 75% ethanol with centrifugation at 7500 rpm. The RNA was re-dissolved 
in ultra-pure H2O and nucleic acid concentration and purity were assessed using a 
spectrophotometer (NanoDrop 3300, Wilmington, Delaware, USA). Because the purity 
of RNA was universally assessed as low, RNA cleanup steps were employed as per 
manufacturer’s  instructions,  using  the  DNA-free  RNA  kit  by  Zymo  Research 
(Cambridge  Bioscience,  Cambridge,  UK).  These  steps  comprised  application  of  a 
binding buffer and multiple passes through the zymo-spin column, following addition of 
RNA  preparation  and  RNA  wash  buffer  solutions.  Following  a  further 
spectrophotometric assessment of RNA yield and purity, cDNA was synthesised using 
the Superscript First-Strand cDNA kit (Invitrogen) and Real Time PCR was set up using 
a SYBR
® Green mastermix. qRT-PCR was performed using a 96-well optical reaction 
plate  and  a  7500  Real  Time  PCR  system  (Applied  Biosystems,  Carlsbad,  USA).  
Following  cDNA  synthesis,  each  sample  underwent  RT-PCR  against  a  panel  of 
osteogenic gene primers (Table 4.4). Values were calculated using the comparative 
threshold cycle (Ct) method and normalised to β-actin expression. 
 
Table 4.4 Osteogenic gene primer sequences used for RT-PCR 
Primer  Sequence 
Beta actin (housekeeping gene)  b-actin 
F: 5’-GGCATCCTCACCCTGAAGTA  
R: 5’-AGGTGTGGTGCCAGATTTTC 
Alkaline Phosphatase  ALP 
F: 5’-GGAACTCCTGACCCTTGACC  
R: 5’-TCCTGTTCAGCTCGTACTGC 
Collagen type I alpha I  Col1A1 
F: 5’-GAGTGCTGTCCCGTCTGC  
R: 5’-TTTCTTGTTCGGTGGGTG  
Runt-related transcription factor 2  RUNX-2 
F: 5’-GTAGATGGACCTCGGGAACC 
R: 5’-GAGCTGGTCAGAACAAAC 
Sex determining region Y, box 9  SOX-9 
F: 5’-CCCCAACAGATCGCCTACAG 
R: 5’-GAGTTCTGGTCGGTGTAGTC 
F = Forward, R = Reverse. Courtesy of Dr R. Tare, Bone and Joint Research Group, University 
of Southampton 
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4.4.10  In vivo studies 
 
4.4.10.1  Scaffold preparation prior to implantation 
Discs  of  the  single  best-performing  polymer  blend  were  mounted  onto  21  gauge 
needles,  sterilised  in  antibiotic/antimycotic  solution  overnight,  washed  in  PBS  and 
exposed to UV irradiation for a further 12 hours, before degassing and soaking in basal 
medium overnight. These scaffolds were then seeded overnight in batches of 5 discs 
with  10
7  STRO-1  positive  cells  per  2  ml  of  basal  medium,  as  previously  described 
(section 4.4.7). Similar samples of control scaffold were treated in an identical manner, 
but  were  incubated  without  stem  cells.  In  addition,  silicone  cylinders  of  identical 
dimensions to the polymer discs were prepared and sterilised as above, to act as inert 
spacers and therefore negative controls. 
 
4.4.10.2  Implantation into the murine femoral segmental defect 
This segmental bone defect  allows evaluation  of new bone formation in a clinically 
relevant model. A standard mouse femoral bone defect model was used, with a 5 mm 
femoral diaphyseal segmental osteotomy. This part of the study  was  carried out in 
accordance with the protocol described previously by Kanczler et al. (Kanczler et al. 
2010) 
 
Four  mice in three study groups underwent the procedure: for the control group, a 
critical diaphyseal defect was made in the femur, and stabilised with intramedullary 
fixation, using a silicone disc as a control spacer. The second group underwent the 
same  procedure,  except  with  interposition  of  the  polymer  scaffold  alone  within  the 
defect. The third group received the polymer scaffold that had been seeded with 5x10
6 
STRO positive cells. 
 
MF-1  nu/nu  immunodeficient  mice  were  anaesthetised  intraperitoneally  using  a  1:1 
ratio of Hypnorm (fentanyl/fluanisone) to Hypnovel (midazolam), with dosage adjusted 
to weight. The animals were placed on a thermostatically-controlled blanket and full 
aseptic  technique  was  employed  throughout  each  procedure.  Following  skin 
preparation with chlorhexidine-alcohol solution, an incision was made directly over the 
palpable right femoral shaft and brought proximally over the posterior aspect of the 
right thigh. Careful blunt muscular dissection was used to expose the femoral shaft and 
tendon insertions at the trochanter proximally. The femoral shaft was supported with 
forceps whilst a 23 gauge hypodermic needle was introduced through the trochanter 
into  the  femoral  intramedullary  canal  and  advanced  through  the  supracondylar 138 
 
metaphysis until the tip was visible at the knee. The needle was then gently retracted 
into the proximal femur and a 5 mm mid-femoral shaft osteotomy was created using a 
micro-sagittal  saw,  before  re-inserting  the  needle  through  3  discs  of  test  scaffold 
(incubated  a  priori  in  osteogenic  conditions  with  or  without  SSCs,  as  described  in 
section  4.4.10.1)  or  a  silicone  spacer.  Correct needle  placement  was confirmed  by 
Faxitron  specimen  X-ray  imaging  (MX-20,  Qados  Ltd,  Sandhurst,  UK),  and  careful 
attention was paid to remove loose bone fragments within or around the osteotomy 
site. The ends of each needle were bent, cut and positioned subcutaneously to prevent 
injury  or  irritation  to  the  animals.  Sufficient  angulatory  and  rotational  stability  was 
achieved through the interference fit at the dense trochanteric and supracondylar bone 
to  allow  post-operative  weight-bearing.  The  skin  was  closed  with  non-absorbable 
monofilament  sutures  and  the  wound  site  protected  with  a  permeable  spray  film 
dressing (Opsite spray, Smith & Nephew, London, UK). 
 
After recovery, the animals were monitored on a daily basis for potential complications 
and killed by a Schedule 1 method (carbon dioxide inhalation) at 28 days. 
 
4.4.10.3  Preparation of murine femoral samples 
The entire right femur was disarticulated at the hip and sectioned through the tibia of 
each mouse before careful dissection of superficial tissue layers over the defect site 
(Fig. 4.4) 
 
 
Fig. 4.4  Femoral  specimens  following  harvesting:  a)  medial  and  b)  lateral  views.  The 
intramedullary device is visible; it inserts into the greater trochanter, through the defect site and 
exits through the knee. The disarticulated femoral head is visible in a) (arrow). Scale bar: 1 cm 
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4.4.10.4  Radiographic analysis of bone formation 
Plain radiographic analysis was performed by Faxitron imaging prior to fixation of each 
sample in periodate-lysine-paraformaldehyde (PLP) fixative for 48 hours within a 5 ml 
bijou tube. Quantitative 3D analysis was performed using the X-TEK benchtop 160Xi 
CT scanner for Micro computed tomography (µCT, X-TEK Systems Ltd, Tring, UK), 
equipped with a Hamamatsu C7943 X-ray flat panel sensor (Hamamatsu Photonics, 
Welwyn Garden City, UK). Samples were scanned using a molybdenum target at 100 
kV, 70 µA, with an exposure time of 2134 ms and 1x digital gain. Following successful 
data acquisition and initial image reconstruction of each entire femur with a 15 µm 
voxel  resolution,  the  femora  were  decalcified  in  Tris-EDTA  (0.1  M 
tris(hydroxymethyl)aminomethane- 5% ethylenediaminetetraacetic acid) at pH 7.3, for 4 
weeks, with regular changes of solution and constant agitation. Faxitron imaging was 
undertaken between the third and fourth week to identify adequate decalcification and 
guide the timing of histological processing. 
 
4.4.10.5  CT image analysis 
Following image reconstruction, a constant region of interest with dimensions 5 mm x 5 
mm x length of original defect, was assigned within each femur with reference to the 
Faxitron images acquired at day 0 and 28. The reconstructed images were visualised 
and analysed using Studio Max 1.2.1 software (Volume Graphics GmbH, Heidelberg, 
Germany). Manual thresholds were selected to exclude soft tissue and scaffold, and 
the metal intramedullary needles were digitally  subtracted to quantify bone volume, 
bone surface/ bone volume, bone volume/ total volume, trabecular number, trabecular 
thickness and trabecular spacing. GraphPad Prism software was used for statistical 
analysis. Differences between groups were determined by one-way ANOVA with a post 
hoc Tukey test and were considered to be significantly different if p<0.05. 
 
4.4.10.6  Histological and Immunohistochemical analysis 
Following  decalcification,  samples  were  dehydrated  through  graded  ethanol 
concentrations (50%, 1 hour; 90%, 1 hour; 100%, 1 hour, and 100%, 1 hour), prepared 
with histoclear and embedded in low-melting point paraffin wax using an automated 
Shandon Citadel 2000 tissue processor. The use of chloroform was avoided because 
pilot  experiments  indicated  dissolution  of  the  polymers  occurred  during  prolonged 
exposure. A microtome was used to cut each sample into twenty semi-sequential 6 µm 
sections before mounting onto glass microscope slides. 
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4.4.10.6.1  Histochemical staining 
Sections were brought to room temperature, de-waxed in Histoclear and hydrated with 
graded methanol concentrations (2 x 100% for 2 minutes, 90% for 2 minutes, 70% for 2 
minutes,  50%  for  2  minutes)  and  finally  100%  H2O  for  5  minutes  before  each 
procedure: 
 
- Weigert’s haematoxylin/Alcian blue/ Sirius red (A/S) staining 
Weigert’s haematoxylin (10 g haematoxylin in 1 L methanol left to ripen for four weeks, 
6 g ferric chloride, 500 ml H2O, 5 ml conc. HCl) was applied for 10 minutes prior to 
immersing briefly in acid/alcohol (2% HCl in 50% methanol). Sections were stained in 
Alcian blue (1.5 g Alcian blue 8GX, 300 ml distilled H2O, 3 ml concentrated ethanoic 
(acetic) acid) for 10 minutes, 1% fresh molybdophosphoric acid for 20 minutes, and 
Sirius red (0.3 g Sirius red F3B, 100 ml saturated picric acid, 200 ml distilled H2O) for 
60 minutes. Sections were rinsed thoroughly in water between each stain. Slides were 
dehydrated in methanol and mounted in DPX (Distyrene, Plasticer and Xylene; BDH 
Laboratory Supplies, Poole, UK). 
 
- Goldner’s Trichrome 
Weigert’s haematoxylin was applied for 10 minutes, immersed in acid/alcohol briefly 
and  rinsed  in  water  before  staining  in  Ponceau-fuchsin-azophloxin  solution  for  5 
minutes (composed of 10 ml Ponceau-fuchsin solution (0.75 g Ponceau 2R, 0.25 g acid 
fuchsin with 100 ml dilute ethanoic acid) added to 0.5 g azophloxin with 100 ml dilute 
ethanoic  acid)  and  rinsing  in  1%  ethanoic  acid.  Slides  were  then  stained  in 
phosphomolybdic  acid/  orange  G  solution  for  20  minutes  (composed  of  5  g 
phosphomolybdic  acid,  2  g  Orange  G,  a  single  crystal  of  thymol  (2-isopropyl-5-
methylphenol) dissolved in 500 ml H2O), rinsed in 1% ethanoic acid, before staining 
with light green for 5 minutes and mounting in DPX. 
 
4.4.10.6.2  Immunohistochemical staining 
Immunohistochemical staining  for collagen type I and von Willebrand’s Factor (vWF) 
was performed as described previously in section 4.4.9.1, however due to unavailability 
of the appropriate confocal laser required for fluorescent analysis, visualisation was 
achieved using the avidin/biotin method with peroxidise and 3-amino-9-ethylcarbazole 
(AEC),  which  yielded  a  brown  reaction  product.  Negative  control  samples  were 
included in each staining run, which yielded no evidence of staining. 
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4.5  Results 
 
4.5.1  Physical characteristics of selected blends 
 
Assessment of cell adherence to the polymer blend microarrays was used to select 
candidate scaffolds for larger scale fabrication and the physical characteristics of these 
scaffolds were assessed for suitability as a potential tissue engineering construct: 
 
Blend 1 (CS/PVAc/PEI 50/25/25) – A porous cylinder, approximately 15 mm diameter, 
cream  in  colour  with  a  heterogeneous  structure,  dense  centrally  and  less  dense 
circumferentially, with a fibrous consistency. 
 
Blend 2 (PEI/PHEMA/PCL 50/25/25) – This blend could not be fabricated in sufficient 
quantities and was therefore not assessed further. 
 
Blend 3 (CS/PEI/PLLA 50/25/25) – Fragile, porous incomplete cylinders, with a dark 
cream colour. The material readily disintegrated to form a powder. 
 
Blend  4  (CS/PVAc/PLLA  50/25/25)  –  Rigid,  malleable  bright  white  cylinders 
(approximately 17 mm diameter). Small pores (approximately 50-500 µm diameter), but 
a homogeneous structure throughout. 
 
 
Fig. 4.5  Characteristics of polymer ternary blends as received. Scale bar: 1 cm 142 
 
4.5.2  Solubility/ stability assessment 
 
Characteristics were assessed following immersion of 4 mm diameter discs of each 
ternary  blend  in  various  standard  solvents/solutions  used  for  processing/  analysis 
(Table 4.5). 
 
Table 4.5  Assessment of solubility and stability of each polymer blend. 4 mm diameter 
discs were immersed in standard solvents for 24 hours and 7 days to assess their physical 
stability. 
 
 
 
4.5.3  Seven day in vitro pilot culture 
 
At  the  end  of  the  pilot  culture  period,  cell  viability  analysis  and  ALP  staining  was 
performed (Table 4.6, Figs. 4.6 – 4.8). Analysis of live cells was impeded by intense 
green auto-fluorescence of the polymers and multi-dimensional acquisition (overlaying 
images acquired with different filters) was used in some cases to differentiate polymer 
auto-fluorescence from true cellular activity (Fig. 4.8 f and h). Blend 4 (CS/PVAc/PLLA 
50/25/25) possessed better structural properties than the other two blends tested, and 
was less susceptible to degradation following exposure to solvents (Table 4.5). It did 
however  dissolve  entirely  in  chloroform,  so  alternative  methods  were  employed  to 
embed  the  polymer  for  histological  analyses.  Furthermore,  blend  4  supported 
substantially greater numbers of live cells in both basal and osteogenic conditions in 
the day 7 in vitro culture tests (Fig. 4.6 – 4.8). Therefore, blend 4 was used for further 
in vitro and in vivo analysis. 
 
Blend 
24 hours  7 days 
PBS  90% Ethanol  Histoclear  Chloroform  Basal media 
1 
CS/PVAc/PEI 
No change 
Expanded by 
~ 25% 
No change  No change 
Expanded by 
~ 10%, fragile 
3 
CS/PEI/PLLA 
Expanded 
by ~ 50% 
Dissolved  No change 
Dissolved 
slightly 
Disintegrated 
4 
CS/PVAc/PLLA 
No change  No change  No change 
Dissolved 
entirely 
No change 143 
 
Table 4.6  Analysis of cell viability, ALP staining and pH following pilot 7 day in vitro 
culture of SSCs on each polymer blend 
Blend  Medium  pH  Live/dead result  ALP stain result 
1 
 
CS/PVAc/PEI 
Basal  7.88 
Occasional live cells 
centrally 
Light patchy 
staining throughout 
Osteo  7.94  Multiple live cells  Light staining 
Control  7.95  No cells  No staining 
3 
 
CS/PEI/PLLA 
Basal  7.83 
Live cells throughout 
remaining fragment 
Intense staining 
throughout 
Osteo  7.92  Dissolved  Dissolved 
Control  7.95  Dissolved  No staining 
4 
 
CS/PVAc/PLLA 
Basal  7.91 
Live cells throughout, 
some apoptotic cells 
centrally 
Consistent light 
staining throughout 
Osteo  7.89 
Multiple live cells 
throughout 
Light staining with 
patches of intense 
staining 
Control  7.94  No cells  No staining 
 
 
 
Fig. 4.6  Analysis  of  ALP  staining  and  cell  viability  for  discs  of  ternary  blend  1 
(CS/PVAc/PEI 50/25/25). a) – c) ALP stain and d) – f) Live/dead stain, of polymer incubated 
with no cells (control) and with cells in basal and osteogenic medium respectively. Scale bars: 
500 µm 
 144 
 
 
Fig.  4.7  Analysis  of  ALP  staining  and  cell  viability  for  discs  of  ternary  blend  3 
(CS/PEI/PLLA 50/25/25). a) - c) ALP stain, d) - f) Live/dead stain, of polymer incubated with no 
cells (control) and with cells in basal and osteogenic medium respectively. Scale bars: 500 µm 
 
 
Fig. 4.8  Analysis  of  ALP  staining  and  cell  viability  for  discs  of  ternary  blend  4 
(CS/PVAc/PLLA 50/25/25). a) – c) ALP stain, d) – i) low and high magnification images of 
live/dead  stain,  of  polymer  incubated  with  no  cells  (control)  and  with  cells  in  basal  and 
osteogenic  medium  respectively,  f)  and  h)  are  multidimensional  acquisition  images,  where 
polymer fluoresces blue with the DAPI filter and live cells are green with the FITC filter. Scale 
bars: a) – f) 500 µm, g) – i) 200 µm 145 
 
4.5.4  In vitro analysis of selected polymer scaffold – Blend 4 (CS/PVAc/PLLA 
50/25/25) 
 
4.5.4.1 Analysis of ALP production and cell viability 
Following  culture  in  both  basal  and  osteogenic  conditions,  there  was  evidence  of 
prolific cell growth on the scaffold as demonstrated by confocal microscopy, with early 
osteogenic differentiation on ALP stain, which was enhanced by osteogenic conditions.  
Cell  viability  analysis  demonstrated  live  cells  throughout  the  scaffold matrix  in  both 
basal and osteogenic conditions, and this was confirmed using confocal microscopy. 
 
Fig. 4.9  Analysis  of  ALP  staining  and  cell  viability  for  discs  of  ternary  blend  4 
(CS/PVAc/PLLA 50/25/25) following 28 days in vitro culture. a) – c) ALP stain indicates early 
osteogenic differentiation, particularly in c); d) – f) live/dead analysis demonstrates multiple live 
cells (green) and no dead cells (red); g) – i) Confocal images confirm viable STRO-1 positive 
cells stained with CellTracker
™ Green, with the superimposed auto-fluorescence of the polymer 
matrix using the DAPI filter (blue). Scale bars: a) – c) 500 µm, d) – f) 200 µm, g) – i) 250 µm 
 
 
4.5.4.2 Immunostaining for osteogenic bone-matrix proteins 
Immunostaining  confirmed  the  expression  of  osteogenic  collagenous  and  non-
collagenous bone-matrix proteins (Fig. 4.10). Patterns of expression differed between 
antibodies, with collagen type I staining closely following the ECM of the cells, although 146 
 
other antibodies stained specific (sometimes punctate) regions around the cells. Apart 
from  osteocalcin,  the  cells  produced  all  the  osteogenic  proteins  tested.  This  was 
verified by the absence of staining in all negative controls, visualised using the same 
threshold values (Fig. 4.10 k) and l)). 
 
Fig. 4.10  Immunostaining  for  osteogenic  bone-matrix  proteins  produced  by  STRO-1 
positive cells cultured on ternary blend 4 (CS/PVAc/PLLA 50/25/25) scaffold. Cell nuclei 
are stained with DAPI (green) and each bone-matrix protein is demonstrated by the Alexa 594 
fluorochrome-conjugated  secondary  antibody  (red).  Controls  are  k)  no  cells  but  full 
immunostaining protocol, l) polymer cultured with cells but with primary antibody omitted. Scale 
bars: low power 200 µm, high power and controls 500 µm 147 
 
5.4.4.3 Molecular profiling 
RNA extraction proved unsuccessful despite use of Gibco’s TRIzol extraction method 
with  collagenase  IV,  trypsin,  sonication  and  also  a  proprietary  RNA  extraction  kit 
(Qiagen AllPrep Micro Kit). Spectrophotometric assessment yielded universally poor 
RNA yields and purity ratios even after RNA cleanup steps. cDNA synthesis and RT-
PCR produced amplification plots and Ct values that were not deemed representative 
of  the  cellular  activity  demonstrated  on  the  other  experimental  modalities. 
Consequently, these results have not been presented here, and the reasons for failure 
of molecular profiling on this occasion will be detailed in the discussion.  
 
 
4.5.5  In vivo analysis of Blend 4 (CS/PVAc/PLLA 50/25/25) 
 
4.5.5.1 Radiographic analysis 
The  load-bearing  murine  critical-sized  femoral  defect  model  was  employed  to 
investigate the osteogenic potential of human STRO-1 positive cells seeded on the 
polymer scaffold. 
 
Two-dimensional in vivo digital x-ray images were used to assess the positioning of the 
diaphyseal defect, intramedullary device and scaffold, and to visualise bone formation 
over the study period. In addition, 3D images of the entire femora were generated by 
µCT analysis following 28 days implantation, to evaluate the extent of bone healing in 
femoral defects implanted with cell-seeded scaffolds, scaffolds without cells, or spacers 
(Figs. 4.11 – 4.13). No intra-operative or post-operative deaths occurred during the 
study period. A single intra-operative complication was noted in mouse 6, where the 
intramedullary device was placed outside of the femur distal to the osteotomy site (as 
described in section 4.5.5.1.2). Despite resulting in an unstable construct, the mouse 
showed  no  signs  of  discomfort  and  mobilised  adequately  post-operatively,  and  the 
results were included in the final analysis. No post-operative infections or abrupt weight 
loss occurred during the study period.  
 
4.5.5.1.1  Control samples 
The control samples showed negligible bone regeneration (Fig. 4.11). Bone that was 
present at day 28 also appeared in the day 0 samples as remaining fragments left 
following creation of the osteotomy. The only exception was sample 4, where a bridge 
of new bone does appear to have formed over the incubation period, although even in 
this  sample  no  bone  continuity  is  present.  No  samples  were  excluded  in  further 148 
 
quantitative analysis, although for subsequent µCT analysis, remaining fragments of 
bone seen within the osteotomy site at day 0 were digitally excluded from the analysis 
of all samples. 
 
Sample  Prior to 
osteotomy  Day 0  Day 28  Day 28 (CT) 
1 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
Fig. 4.11  Radiographic analysis of the murine femoral defects at day 0 and day 28 – 
Control samples 1-4, containing a defect with silicone spacer. Scale bar: 3 mm for all images 
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4.5.5.1.2  Polymer alone samples 
Samples containing the polymer scaffold demonstrated more new bone formation when 
compared to control samples. New calcification was appropriately positioned in relation 
to the segmental defect site, with the impression of robust bone formation (Fig. 4.12). 
 
Sample  Prior to 
osteotomy  Day 0  Day 28  Day 28 
(CT) 
5 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
 
 
 
 
8 
 
     
 
 
 
Fig. 4.12  Radiographic analysis of the murine femoral defects at day 0 and day 28 – 
Polymer alone samples 5-8, containing a defect with ternary blend polymer 4. Scale bar: 3 mm 
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Sample  6  displays  a  technical  error  in  intramedullary  device  insertion:  following 
reinsertion of the pin (day 0 Faxitron), it is seen to bypass the distal femur entirely, 
resulting  in  an  unstable  construct.  The  action  of  weight-bearing  appears  to  have 
improved the initial poor angulation; however the macro-movement induced by such an 
unstable construct is likely to have had a negative impact on bone healing at this site. 
Despite  this  shortcoming,  it  was  included  in  the  final  quantitative  analysis  of  bone 
formation as omission would have resulted in a significantly smaller sample group. 
 
 
 
4.5.5.1.3  Polymer + SSCs samples 
Radiographic images of the polymer + SSCs group showed robust new bone tissue 
formation at day 28, with calcified tissue filling the osteotomy site and in several cases 
extending well beyond this region. All samples in this group showed complete bone 
bridging within or around the osteotomy site. In all samples there was also evidence of 
surrounding callus formation and in several specimens there was bone formation at 
ectopic sites not seen in either of the other groups (Fig. 4.13, samples 10 and 11). This 
ectopic bone formation correlates with the position of the scaffold and was interfaced to 
the new bone within the osteotomy site. 151 
 
 
Sample  Prior to 
osteotomy 
Day 0  Day 28  Day 28 (CT) 
9 
 
 
 
 
 
 
 
 
 
10 
 
       
11 
 
       
12 
     
 
 
 
Fig 4.13  Radiographic analysis of the murine femoral defects at day 0 and day 28 – 
Polymer + SSC samples 9-12, containing a defect with ternary blend polymer incubated with 
SSCs. Scale bar: 3 mm for all images 
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4.5.5.2 Analysis of change in femoral length 
Using the faxitron images, the intramedullary device length was measured for each 
specimen  (distance  between  trochanteric  insertion  point  and  distal  exit  point)  to 
compare lengths at day 0 with day 28, this enabled quantification of any compression 
that may have occurred during the incubation period (Fig. 4.14). 
 
 
Fig. 4.14  Changes  in  femoral  length,  measured  before  nail  insertion,  immediately 
following  nail  insertion  (T0),  and  at  day  28  (T28)  after  the  experimental  period.  Mean 
values  +/-  SD  are  indicated.  There  was  no  statistically  significant  difference  in  nail  length 
throughout the experiment. 
 
A mean value was taken for each group, and standard deviations were calculated. The 
mean femoral length before osteotomy was 19.49 mm (SD 2.40), immediately following 
osteotomy was 18.94 mm (SD 1.86) and at the end of the 28 day experimental period 
was 18.41  mm (SD 1.83). Using one way repeated measures ANOVA  (Analysis of 
Variance),  Mauchley’s  test  of  sphericity  was  calculated  at  0.277,  with  an  F-ratio of 
1.675, indicating a very low probability of significant difference. 
 
 
4.5.5.3 Quantitative µCT analysis 
High resolution CT scans of the defect regions implanted with the polymer blend 4 
scaffold at day 28 clearly demonstrated increased bone healing in both scaffold groups 
compared to control samples. The difference between the two scaffold groups was less 
marked, however the visibility of the intramedullary device was reduced in the scaffold 
+ SSCs groups when compared to the polymer alone samples, indicating greater bone 
formation in the former group, obscuring the nail (Fig. 4.15). 153 
 
 
Fig 4.15  Selected  regions  of  interest  within  the  osteotomy  defect  analysed  by 
quantitative µCT after 28 days. The intramedullary device is visible in these specimens, but 
was digitally subtracted prior to quantitative analysis of bone formation. Scale bar: 1 mm, all 
images 
 
To assess bone remodelling, indices of bone histomorphometry were measured from 
the 3D µCT data (Fig. 4.16). A trend towards increased bone volume was observed in 
the defect regions implanted with scaffold alone and with scaffold and SSCs, although 
neither was statistically significantly different from the control. Quantitative analysis of 
bone  volume  (BV)  was  much  lower  in  sample  12  than  any  of  the  other  polymer 
samples, and this in part, accounts for the wide error bars. The ratio of BV/ total volume 
(TV) showed a significant increase in the defect regions implanted with scaffolds alone 
(8.9 +/- 2.3) compared to controls (3.9 +/- 1.3), although the addition of SSCs to the 
scaffold  did  not  enhance  this  significantly  (10.2  +/-  1.6).  Examination  of  trabecular 
number showed a significantly increased density within defect regions associated with 
the scaffold + SSCs group (4.2 +/- 0.4) and scaffold only group (3.5 +/- 0.8) when 
compared to the control group (1.9 +/- 0.6) and trabecular spacing was significantly 
reduced  in  the  scaffold  +  SSCs  group  (0.112  +/-  0.015)  when  compared  to  both 
scaffold alone (0.119 +/- 0.026) and control (0.151 +/- 0.007). There was no significant 
difference  between  the  groups  for  bone  surface/bone  volume  ratio  or  trabecular 
thickness. 154 
 
 
Fig. 4.16  Assessment of new bone regeneration in the defect regions in femora of mice 
at 28 days following implantation, using indices of a) bone volume (BV), b) bone volume/ 
total volume (BV/TV), c) bone surface/ bone volume (BS/BV), d) trabecular thickness (TbTh), e) 
trabecular number (TbNo) and f) trabecular spacing (TbSp). Results are expressed as mean +/- 
SD, n=4 per group, *= p<0.05, **= p<0.005. 
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4.5.5.4 Histological analysis 
For each specimen, transverse sections of the entire femur were constructed at low 
magnification to enable identification of regions of interest: 
 
 
Fig. 4.17  Whole femur stained with A/S. Note the empty control diaphyseal defect (arrow), 
and the intramedullary defect made by the nail (outline). Scale bar: 1cm 
 
 
4.5.5.4.1  Empty defect control samples 
Control samples typically showed negligible or no bone formation within or around the 
defect site. The cortical bone of the mouse femora were stained red with Sirius red, 
and  the  physeal  zones  that  contain  proteoglycans  stained  blue  with  Alcian  blue, 
however there was universally negligible stain around the defect site with A/S stain 
(Fig. 4.17 and 4.18). Although cells could be appreciated on higher magnification views 
within the medullary canal and trabecula (Fig. 4.18 b), these did not infiltrate the defect 
itself in any of the control samples. 
 
 
Fig 4.18  Images  of  proximal  femur  and  defect  region  of  an  empty  control  sample, 
stained with A/S. Low a) and high b) magnification images. There is red staining around the 
edges of the defect suggestive of new collagen formation; however this has not extended into 
the defect site. Scale bars: a) 250 µm, b) 50 µm 156 
 
Goldner’s Trichrome stain also confirmed trabecula within the metaphysis, containing 
multiple  cells,  however  few  cells  were  present  within  or  around the  defect,  and  no 
osteoid was laid down, as demonstrated by an absence of red staining (Fig. 4.19). 
 
 
Fig. 4.19  Goldner’s Trichrome stain – empty defect control. Minimal osteoid has been laid 
down around the defect region (arrow), as demonstrated by an absence of red staining. Scale 
bar: 500 µm 
 
Collagen I immunohistochemistry stained positive in areas of existing cortical bone and 
also around the edges of the defect site, however there was limited collagen I activity 
around the defect (Fig. 4.20 a). 
 
 
Fig. 4.20 Immunohistochemistry of part of an empty defect control sample. a) Collagen 
type  I  staining  confirmed  expression  in  areas  of  existing  cortical  bone,  but  limited  staining 
around the defect itself. Low (b) and higher magnification areas (c, d) of a section stained for 
vWF  show  little  staining  around  the  defect  site,  although  there  was  evidence  of  expression 
within the medullary canal. Scale bars: a) and c) 500 µm, b) 250 µm, d-e) 50 µm 157 
 
Minimal staining for vWF was encountered around the defect sites of these control 
samples,  although  some  staining  of  the  cells  within  the  medullary  canal  occurred, 
consistent normal endothelial cell activity within this region (Fig. 4.20 b-d). 
 
4.5.5.4.2  Polymer alone samples 
These  samples  exhibited  significantly  more  cellular  activity  within  and  around  the 
defect  region  (Fig.  4.21).  A/S  staining  revealed  the  cut  ends  of  the  bone  at  the 
osteotomy sites closed over with new bone matrix, similar to the empty defect controls. 
In contrast however, the site occupied by the polymer had significant cellular infiltration 
(seen particularly in Fig. 4.21 c-e). 
 
 
Fig.  4.21  Low  magnification  image  of  femoral  segmental  defect  treated  with  polymer 
alone (inset) along with 5 regions of interest (a-e) stained with A/S. Note the significant 
cellular  infiltration  and  new  osteoid  seen  within  a  distinct  ‘pseudo-capsule’  between  the  two 
bone ends. a) The cut end of the bone has sealed with new osteoid and significant trabecular 
bone  formation  is  seen  around  this  area.  b)  A  peripheral  area  demonstrating  fragmented 
remains of the translucent polymer scaffold surrounded closely by new osteoid (red) and cells 
(cell nuclei stained with Weigert’s Haematoxylin). c) A central region directly between the bone 
ends  with  significant  cell  infiltration  and  evidence  of  osteoid  formation.  d  and  e)  Peripheral 
zones,  both  distant  from  the  defect  region  showing  abundant  cells  and  bone  formation, 
consistent with callus formation. Scale bars: inset 500 µm, a-e) 50 µm 158 
 
Fragmented remains of the polymer were clearly visible on high power images, with 
new trabecula forming around these pieces (Fig 4.21 a, b, e). These new trabecula 
formed at sites distant to the osteotomy (d and e), although the whole process was 
well-defined within a ‘pseudo-capsule’, bounded by the muscle around the femur. Fig. 
4.21 c shows an area directly between the two bone-ends within the defect region with 
a particularly high concentration of infiltrated cells. 
 
Collagen I immunohistochemistry revealed positive expression throughout the femoral 
cortex as seen previously, but staining was also observed within the defect region, and 
throughout those areas infiltrated with cells (Fig 4.22). 
 
 
Fig. 4.22  Collagen type I immunohistochemistry for a sample within the polymer alone 
group. Note increased expression throughout the defect region as compared to control samples 
(Fig. 4.20 a), with localisation to the new osteoid. Scale bars: a) 500 µm, b-d) 50 µm 
 
vWF staining for endothelial cells showed limited expression within the defect region 
itself  (Fig.  4.23  b-d),  however  the  area  characterised  by  cellular  infiltration  was 
surrounded  by  tissue  that  stained  positive  for  vWF  (Fig  4.23  a).  The  remaining 
fragments of polymer also took up some of the brown oxidation product. This is unlikely 159 
 
to reflect true endothelial cells expression, but is distinguished from other regions of 
true expression, particularly in higher power images. 
 
 
Fig. 4.23  vWF immunohistochemistry of a polymer alone sample, confirming expression 
within the tissues surrounding the defect, and also to a limited degree within the defect region 
itself  (white  box  in  a),  magnified  in  b)).  Note  the  brown  uptake  of  the  remaining  polymer 
fragments which is easily distinguished from true expression in the higher magnification images 
(c) and d), magnified sections from white and black boxes of b) respectively). Scale bars: a) 1 
mm, b) 200 µm, c) – d) 50 µm 
 
 
4.5.5.4.3  Polymer + SSCs samples 
A/S staining of the entire femoral sections revealed abundant osteoid formation with 
the  development  of  morphologically  normal  trabecula  and  cellular  infiltration. 
Furthermore, there was evidence of mature chondrocytic differentiation particularly at 
the  intersection  of  the  newly  laid  down  matrix,  with  evidence  of  an  endochondral 
ossification process, seen only in this group of samples (Fig. 4.24). 160 
 
 
Fig. 4.24  Cross-sectional overview of an entire femur from the polymer + SSCs group, 
demonstrating abundant new bone matrix within the osteotomy site and throughout the defect 
region. There is evidence of organised bone healing within a well-defined region around the 
osteotomy  site,  with  mature  trabecular  formation  and  a  ‘watershed’  area  of  chondrocytes 
suggesting a process of endochondral ossification. Scale bar: 2 mm 
 
 
Fig. 4.25  Regions of interest from Fig. 4.24: a) Well-defined trabecula are clearly seen with 
surrounding cellular infiltration. A distinct zone of chondrocytic differentiation is demonstrated at 
the interface between the two advancing bone matrix zones. An endothelial lined cyst is visible 
superficial to the regenerated bone area, which may represent a bursa, formed as a reaction to 
the  intense  bone-formation.  b)  10x  magnification  image  of  the  central  regenerated  area, 
demonstrating a distinct zone of chondrocytes. c) 20x magnification of the most superficial part 
of this zone; the chondrocytes are situated within the trabecula of newly-formed bone matrix. 
With  increasing  distance  from  this  area,  chondrocytes  become  progressively  sparser,  with 
increasing  numbers  of  undifferentiated  cells.  d)  40x  magnification  of  a  region  in  c).  Clonal 
chondrocytic  clusters  are  visible,  suggestive  of  intense  cellular  activity  and  turnover  in  this 
region. Scale bars: a) 1 mm, b) 150 µm, c) 50 µm, d) 20 µm 161 
 
Collagen  type  I  immunohistochemistry  of  the  polymer  +  SSCs  group  confirmed 
expression throughout the trabecula of the newly-formed bone within the defect site. 
Expression is very similar to that of native bone, as seen in Fig. 4.26 of the polymer 
alone sample, stained for collagen type I. 
 
 
Fig. 4.26  Collagen  type  I  immunohistochemistry  of  a  sample  containing  polymer  + 
SSCs. a) Overview of the same region seen in Fig. 4.2. Expression is seen throughout the 
newly-formed trabecula. b-d) Higher magnification images of regions of interest; b) Collagen 
expression is seen just behind the advancing zone of chondrocytes at the transition area; c) 
Expression is observed within some chondrocytes adjacent to the new bone; d) Fragments of 
polymer remain, these take up the brown stain, but are seen quite distinctly from the new bone 
formation on higher magnification sections. Scale bars: a) 1 mm, b-d) 200 µm 
 
vWF immunohistochemistry of the polymer + SSC samples demonstrated expression 
around the undifferentiated cells behind the advancing area of chondrocytes within the 
osteotomy site (Fig. 4.27). There was also a discrete layer of expression within the 
space at the interface. vWF was expressed within the osteoid in the central defect 
area, and although there was artefactual uptake of oxidation product by the fragmented 
polymer,  this  was  easily  distinguishable  from  true  cellular  expression  on  higher 
magnification images. 162 
 
 
Fig. 4.27  vWF immunohistochemistry of a sample from the polymer + SSCs group.  a) 
Overview of entire femoral section. b-d) Higher magnification images of regions of interest; b) 
vWF expression is seen mainly around the undifferentiated cells behind the advancing area of 
chondrocytes, but there is also a discrete layer of expression within the space at the interface. 
c) vWF is expressed within the osteoid in the central defect area, it is seen distinctly from the 
staining of fragmented polymer. d) Several zones of vWF expression are seen, such as this 
layer demonstrating expression near the central area of the osteotomy defect. Scale bars: a) 2 
mm, b-d) 200 µm 
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4.6  Discussion 
 
The aim of these studies was to investigate the potential of polymeric ternary blend 
biomaterials  to  facilitate  cell-attachment  and  differentiation  suitable  for  skeletal 
regeneration strategies. By combining a high throughput  approach  – which allowed 
rapid synthesis of a large number of chemically diverse polymeric materials, with the 
multiplexing  potential  of  a  microarray  platform  –  large  libraries  of  synthetic  but 
biodegradable polymer blends were screened for characteristics including the ability to 
support skeletal progenitor cell growth and differentiation. Three candidate polymeric 
blends that could be fabricated in sufficient quantities for macroscopic analysis were 
then examined individually in vitro for their efficacy in supporting the generation of a 
differentiated osteoblast population of STRO-1 positive stem cells. To minimise the use 
of animals, only the most efficacious blend underwent further analysis for its ability to 
provide a robust 3D scaffold for skeletal tissue regeneration in immunocompromised 
mice.  The  current  data  show  that  certain  polymeric  ternary  blends,  in  particular 
CS/PVAc/PLLA, are capable of enhancing skeletal regeneration, both in vitro and in a 
small animal model, although these data remain inconclusive regarding the additional 
ability of incorporated exogenous SSCs as a true tissue engineering construct. 
 
Polymer  blend  1  (CS/PVAc/PEI)  consisted  of  a  heterogeneous  structure  that  was 
denser in the central portion of each cylinder. Although this may produce a relatively 
strong scaffold under compression, it would not permit predictable cellular infiltration 
and would be unlikely to undergo complete or consistent bio-absorption. Furthermore, 
this blend supported SSCs poorly in vitro. Blend 3 (CS/PEI/PLLA) showed good cell 
adherence and ALP positivity on pilot in vitro culture, although its delicate structural 
characteristics and high solubility made it unsuitable as a test polymer. Despite strong 
ALP staining on the basal cultured sample, it dissolved readily even within the culture 
medium. If a similar blend could be fabricated with improved structural properties, this 
would be a good candidate for future assessment. 
 
Blend 4 (CS/PVAc/PLLA) was homogeneous with a uniform pore-size, ideal for cellular 
infiltration (50-500 µm diameter). It did not dissolve or disintegrate readily in the test 
solutions and consistently bound to, and supported SSCs in vitro, at 7 and 28 days 
culture.  However,  it  did  require  the  presence  of  exogenous  osteoinductive  factors 
(BMP-2,  ascorbate  and  dexamethasone)  to  stimulate  the  production  of  a  mature 
osteoblast population in vitro, as demonstrated by positive ALP staining (Fig. 4.9).  
 164 
 
Other osteogenic bone-matrix proteins were expressed following osteoinduction of cells 
grown  on  blend  4,  with  strong  consistent  staining  for  collagen  type  I,  osteopontin, 
osteonectin and bone sialoprotein. However osteocalcin was not expressed, perhaps 
because this is a late marker of osteogenesis (Sharma et al. 2006), and may not yet 
have been produced in sufficient quantities. The staining pattern was variable when 
using  immunofluorescent  staining  with  these  antibodies:  collagen  type  I  produced 
typical strand-like staining, whereas the localisation of osteopontin and BSP was more 
sporadic with punctate fluorescence. The true nature of this fluorescence was verified 
though,  by  using  positive  and  negative  control  samples  for  each  specimen  without 
adjusting threshold sensitivity values between specimens. 
 
Molecular  profiling was  attempted using differing methods without  success. Several 
causes for this are likely: only 4 discs were available from each group for molecular 
assessment,  so  cellular  yield  was  relatively  low.  Additionally,  cells  were  found  to 
adhere strongly to the polymer and all methods of removal caused fragmentation of the 
polymer. The resulting mixture of fragmented and partially dissolved scaffold, combined 
with whole and lysed cells became difficult to separate, resulting in impure RNA, which 
impeded  subsequent  extraction  and  analysis  using  PCR.  Future  molecular  analysis 
may require culture of cells on a larger scale to gain a significant yield. Separation of 
the polymer from the cells could be achieved in future by trialling different solvents to 
identify one that would dissolve the polymer into solution without damaging the cells, 
allowing the latter to be readily separated by mechanical filtration. 
 
Multiple, well-validated small in vivo models are available for the analysis of putative 
scaffold  materials  for  skeletal  regeneration  (Coraca  et  al.  2008,  Matsushima  et  al. 
2009, Kanczler et al. 2008, Kanczler et al. 2010, Khan et al. 2010). Our group has 
considerable  expertise  using  the  load-bearing  murine  critical-sized  femoral  defect 
model employed in this study, and the results confirm this model to have been an 
appropriate choice. All mice survived the study protocol with little morbidity. A single 
complication occurred, where the distal portion of the intramedullary pin was placed 
outside of the femur. Although this is clearly visible on the CT reconstruction following 
the study period, this was not appreciated on initial plain radiographic analysis. Several 
methods of securing the murine femoral osteotomy are available, including external 
fixators, locking plates and intramedullary locking nails (Cheung et al. 2003, Histing et 
al. 2010, Garcia et al. 2010). Each system has its advantages and disadvantages, in 
particular:  external  fixation  ensures  the  stabilising  construct  is  distant  from,  and 
therefore cannot interfere with the bone regenerative site. This potentially allows for 165 
 
easier analysis, but carries the disadvantage of higher infection rate through the pin 
tracts; plates can provide good stability, but because they provide stability from a single 
cortex, construct failure is a risk and the minute screws can be demanding to apply in a 
mouse  model;  locked  intramedullary  devices  require  the  use  of  a  jig  to  locate  the 
proximal and distal interlocking holes, leading to technical difficulties when performed 
on  an  extremely  small  scale,  they  also  carry  the  disadvantage  of  passing  directly 
through the test osteotomy site. The non-interlocked intramedullary pin was selected 
for this study following successful use in previous similar studies Kanczler et al. 2008, 
Kanczler  et  al.  2010,  Khan  et  al.  2010.  Despite  a  lack  of  rotational  stability,  the 
interference  fit  within  the  bone  ends  resulted  in  no  significant  shortening  of  the 
construct throughout the study period (see Fig. 4.14). In addition, comparison of the 
radiographic images confirmed little rotational movement between day 0 and day 28 of 
the study period, therefore it can be concluded that our model is adequate for the 
current  study.  Furthermore,  absolute  stability  would  have  resulted  in  healing  by 
intramembranous  ossification,  whereas  relative  stability  (as  in  our  model)  results  in 
slower  endochondral  ossification  by  fracture  callus  (Histing  et  al.  2010).  The  latter 
emulates the clinical scenario more closely, and is therefore more applicable to this 
study. In addition, we were confident that removal of the intramedullary device, either 
physically  or  digitally  following  the  test  period  would  facilitate  analysis  of  bone 
regeneration. 
 
Review  of  the  radiographic  images  (including  µCT  reconstructions)  demonstrates 
greater bone formation within the osteotomy site of the femora treated with the polymer 
blend when compared with controls and this was further enhanced by the addition of 
SSCs to the construct. Statistical analysis did not prove the latter enhancement to be 
significant  by  most  measures  of  bone  formation,  although  a  definite  trend  is 
demonstrated.  Histological  analysis  corroborates  this  trend,  demonstrating  greater 
cellular  infiltration  within  the  polymer  samples,  which  was  further  enhanced  in  the 
polymer + SSCs group. Hydrolytic degradation of the polymer appeared to match new 
bone  in-growth,  and  new  trabecula  were  seen  in  both  the  polymer  groups  with 
coincident, appropriate collagen type I expression. 
 
Histological differences were encountered between the polymer groups – samples in 
the polymer alone group showed mainly woven bone generation within the osteotomy 
gap,  although  samples  in  the  polymer  +  SSCs  group  demonstrated  endochondral 
ossification, with a widespread callus reaction and mature chondrocyte development, 
prior to the formation of well-organised trabecula. Endothelial tissue infiltration into and 166 
 
around the osteotomy site (as demonstrated by positive vWF staining) was confirmed 
in both polymer groups, suggesting vascularisation was taking place – a pivotal pre-
requisite for osteogenesis. 
 
Although some of the statistical analyses of bone formation did not reach statistical 
significance, histological and radiographic evidence confirms enhanced osteogenesis 
in  both  polymer  groups.  Regeneration  appears further  enhanced  by  the  addition  of 
SSCs,  although  characteristics  of  the  polymer  scaffold  alone  appear  to  have  been 
beneficial in providing an appropriate spatial and biologically favourable environment 
for osteogenesis. It should be noted that digital subtraction of the intramedullary device 
was more difficult than anticipated, and this is likely to have led to an underestimation 
of  bone  formation  in  the  test  groups,  particularly  with  the  few  samples  analysed. 
However  the  ability  of  polymeric  scaffolds  functionalised  with  biological  cues  to 
stimulate  tissue  formation  without  the  application  of  progenitor  cells  is  not  a  novel 
concept  –  Lee  et  al.  have  shown  regeneration  of  rabbit  humeral  head  cartilage  by 
implantation of polycaprolactone and hydroxyapatite bioscaffolds spatially infused with 
TGF-β3-adsorbed  hydrogel  (Lee  CH  et  al.  2010).  Future  experiments  would  be 
required with larger numbers over a longer time period to differentiate the effect of 
addition of SSCs to the polymer, and to deduce whether there is a true requirement for 
exogenous SSCs with the polymer to produce adequate bone healing, as this study 
suggests  the  polymer  alone  has  a  very  beneficial  therapeutic  effect. This  could  be 
combined with functionalisation of the ternary blend with osteoinductive factors, such 
as  BMP  or  VEGF  for  temporal  release,  to  further  enhance  osteogenic  properties 
(Kanczler et al. 2010). Furthermore, the translation of this technology to larger scale 
models would be required to validate ternary blend biomaterials for their functionality 
with respect to weight-bearing and remodelling capacity prior to clinical application. 
 
In conclusion, the null hypotheses that: ‘polymeric ternary blend biomaterials do 
not  facilitate  cell-attachment  and  lineage-differentiation  suitable  for  skeletal 
regeneration  strategies’,  and  ‘polymeric  ternary  blend  biomaterials  do  not 
function as suitable scaffolds for skeletal regeneration strategies’ can both be 
rejected,  however  it  is  still  unclear  if  the  proven  osteoregenerative  capacity  of  the 
ternary blend polymer under test in vivo is further enhanced by the addition of SSCs. 167 
 
 
 
Chapter V 
 
In vivo evaluation of a candidate binary polymer blend 
scaffold for skeletal tissue engineering strategies using 
an ovine model 
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5.1  Introduction 
 
 
5.1.1  The requirement for large animal studies 
 
Although many successful in vitro and in vivo laboratory studies have shown potential 
application  for  a  variety  of  tissue  regenerative  strategies,  to  date,  there  has  been 
limited translation to clinical practice. There exists a considerable translational gap due 
to the paucity of potential strategies that undergo ‘up-scaling’ prior to pre-clinical trials, 
primarily due to considerations of cost, regulation, logistics and expertise (see chapter 
VII).  Currently,  no  synthetic  system  is  able  to  replicate  the  diverse  biomechanical 
conditions present within a large organism, so in order to fully evaluate a candidate 
biomaterial  for  skeletal  regeneration  strategies  prior  to  clinical  application,  a  large 
animal study is required to bridge this gap. 
 
 
5.1.2  Selection of appropriate large animal model 
 
The  performance  of  any  biomaterial  must  be  evaluated  for  safety,  efficacy  and 
practicality  in  a  suitable  model  to  simulate  human  in  vivo  conditions  as  closely  as 
possible. Myriad variables must be defined and controlled to ensure the model used 
will  assess  the  most  relevant  attributes  to  the  clinical  domain  of  interest,  whilst 
minimising variations in outcome and also the number of animals required to achieve 
statistical power (Table 5.1) (Muschler et al. 2010).  
 
 
Table 5.1  Variables  within  a  large  animal  model,  which  need  to  be  defined  and 
controlled  
Inherent variables  Modifiable variables  Experimental variables 
Subspecies  Diet/ Nutritional status  Anaesthetic/ pain management 
Gender  Exercise/ activity regime  Surgical procedure 
Partum  Gonadal/ lactation status  Anatomic location 
Age  Temperament  Fixation technique 
Animal to animal variation  Environment  Assessment outcomes 
Adapted from Muschler et al. 2010 
 170 
 
In comparison to humans, the chosen animal model must demonstrate corresponding 
physiological and pathophysiological mechanisms with respect to the intervention being 
considered. This includes tissue repair and regeneration, but also consideration of size 
and  proportions  as  well  as  static  and  dynamic  forces  to  which  the  construct  and 
associated tissues will be subjected. Although dogs, primates, horses, goats, pigs and 
sheep  have  been  used  in  pre-clinical  analysis  of  skeletal  defect  healing,  the  latter 
group  has  become  increasingly  popular  as  test  subjects.  Allowances  are  generally 
accepted for the quadrupedal gait of most large mammals used in research and the 
resultant  variation  in  subjected  mechanical  forces  when  compared  to  the  bipedal 
human gait. The chosen animal should ideally be in sufficient supply, domesticated 
with  a  placid  nature,  of  equivalent  weight  to  an  adult  human,  with  similar  skeletal 
architecture and dimensions. Further criteria include costs of acquisition and care, local 
availability, acceptability to society, tolerance to captivity and ease of housing (Pearce 
et  al.  2007).  Several  previous  studies  have  made  use  of  dogs  as  models  for 
orthopaedic research (Martini  et  al.  2001). Larger breeds closely resemble humans 
with  regard  to  bone  weight,  density,  mineral  composition  and  protein  constituents, 
although significant differences in their bone microstructure and remodelling have been 
described due to their characteristics as fast-growing animals (Aerssens et al. 1998). In 
particular, dog bones have higher rates of trabecular and cortical bone turnover with 
only a limited cortical osteonal structure when compared to human bone. Recently, the 
use of dogs as experimental models has significantly decreased, mainly due to ethical 
concerns, although canine studies still account for approximately 9% of large animal 
musculoskeletal studies published in prominent journals (O’Loughlin et al. 2008). 
 
Ovine  models  have  recently  become  more  popular,  due  partly  to  their  abundant 
availability  and  relatively  low  cost  but  also  because  they  share  several  biological 
attributes with humans: mature sheep have a body mass similar to adult humans and 
similar long bone dimensions, enabling the use of implants designed for humans with 
little modification (Newman et al. 1995). The mechanical loading environment in sheep 
has been characterised, with forces and moments of approximately half of those found 
in humans during normal ambulation (Taylor et al. 2004, Taylor et al. 2006), probably 
because  they  are  quadrupedal.  Furthermore,  ovine  bone  mineral  composition, 
metabolic and remodelling rates are roughly equivalent to those of humans (Ravaglioli 
et al. 1996) however some researchers maintain that significant histological differences 
exist, particularly in younger sheep (less than 7 years old) prior to secondary osteonal 
remodelling (Newman et al. 1995, Reichert et al. 2010). The differentiation potential of 
ovine  derived  SSCs  has  also  recently  been  characterised,  enabling  laboratory 171 
 
protocols to be defined to induce osteogenic differentiation in ovine cells (McCarty et al. 
2009). Sheep are generally favoured over goats because sheep are calmer, with a 
more docile disposition. Although the pig has been described as a highly representative 
morphological  and  biomechanical  model  of  human  bone  regeneration,  their 
appendicular bones are considerably shorter than those of sheep and humans, and 
their obstinate, and sometimes vicious temperament can make handling and safe peri-
operative  care  a  particular  challenge  (Newman  et  al.  1995).  Perhaps  the  most 
compelling factors determining final choice will include previous local experience along 
with appropriate facilities and expertise in using a particular species. 
 
 
5.1.3  Selection of appropriate defect and bone site 
 
Although the humerus is the largest bone in quadrupeds (Muschler et al. 2010), animal 
studies of skeletal regeneration using tissue engineered constructs often make use of 
tibial  segmental  defects  to  more  closely  mimic  the  clinical  circumstance.  The  tibial 
diaphysis is the most common site in humans for problematic post-traumatic skeletal 
defects,  because  of  poor  soft  tissue  coverage,  which  often  complicates  treatment 
(DeCoster et al. 2004). This potential complication can be examined in sheep tibiae 
which have a similar soft tissue envelope to human tibiae. Furthermore, the suitability 
of the tibia in these models is reinforced by facile surgical exposure and a choice of 
fixation systems analogous to the clinical scenario. 
 
 
5.1.4  Critical segmental defect 
 
In order to investigate the effects of various skeletal regenerative approaches and bone 
repair mechanisms, a variety of critical sized tibial defect models have been created. A 
critical sized defect is defined as the smallest intra-osseous defect in a particular bone 
and species of animal that will not spontaneously unite within its lifetime, or as a defect 
which demonstrates less than 10% regeneration (Gugala et al. 2007, Reichert et al. 
2009).  This  size  is  often  quantified  by  multiplying  the  diaphyseal  diameter  by  2.5 
(Lindsey et al. 2006), but is in fact highly variable, and dependent on multiple inherent 
and procedural factors (Table 5.2). 
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Table 5.2  Inherent and procedural factors that affect the size of a critical segmental 
defect 
Inherent  Procedural 
Age  Site, size and method of ostectomy 
Species  Nutrition 
Bone structure  Presence of periosteum 
Mechanical loads/stresses  Fixation method - absolute or relative stability 
 
 
It  has  been  shown  that  unfilled  defects  of  significantly  smaller  than  2.5  times  the 
diaphyseal  diameter  do  not  undergo  spontaneous  healing  when  the  construct  is 
significantly  devascularised,  periosteum  is  stripped  or  removed,  heat  damage  is 
allowed during creation of the ostectomy, or if the construct fixation method only allows 
primary bone healing, such as in absolute stability (Wallace et al. 1991, Kuttenberger et 
al. 2010, Goodship et al. 1993, Epari et al. 2006, Epari et al. 2008). Consequently, the 
best designed studies include a control group where the defect has not been filled with 
scaffold, in order to demonstrate an absence of regeneration in these samples. 
 
 
 
5.1.5  Methods of fixation 
 
Several methods can be employed to achieve fixation of a segmental skeletal defect. 
Clinically,  diaphyseal  tibial  fractures  are  now  most  commonly  stabilised  with 
intramedullary nailing (Giannoudis et al. 2006). Although close correlation to the human 
clinical scenario is beneficial, additional factors have to be considered when selecting 
the most appropriate system for large animal studies. Table 5.3 summarises previous 
ovine segmental defect studies, including fixation technique. 
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Table 5.3  Previous ovine segmental defect studies 
Author, year  Fixation  Approach  Defect 
size  Bone  Age of 
sheep 
Empty 
control  Filler/ scaffold 
Wallace et al. 
1991  Ex-fix  AM  2 mm  Tibia  3 yrs  Y  Nil 
Goodship et al. 
1993  Ex-fix  AM  fracture  Tibia  adult  Y  Nil 
Wallace et al. 
1995  Ex-fix  AM  2 mm  Tibia  adult  Y  Nil 
Augat et al. 
1997  Ex-fix  NS  3 mm  Tibia  2-3 yrs  N  Nil 
Gao et al. 
1997  Plates  NS  16 mm  Tibia  adult  N  Biocoral vs. TCP 
Hente et al. 
1999  Ex-fix  AM  3 mm  Tibia  6-11 yrs  Y  Nil. Dynamic vs. static fixation 
den Boer et al. 
1999  IM nail  AM  30 mm  Tibia  adult  Y  Empty vs. cancellous bone 
Gugala et al. 
1999  Ex-fix  NS  40 mm  Tibia  6-7 yrs  N  PLDLLA membrane +/- 
cancellous bone autograft 
Marcacci et al. 
1999  Ex-fix  AM  35 mm  Tibia  2 yrs  N  HA block 
Petite et al. 
2000  Plate  lateral  6, 12, 
25 mm 
Meta-
tarsus  2 yrs  N  Coral +/- BMA or Coral +/- 
SSCs 
Blokhuis et al. 
2000  IM nail  AM  30 mm  Tibia  ≥ 2 yrs  Y  TCP +/- BMA vs. autologous 
bone 
Kon et al. 
2000  Ex-fix  AM  35 mm  Tibia  2 yrs  N  Porous HA cylinder +/- 
autologous SSCs 
Gugala & Gogolewski 
2002  Ex-fix  NS  40 mm  Tibia  6-7 yrs  N  PLDLLA membrane +/- 
cancellous bone autograft 
den Boer et al. 
2003  IM nail  AM  30 mm  Tibia  adult  Y  Porous HA +/- OP-1 +/- BMA 
+/- corticocancellous autograft 
Augat et al. 
2003  Ex-fix  AM  3 mm  Tibia  4-5 yrs  N  Nil. Axial vs. shear 
movements allowed 
Bloemers et al. 
2003  IM nail  AM  30 mm  Tibia  ≥ 2 yrs  N  CaPO4 vs. autologous bone 
Regauer et al. 
2005  IM nail  NS  50 mm  Tibia  adult  N  DBM +/- OP-1 +/- BMA vs. 
bone autograft 
Schell et al. 
2005  Ex-fix  AM  3 mm  Tibia  2.5-3.5 
yrs  Y  Nil. Rigid vs. semi-rigid ex-fix 
Epari et al. 
2006  Ex-fix  AM  3 mm  Tibia  2.5-3.5 
yrs  Y  Nil. Rigid vs. dynamic ex-fix 
Maissen et al. 
2006  Ex-fix  NS  18mm  Tibia  4-5 yrs  Y  PLDLLA +/- TGF-β vs. bone 
autograft 
Mastrogiacomo et al. 
2006  Plate  NS  48 mm  Tibia  2 yrs  N  Si-TCP and HA-TCP mix +/- 
SSCs 
Sarkar et al. 
2006  IM nail  NS  25 mm  Tibia  5.5-7.5 
yrs  N  PRP-loaded collagen 
Teixeira et al. 
2007 
Plate + 
cage  NS  35 mm  Tibia  4-5 mths  N  Autograft bone vs. HA + 
collagen + BMP + DBM  
Mastrogiacomo et al. 
2007  Plate  NS  40 mm  Tibia  2-4yrs  N  Si-TCP and HA-TCP mix +/- 
SSCs 
Tyllianakis et al. 
2007  IM nail  AM  0-30 
mm  Tibia  16-20 
mths  Y  Nil 
Epari et al. 
2008  Ex-fix  AM  3 mm  Tibia  2-3 yrs  N  Nil 
Field et al. 
2009  IM nail  lateral  50 mm  Femur  3 yrs  Y  TCP/ PLDLLA mesh vs. milled 
allograft vs. cortical strut graft 
Rozen et al. 
2009  Plate  PL  32 mm  Tibia  2 yrs  Y  EPCs 
Schneiders et al. 
2009  IM nail  AM  30 mm  Tibia  NS  N  HA/Collagen +/- chondroitin 
sulphate 
Ex-fix = external fixator, AM = anteromedial, NS = Not stated or unknown, Y = yes, N = no, IM 
Nail  =  Intramedullary  Nail,  HA  =  Hydroxyapatite,  TCP  =  Tricalcium  Phosphate,  PLDLLA  = 
poly(L-lactide-co-D,L-lactide), BMA = Bone Marrow Aspirate, SSC = Skeletal Stem Cell, Si = 
Silicon, BMP = Bone Morphogenetic Protein, OP-1 = Osteogenic Protein – 1, TGF-β = Tumour 
Growth Factor Beta, EPC = Endothelial Progenitor Cell, yrs = years, mths = months 
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5.1.5.1 Intramedullary nails 
Nails  can  be  either  reamed  or  unreamed,  each  with  its  own  advantages  and 
disadvantages: reaming can significantly alter endosteal blood circulation and cause 
thermal  necrosis  (Schroeder  et  al.  2010).  Subsequent  nail  insertion  can  increase 
intramedullary pressure, potentially leading to pulmonary microvascular damage, air or 
fat embolism (Pape et al. 2006). Unreamed nails are generally of smaller diameter and 
often  possess  minimal  interference  fit,  relying  solely  on  the  integrity  of  interlocking 
screws for stability. Such nails may therefore produce relative, rather than absolute 
stability at the fracture/osteotomy site and are more prone to failure (Duan et al.  2012). 
Successful skeletal regeneration studies have been undertaken using intramedullary 
nailing to stabilise segmental defects in ovine tibiae (den Boer et al. 1999, Bloemers et 
al. 2003, Teixeira et al. 2007, Tyllianakis et al. 2007) and femora (Field et al. 2009), 
however the nail becomes an intrinsic part of the osteotomy gap and its presence could 
affect  regeneration,  and  complicate  its  subsequent  radiological  and  histological 
analysis. 
 
5.1.5.2 Internal plate fixation 
Although in the clinical situation, internal plate and screw fixation techniques are most 
commonly used for metaphyseal fractures, plates are also indicated in diaphyseal tibial 
fracture fixation, particularly in the immature skeleton, when damage to physeal growth 
zones  should  be  avoided.  Several  researchers have  used  plating systems  in  ovine 
models with varying success. Optimal reduction can be achieved under direct vision, 
using the same exposure as for the insertion of a putative biomaterial, and the fixation 
can  easily  be  removed  post  mortem  with  little  impact  on  the  osteotomy  site  or  its 
subsequent  analysis.  However,  many  previous  studies  used  conventional  plate 
systems  resulting  in  significant  rates  of  construct  failure.  Modern  limiting-contact 
locking  dynamic  compression  plates  (LC  DCPs)  prevent  high  contact  pressures 
between the plate and cortical bone, avoiding the reduction of periosteal blood flow and 
localised osteoporosis through stress shielding, and potentially reducing implant failure 
rates  (Reichert et al. 2010). 
 
5.1.5.3 External fixation 
Clinically, external fixation is most often employed as a temporary measure to stabilise 
open or grossly contaminated fractures, however they are also frequently used in limb 
lengthening, deformity correction, arthrodesis and salvage procedures. The versatility 
and ease of use of external fixation systems have made them a frequent implant of 
choice for ovine studies. Furthermore, the Schanz screws which stabilise the bone can 175 
 
be inserted with minimal trauma at some distance proximally and distally, leaving no 
hardware whatsoever at or near the experimental site. 
Healing  periods  following  external  fixator  application  have  been  reported  to  be 
significantly longer when compared to other fixation devices, and this may be a function 
of the possibility of obtaining an extremely stiff construct, leading to absolute stability 
with very little movement at the osteotomy site and stress protection (O’Doherty et al. 
1995). Furthermore, the risk of pin site infection and loosening is a concern, and the 
external structure itself may affect the gait of sheep, or cause injury or difficulty with 
wound dressings. 
 
 
5.1.6  Binary blend polymer scaffold 
 
The design, fabrication and assessment of putative biomaterials for potential clinical 
application require the input of many coordinated agencies for success (see Chapter 
VI). Consequently, multiple strategies will often be under simultaneous consideration 
within a single research group. Since each potential biomaterial undergoes a similar 
iteration  during  analysis,  an  ‘evolution’  of  strategies  is  seen  over  time,  where  one 
candidate material will be undergoing large scale in vivo analysis, while a more refined 
material developed using results from testing of the first material will still be undergoing 
preliminary in vitro assessment. 
 
In a prior study, performed within the Bone and Joint Research Group Southampton, 
the  biocompatibility  and  applicability  for  skeletal  regeneration  of  candidate  binary 
polymer blend scaffolds was assessed in vitro as well as in a murine skeletal defect 
model (Khan et al. 2010). These scaffolds are similar to those analysed in the small in 
vivo model in chapter V of this thesis, although these materials were synthesised using 
a combination of just two (rather than three) polymers. The study found the binary 
blend  PLLA/PCL  (20/80)  displayed  a  bone-like  architecture  as  well  as  providing  a 
robust template for STRO-1 positive SSC attachment and bone regeneration in vitro 
and in a murine segmental femoral defect model. This polymer blend was therefore 
chosen as the scaffold for up-scaling to our ovine tibial segmental defect model, with 
the hypothesis that the polymer scaffold would also provide a suitable template for 
ovine SSC attachment and bone regeneration on a larger scale. In addition, an aim of 
this  study  was  to  establish  a  reproducible  technique  for  analysis  of  candidate 
biomaterials in a large animal skeletal defect model. 
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5.2  Objectives 
 
  To establish a consistent and reproducible technique for stabilisation of a 35 
mm tibial critical defect in sheep, for subsequent trialling of tissue regeneration 
strategies. 
 
  To  demonstrate  a  living  cell  composite  using  cultured  skeletal  stem  cells  on 
synthetic scaffold to augment bone formation in a large animal segmental defect 
model. 
 
 
 
 
5.3  Null hypothesis 
 
  The polymeric binary blend biomaterial PLLA/PCL (20/80) does not function as 
a  suitable  scaffold  for  skeletal  regeneration  strategies  in  an  ovine  tibial 
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5.4  Materials and methods 
 
5.4.1  Polymer fabrication 
 
Polymeric binary blend (PLLA/PCL (80/20)) scaffolds were formulated and fabricated 
by  Dr  F  Khan  at  the  University  of  Edinburgh  using  solvent  mixing  techniques  as 
previously described (Chapter IV). 10 identical scaffolds were produced (diameter 23 
mm, length 40 mm) (Fig. 5.1 a). 
 
 
5.4.2  Initial processing of polymer scaffolds 
 
The received polymers required preliminary processing before they were suitable for 
application in the ovine study. Although the polymer is fabricated as a macroporous 
scaffold, during manufacture, each scaffold becomes coated in an impermeable thin 
film  of  polymer.  This  was  carefully  removed  by  peeling  the  film  off  to  reveal  the 
underlying  structure.  The  scaffolds  were  cut  to  precisely  35  mm  in  length  using  a 
scalpel blade, as measured by digital callipers. Additionally, to recreate the medullary 
canal of the ovine tibia and further improve diffusion of medium and cells in culture, a 
central canal was drilled down of each scaffold using an 8 mm High Speed Steel (HSS) 
drill bit at a slow speed to prevent thermal damage to the polymer. The final scaffolds 
were identical in size, shape and surface consistency (Fig. 5.1 b). 
 
 
Fig. 5.1  Binary polymer scaffold, a) as initially received, b) following processing. Scale bar: 
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The  scaffolds  and  off-cuts  produced  during  initial  processing  were  sterilised  by 
immersion in 5 x antibiotic/antimycotic solution and degassing using negative pressure. 
Scaffolds remained in this solution for 24 hours before transfer to basal medium and 
subsequent UV irradiation overnight. 
 
 
5.4.3  Preliminary experiments 
 
Although the previous study (Khan et al. 2010) confirmed good adherence of human 
SSCs onto the test polymer with appropriate osteoinduction on a small scale, no study 
has shown similar effects for ovine cells on larger scaffolds. Additionally, although our 
laboratory  has  considerable  experience  isolating  and  culturing  human  SSCs,  no 
practical experience existed in culturing ovine cells. Therefore, a series of experiments 
was devised to confirm appropriate scaffold characteristics for ovine cell adherence 
and growth and to define the most appropriate protocols for ovine cell seeding and 
initial incubation prior to implantation. 
 
 
5.4.3.1 Confirmation of scaffold porosity and interconnectivity 
 
5.4.3.1.1  Scanning Electron Microscopy 
SEM was performed on cut sections of the scaffold by Dr F Khan to confirm porosity 
and define pore sizes. 
 
5.4.3.1.2  Alcian blue penetration test 
A cuboid of polymer scaffold was prepared (5x5x40 mm) and supported upright in a 
specimen  pot.  The  superior  aspect  was  sealed  circumferentially  using  histology 
embedding wax and Alcian blue dye was infiltrated from the top so that no dye could 
pass around the outside of the scaffold. Following 12 hours, the scaffold below the wax 
seal was sectioned and examined for the presence of the dye within the pores. 
 
 
5.4.3.2 Acquisition of ovine iliac crest BMA 
Iliac crest aspirates were obtained from mature ‘cull’ ewe sheep (Northern Mule, weight 
approximately 70-80 kg) undergoing experimental surgery as approved by the relevant 
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were in possession of a current and valid Personal Licence and all sheep used in this 
study were appropriately assessed, screened and quarantined prior to any intervention. 
 
Following appropriate sedation and anaesthesia (see appendix for protocol), the sheep 
were placed in right lateral recumbency. The aspiration site in the left posterior superior 
iliac crest was identified and wool was shaved to a diameter of approximately 5 cm 
around this area. The hide was prepared with two applications of aqueous iodine scrub 
solution  and  draped  appropriately.  Sterile  technique  was  maintained  henceforth.  A 
scalpel blade was used to make a small incision over the aspiration site, directly onto 
bone. The trocar, 11 gauge aspiration needle (Rocket Medical) and 20 ml Luer lock 
syringe  were  pre-heparinised  with  0.5  ml  of  1000  units/ml  heparin.  The  trocar  and 
aspiration needle were passed through the incision, directly into the iliac crest and in an 
antero-caudal  direction.  Care  was  taken  to  ensure  the  needle  remained  within  the 
cancellous bone of the iliac crest. The trocar was removed and the syringe screwed 
onto the aspiration needle tightly to ensure a tight seal. Aspiration was achieved by 
gentle pressure on the syringe. Once the required quantity of bone marrow (approx 5 
ml) had been aspirated, the needle was withdrawn and gentle pressure was applied to 
the aspiration site until haemostasis was achieved. The aspiration site was closed with 
a  single  nylon  suture  (Ethilon,  Ethicon,  Livingstone,  UK).  The  aspirate  was  gently 
agitated to mix with heparin inside the syringe before storage at 5ºC. 
 
 
Fig 5.2  a) Mature Northern Mule ‘cull’ sheep used for the study. b) Aspiration technique 
from iliac crest using needle and trocar. The gloved thumb and forefinger mark either side of 
the  iliac crest. The same technique  was  used  throughout the main experimental  procedure, 
although a wider surrounding area was sheared, prepared and draped to maintain full asepsis. 
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5.4.3.3 Isolation and culture of ovine SSCs 
BMAs  were  transported  to  the  laboratory  and  cultured  expediently.  Aspirates  were 
centrifuged  at  11000  rpm  for  4  minutes  and  the  supernatant  removed  before  re-
suspending and seeding the cells onto tissue culture plastic in osteogenic conditions at 
a  density  of  1x10
6  cells  per  T175  flask.  An  initial  ovine  BMA  sample  was  used  to 
ensure these standard isolation and monolayer culturing techniques would be suitable 
for ovine cells, and this sample was split, with half the cells cultured in basal and half in 
osteogenic conditions. Medium changes were performed every three days until cells 
achieved approximately 75 – 80% confluence (approximately one week). 
 
 
5.4.3.4 In vitro incubation of ovine SSCs with test scaffold 
Cells were released from the tissue culture plastic flasks with trypsin and prepared as 
four varying concentrations of cells in basal medium: 1x10
4; 1x10
5; 2.5x10
5, and 5x10
5 
cells/ml. One ml of each concentration was then seeded onto prepared 10 mm cubes 
of polymer  scaffold (n=3) for three hours before static incubation in either basal or 
osteogenic conditions for 28 days. Following culture, the scaffolds were prepared for 
fluorescent viable cell analysis (using Vybrant
® Green), and quantitative ALP and DNA 
analysis as previously described (Chapter III). 
 
 
5.4.4  Ovine tibial segmental defect model 
 
In order to adequately assess the utility of the candidate polymer scaffold in an ovine 
tibial segmental defect model, this study required a complete set of results from three 
groups of four study animals. It was therefore decided that any failure of an animal to 
recover, or death before the completion of the protocol would result in that particular 
test being repeated to ensure a complete set of results. 
 
Northern Mule sheep with a body weight of approximately 70 – 80 kg at the start of the 
study period were all subjected to pre-operative iliac crest bone marrow harvest and 
underwent equivalent standard anaesthetic, analgesic and skeletal fixation regimes, 
with similar management post-operatively. Apart from varying management at the tibial 
defect site, all other pre-, peri- and post-operative variables were minimised to ensure 
comparability between study groups. 
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This study was performed under Home Office Animal Licence Approval with Professor 
Goodship  as  Project  Licence  holder  and  Research  Fellows  from  Southampton 
operating under secondary availability within the authority of their Personal Licences. 
All  the  procedures  were  designed  to  comply  with  Home  Office  stipulations  and  to 
adhere to the principles of animal experimentation (Russell et al. 1959). 
 
 
5.4.4.1 Fixation design and selection 
A thorough literature review was undertaken and the potential benefits of using internal 
plate and screw, intramedullary nail, or external fixation systems was assessed prior to 
making a final decision (see Section 5.15). In addition to local laboratory scientist and 
veterinary expertise, advice was sought from centres with experienced personnel who 
are conducting similar ovine studies. This included visits to the laboratories of: Prof 
John Field (Adelaide, Australia), an advocate of intramedullary fixation; Prof Dietmar 
Hutmacher  (Brisbane,  Australia),  who  uses  internal  plate  fixation,  and  Prof  Allen 
Goodship (Royal Veterinary College, Hertfordshire), who prefers external fixation. The 
opportunity to assist in some operative procedures at all centres, helped to inform the 
preferred fixation method chosen for the present study. 
 
 
5.4.4.2 Cadaveric procedures 
We  obtained  several  disarticulated  fresh  sheep  tibiae  (Uptons  Butchers  of  Bassett, 
Southampton, UK) and trialled these with both a custom-made intramedullary nail and 
external  fixator.  The  external fixator  method  was  preferred  as  it  provided  improved 
stability of fixation over the intramedullary device. In addition, the procedure could be 
tailored to account for an array of bone lengths and diameter, and external fixation did 
not  cause  collateral  damage  to  the  knee  joint  which  may  have  hampered  post-
operative  mobilisation  and  weight  bearing.  Additionally,  Prof  Goodship  had  most 
experience with external fixation models in ovine segmental defects and rarely suffered 
post-operative complications. Further cadaveric procedures using whole sheep hind 
limbs were therefore undertaken using the external fixator. These cadaveric ‘dry run’ 
procedures were performed to ensure familiarity  with the equipment and processes 
involved and reduce unexpected live animal morbidity (Fig. 5.3). 
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Fig. 5.3  Cadaveric  ‘dry  run’  procedure  using  a  whole  sheep  hind  limb.  a)  The  tibial 
diaphysis has been exposed and the jig applied using forceps. A Schanz screw is inserted by 
hand  to  prevent  thermal  necrosis.  b)  The  external  fixator  has  been  tightened  onto  the  six 
Schanz screws and the segmental defect is removed using a sagittal saw. c) The final construct 
following removal of the defect 
 
 
5.4.4.3 Study cohorts 
12 sheep were randomly assigned to one of three treatment groups: 
 
•  Group 1 – negative controls (4 sheep) 
Empty 35 mm tibial defect with skeletal fixation only 
 
•  Group 2 – positive controls (4 sheep) 
35 mm tibial defect with polymer scaffold and fixation 
 
•  Group 3 – treatment group (4 sheep) 
35 mm tibial defect with polymer scaffold, autologous SSCs and fixation 
 
 
5.4.4.4 Bone marrow harvesting 
All live sheep underwent bone marrow aspiration from the iliac crest as a separate 
procedure (see Section 5.4.3.2) approximately two weeks prior to the segmental defect 
operation. Marrow from sheep assigned to group 1 and 2 that was not required for re-
implantation, was used for in vitro preliminary experimentation. Marrow from sheep in 
group 3 was transported to the laboratory for isolation, culture and seeding onto the 
polymer scaffold. 183 
 
5.4.4.5 Scaffold preparation and cell seeding prior to implantation 
Polymer scaffolds were prepared and sterilised as previously described (Section 5.4.2). 
For scaffolds in group 3, autologous ovine SSCs that had been grown in monolayer 
culture to approximately 75% confluence were released and seeded onto the scaffolds 
at a concentration of 5x10
5 cells/ml (20 ml total). The seeded scaffolds were gently 
rotated in osteogenic medium for 7 days prior to implantation into the tibial segmental 
defect model. Scaffolds from group 2 underwent the identical processes, except no cell 
seeding  took  place.  On  the  day  of  implantation,  the  scaffolds  were  assessed 
microscopically to confirm absence of infection before undergoing a change of medium, 
and transportation at 37°C to the operating facility. 
 
 
5.4.4.6 Surgical procedure 
 
5.4.4.6.1  Premedication, anaesthesia and preparation 
Sheep were allocated individual pens and food was withheld prior to surgery (Fig. 5.4 
a). A fentanyl transdermal patch (Durogesic, Jannsen Cilag, High Wycombe, UK) was 
applied 12 hours pre-operatively. 
 
Prior  to  anaesthesia,  xylazine  (Rompun,  Bayer  Healthcare,  Newbury,  UK) 
premedication was administered and each sheep was weighed (Fig. 5.4 c). Following 
venous cannulation, anaesthesia was induced using intravenous ketamine (Ketaset, 
Fort Dodge Animal Health, Southampton, UK) and maintained on the inhalational agent 
isoflurane (Isoflo, Abbott, Maidenhead, UK). 
 
Once unconscious, the sheep were intubated with a cuffed endotracheal tube (Fig. 5.4 
d), and connected to an anaesthetic machine for maintenance and close monitoring for 
the  duration  of  surgery.  Cefalexin  (Ceporex,  MSD  Animal  Health,  Hoddesdon, 
Hertfordshire, UK) and maintenance fluids were administered intravenously. The sheep 
were secured in right lateral recumbency and wool was shaved from the entire limb and 
hindquarter.  The  hide  was  prepared  with  two  applications  of  aqueous  iodine  scrub 
solution and draped appropriately. Sterile technique was maintained henceforth (Fig. 
5.4 e). 
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Fig. 5.4 Premedication, anaesthesia and preparation: a) Sheep were housed in individual 
pens both pre- and post-operatively b) Operating theatre prepared for sheep surgery, note the 
anaesthetic  machine,  cardio-respiratory  monitoring,  suction,  lighting,  diathermy  machine, 
warming  blanket  and  bucket  for  collecting  rumen  fluid  intra-operatively.  c)  All  sheep  were 
weighed immediately prior to induction. d) Intubation using a long straight-bladed laryngoscope, 
standard  human  adult  endotracheal  tube  and  bougie.  e)  Once  anaesthetised,  sheep  were 
secured in lateral recumbency before shaving, antiseptic hide preparation and draping. 
 
 
5.4.4.6.2  Operative procedure 
 
5.4.4.6.2.1  Incision and approach 
An anteromedial approach was used to access the diaphyseal portion of the right tibia 
through an approximately 12 cm incision. The periosteum was carefully and entirely 
removed around the site of the proposed ostectomy. 
 
 
5.4.4.6.2.2  Fixation and creation of defect 
The proprietary jig was secured against the bone in the required position ensuring all 
the guides for the Schanz screws corresponded with the centre of the tibial shaft. The 
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were drilled through the jig guides and a Schanz screw was carefully inserted into each 
hole by hand to avoid thermal necrosis or splitting of the bone. Because ovine tibiae 
widen  significantly  distal  to  the  proximal  metaphyseal  flare,  we  used  two  Schanz 
screws with a 30 mm long threaded section proximally and four Schanz screws with a 
20 mm long threaded section distally. This was replicated for each sheep, and ensured 
sound  bicortical  fixation  for  every  screw.  Furthermore,  the  order  of  insertion  of  the 
Schanz  screws  was  also  standardised  (Table  5.4).  The  jig  was  removed  and  the 
custom-made modular external fixator (Orthofix, Maidenhead, UK) was applied to the 
Schanz screws and secured in place at a distance of precisely 30 mm from the near 
tibial cortex. The 35 mm ostectomy was made at the pre-marked site using an electric 
reciprocating sagittal saw (Bosch, Uxbridge, UK) with the external fixator in place. Care 
was  taken  to  ensure  perpendicular  cuts  and  normal  saline  was  instilled  throughout 
sawing to provide lubrication and prevent thermal necrosis. The segment of bone was 
removed along with any remaining periosteum. 
 
Table 5.4  Insertion order of Schanz screws into the ovine tibiae. Note screws at position 
A and B had a 30 mm threaded section (20 mm for all other screws). 
Schanz 
screw 
Order of insertion 
(1 to 6) 
 
 
Proximal 
 
A  6 
B  2 
C  4 
 
 
Defect 
 
 
D  3 
E  5 
F  1 
Distal 
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Fig. 5.5  Tibial  segmental  defect  operative  procedure.  Following  hide  preparation  and 
draping: a) an anteromedial approach was used to access the diaphyseal portion of the right 
tibia, b) The periosteum was carefully and entirely removed around the site of the proposed 
ostectomy, c) The proprietary jig was secured against the bone and the 35 mm ostectomy was 
marked on the tibia using diathermy, d) Six 4 mm diameter holes were drilled through the jig 
guides and e) Schanz screws were inserted in a standardised order. f) The jig was removed 
and the external fixator was secured in place. g) The ostectomy was made at the pre-marked 
site using an electric reciprocating sagittal saw. h) The segment of bone was removed along 
with any remaining periosteum. i) Appearance following closure. 
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5.4.4.6.2.3  Scaffold insertion and stabilisation 
The defect was gently washed with saline to remove excess bone debris. For animals 
assigned  to  group  1  (negative  controls),  5  ml  of  0.25%  bupivacaine  (Marcain, 
AstraZenica UK Ltd, Luton, UK) was infiltrated around the wound for post-operative 
analgesia prior to closure. Animals in groups 2 and 3 (positive controls and treatment 
group) received the polymer without and with autologous ovine SSCs respectively (Fig. 
5.6), prior to infiltration of 5 ml of 0.25% bupivacaine. 
 
 
Fig. 5.6  a) Empty defect and b) scaffold in situ, immediately prior to closure 
 
A  calibration  screw  on  the  external  fixator  allowed  incremental  modifications  in  the 
defect size, enabling compression fitting of the scaffold between the two cut bone ends. 
Furthermore, this allowed final adjustments to be made to the size of the ostectomy 
gap, to ensure the gap was exactly 35 mm. 
 
5.4.4.6.2.4  Closure and dressings 
The fascia was closed with continuous 0 polyglactin (Vicryl, Ethicon) sutures and the 
hide closed with interrupted 3/0 nylon (Ethilon, Ethicon) mattress sutures. OpSite spray 
(Smith & Nephew, Hull, UK) and gauze dressings were applied to the operative site. All 
nuts  and  bolts  on  the  external  fixator  where  checked  to  ensure  tightness  and  the 
protruding ends of the Schanz screws were cut short using bolt cutters. The entire 
construct was dressed with wool and crepe bandages and secured using adhesive 
tape. 
 
5.4.4.6.3  Peri-operative radiography 
Anteroposterior  and  lateral  radiographs  were  made  of  the  entire  tibia  before 
anaesthetic  reversal,  each  including  a  radiographic  aluminium  step  wedge  (CNMC, 
Nashville, USA) for densitometric analysis (fig. 5.7 a). 
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5.4.4.6.4  Post-operative procedure 
Following  extubation,  the  sheep  were  sat  up  and  rested  against  the  side  of  their 
individual enclosures. Careful observations were taken with reducing frequency over 
the  initial  24  hour  post-operative  period.  Five  cefalexin  doses,  once  daily  were 
administered  and  post-operative  analgesia  consisted  of  a  Fentanyl  patches  for  48 
hours followed by buprenorphine (Vetergesic, Alstoe Animal Health, Melton Mowbray, 
UK) intramuscular injection once daily as required. Sheep were allowed to mobilise full 
weight bearing immediately as tolerated with unhindered access to food and water for 
the  remainder  of  the  study  period  (Fig.  5.7  b).  Weekly  checks  were  made  of  the 
wounds and fixators to ensure there was no loosening, and sutures were removed after 
14 days. 
 
 
Fig. 5.7  Post-operative  procedure:  a)  Portable  x-ray  machine  used  to  make  radiographs 
post-operatively.  b)  A  sheep  within  two  hours  post-operatively  standing  fully  weight-bearing. 
Note the dressings securely covering the external fixator and operative site. 
 
5.4.4.7 Post-operative analysis 
Sheep underwent sedation (as previously described) for further radiography of the tibia 
at two and six weeks post-operatively. 
 
5.4.4.8 Euthanasia and specimen harvest 
Euthanasia was performed 12 weeks after the operative day with pentobarbital solution 
20% (Pharmasol Ltd, Andover, UK). The tibiae were disarticulated with fixators in situ, 
surrounding musculature and soft tissue were carefully removed without disturbing the 
constructs  and  final  radiographs  were  made.  The  contralateral  tibiae  were  also 
harvested and prepared similarly to act as controls for mechanical testing. Specimens 
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5.4.4.9   Post-mortem specimen analysis 
In  addition  to  post-operative  radiographs,  each  specimen  underwent  the  following 
analysis: 
 
5.4.4.9.1  µCT analysis 
External fixators were removed from the frozen specimens, however the Schanz pins 
were left in situ and used to support specimens during CT scanning. All samples were 
scanned  using  an  Xtek  Benchtop  160Xi  scanner  (Xtek  Systems  Ltd,  Tring,  UK) 
equipped with a Hamamatsu C7943 X-ray flat panel sensor (Hamamatsu Photonics, 
Welwyn Garden City, UK). Scan resolution was up to 31 µm at 150 kV and 60 µA, 
using a molybdenum target with an exposure time of 534 ms and four-fold digital gain. 
Reconstructed  volume  images  were  analysed  using  VGStudio  Max  1.2.1  software 
(Volume  Graphics  GmbH,  Heidelberg,  Germany).  Initial  scans  were  used  as  an 
overview of new tissue formation, and captured a 60 mm length, centred upon the 
segmental defect. Further high-resolution scans were made of regions of interest. 
 
5.4.4.9.2  Mechanical testing 
Following CT visualisation, the specimens were defrosted entirely and the constructs 
were assessed for maximum strength under torque loading. This was deemed the most 
suitable  method  as  the  mode  of  failure  of  long  bones  of  the  lower  limbs  is  most 
frequently  through  compressive  torque.  Test  constructs  were  compared  with  whole 
tibiae from the contralateral side. The soft tissue at the ends of the tibiae was removed 
before  being  potted  in  quick-set  cement  (Polycell,  ICI,  London,  UK)  in  a  custom 
designed rig. The gauge length was measured as the distance between the potted 
ends of the tibia. The tibiae were tested at a rate of 1° per second in an Instron 8874 
(Instron Corp., MA, USA) to 90° of rotation (Fig. 5.8). 
 
Dimensions of the bones were obtained from the intact tibiae after failure. The control 
tibiae were assumed to be hollow cylinders, with the dimensions based on an average 
of  three  measurements  of  the  diameter  and  wall  thickness.  Values  for  the  tibiae 
containing scaffolds were calculated using the scaffold dimensions. The shear modulus 
(GPa), bone stiffness (Nm/degree and Nm/radians), maximum torque (Nm), maximum 
shear  stress  (MPa)  and  the  maximal  angular  deformation  at  failure  (degrees)  was 
calculated for each sample where a definite failure occurred. 
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Fig. 5.8  Constructs and intact tibiae (shown here) were assessed for maximum strength under 
torque loading using an Instron testing rig 
 
 
5.4.4.9.3  Macroscopic analysis 
Preparation  of  the  specimens  for  analysis  also  enabled  a  thorough  macroscopic 
evaluation of the integrity of scaffold material as well as an assessment of scaffold 
integration and mode and site of failure. 
 
5.4.4.9.4  Histology 
Following mechanical testing, several samples, each measuring approximately 10 mm
3 
and representing a region of interest (ROI), were removed from each construct. ROI 
were as follows (Fig. 5.9): 
 
A  –  the  interface  between  the  proximal  cut  end  of  tibia  and  polymer  scaffold;  to 
demonstrate any integration that may strengthen the construct. 
 
B – an area on the surface of the mid-section of scaffold; to demonstrate any new 
tissue at the furthest distance from native bone ends, but closely exposed to the host 
vasculature. 
 
C – an area on the inner face of the scaffold mid-section; to demonstrate new tissue at 
the furthest distance from the bone ends, and also distant from host vasculature, thus 
relying upon diffusion and new vessel in-growth for regeneration to take place. 191 
 
 
 
 
Fig. 5.9  Cubes of tissue/polymer were taken from the indicated regions for histological 
analysis: a) the interface between the proximal cut end of tibia and polymer scaffold, b) an 
area on the surface of the mid-section of scaffold, c) an area on the inner face of the scaffold 
mid-section 
 
 
Each ROI specimen was decalcified over a period of approximately four weeks using 
Tris-EDTA  (using  Faxitron  analysis  to  confirm  complete  decalcification),  before 
embedding in wax and cutting into 5 µm semi-sequential sections and mounting on 
slides  (as  previously  described  in  Chapter  IV).  Slides  were  stained  with  A/S  (see 
Chapter IV) before visualisation using a Zeiss Axiovert 200 inverted microscope (Carl 
Zeiss Ltd. Welwyn Garden City, UK). 
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5.5  Results 
 
5.5.1  Preliminary experiments 
 
5.5.1.1 Confirmation of scaffold porosity 
Although this polymeric scaffold had previously been produced on a small scale and 
assessed for its utility in a murine in vivo model (Khan et al. 2010), it was necessary to 
verify that scaffolds manufactured to a scale suitable for clinical implantation would 
possess the same architecture and overall structure. SEM confirmed a range of pore 
diameters from 300 µm to 1.5 mm, with significant pore interconnectivity (Fig. 5.10). 
 
 
 
Fig. 5.10  SEM  images  of  polymer  scaffold  demonstrating  multiple  pores  of  varying 
dimensions necessary for rapid cellular infiltration 
 
 
The Alcian blue penetration test showed considerable permeation of the dye through 
the scaffold structure, which was confirmed to exist throughout the scaffold by cutting 
sections through it (Fig. 5.11). This further confirmed pore interconnectivity sufficient for 
diffusion of nutrients and metabolic waste products from cells within the polymer matrix. 
These properties are critical to allow cellular adhesion, penetration and infiltration. 
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Fig. 5.11  Alcian blue penetration test: a) experimental set-up, the polymer is suspended in a 
perforated specimen container and the proximal end ‘sealed’ with histology wax before addition 
of Alcian blue. b) Polymer scaffold following experiment and removal of wax, note the blue dye 
is  visible  throughout  the  sample.  c)  The  scaffold  was  dissected  into  four  pieces.  d)  Cross 
sections of the scaffold from proximal (left) to distal (right), demonstrating even penetration of 
the dye throughout the specimen, with  particular staining  around the larger pores. Note the 
absence of a diffusion gradient. 
 
 
5.5.1.2 Isolation and culture of ovine SSCs 
Following standard isolation and monolayer culture techniques on tissue culture plastic, 
ovine cells grew to full confluence in both basal and osteogenic medium (Fig. 5.12). No 
major differences in morphology or speed of growth were observed between the two 
groups and therefore the decision was made to seed the ovine SSCs for group 3 of the 
segmental defect model in osteogenic conditions. 
 
 
Fig. 5.12  Ovine BMA cells grown to confluence on monolayer tissue culture plastic in a) 
basal and b) osteogenic conditions. Scale bar: 200 µm 194 
 
5.5.1.3 In vitro incubation of ovine SSCs with test scaffold 
Analysis of DNA concentration (Fig. 5.13 a) showed the scaffolds with cells incubated 
in osteogenic conditions contained substantially more DNA after 28 days incubation, 
indicating  improved  cell  survival  and  proliferation  over  those  incubated  in  basal 
conditions.  Seeding  density  did  not  appear  to  be  such  an  important  factor.  ALP 
concentration  (Fig.  5.13  b)  was  similar  amongst  all  seeding  densities  and  culture 
conditions, with substantial ALP production even in cells cultured in basal medium. 
Note that even though basal samples were seeded at a higher density (5x10
5 cells/ml) 
than any of the osteogenic samples, all of the latter samples resulted in higher DNA 
and ALP concentrations. 
 
 
 
Fig. 5.13  a)  DNA  and  b)  ALP  assays  of  ovine  cells  cultured  with  10  mm  cubes  of 
polymer scaffold in either basal or osteogenic (osteo) conditions. Error bars denote SD, all 
results analysed in triplicate. 
 
 
Vybrant
® Green staining of scaffolds incubated for 28 days with ovine SSCs in both 
basal  and  osteogenic  conditions,  revealed  intense  staining  of  live  cells  coating  the 
polymer.  Additionally,  when  cultured  in  osteogenic  conditions,  the  cells  displayed 
bridging across the porous network of the scaffold and were seen to penetrate deeply 
within the polymer structure (Fig. 5.14). 
 
Following these preliminary investigations, it was therefore decided that the scaffolds 
should be incubated with ovine cells at a concentration of 5x10
5 cells/ml, in osteogenic 
medium, for 7 days prior to transfer into the in vivo ovine segmental defect. 
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Fig. 5.14  Vybrant
®  Green  cell  viability  analysis  for  ovine  cells  grown  on  polymer 
scaffold  for  28  days,  a)  in  basal  conditions,  b-d)  in  osteogenic  conditions,  c)  higher 
magnification confirming bridging of the cells across the polymer pores, d) higher magnification 
of the cut surface of polymer revealing a pore in cross sectional profile, note deep penetration of 
cells into the pore. Scale bars: a) and b) 200 µm, c) and d) 500 µm 
 
 
5.5.2  Ovine tibial segmental defect model 
 
5.5.2.1 Complications of surgical procedure and anaesthesia 
All  aspiration,  cell  culture  and  surgical  procedures  were  technically  successful.  No 
sample  became  infected  during the  in  vitro  stage  of  the study.  None  of  the sheep 
suffered superficial or deep wound infection, and all ambulated and were fully weight-
bearing at one week following operative intervention (Table 5.5). 
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Table 5.5  Summary  of  segmental  tibial  defect  operative  procedures  in  this  study, 
presented in the order of the operative procedure 
Study 
number 
Pre-operative 
weight (kg) 
Operative group 
Analysis 
number 
Complications/notes 
5960  84  Scaffold  5   
5849  78  Empty defect  1   
5840  75  Scaffold + SSCs  9   
5962  85  Scaffold + SSCs  10   
6020  75  Scaffold + SSCs  11   
5987  65  Empty defect  2   
6003  70  Scaffold  6   
6016  60  Scaffold  7   
5922  75  Scaffold + SSCs  12   
6017  60  Scaffold  8   
5948  65  Scaffold  -  Post-operative death 
5964  75  Empty defect  3  Post-operative slip of fixation 
5846  80  Empty defect  4   
Analysis number refers to the number assigned to the specimen for post-mortem analysis and is 
henceforth indicated in this report. 
 
There was one sheep death secondary to anaesthetic complications and one minor 
failure of fixation: 
 
One  sheep  suffered  respiratory  difficulties  intra-operatively  during  segmental  defect 
fixation. Respiratory support could only be withdrawn slowly during recovery and the 
sheep suffered cardio-respiratory arrest approximately 15 minutes following extubation 
and could not be revived. Post mortem analysis revealed lungworm infestation. Another 
sheep from the same flock was used to take its place and maintain the original study 
number of 12 animals. 
 
The external fixator of one sheep (number 3) slipped by approximately 1 mm, as noted 
on  the  second  post-operative  radiograph.  The  fixator  bolts  were  re-tightened 
immediately  in  situ  following  recognition  of  this  complication,  and  no  further  slip 
occurred. Following this, a supplementary rigid metal bar was attached between the 
proximal and distal body of each external fixator to avoid any undetected compression. 197 
 
 
5.5.2.2 Radiographic analysis 
Lateral radiographs  of each  tibia  were  made at  incremental  periods throughout  the 
study (at day 0 and weeks 2, 6 and 12 post-operatively), using the same protocol and 
arranged  to  allow  a  comparison  of  defect  size  throughout  the  experimental  period 
(Figs. 5.15 – 5.17). 
 
No fracture or fixation failure was noted in any group and the fixator stability and defect 
size was such that union was prevented in all empty defect samples – confirmation of a 
critical sized defect (Fig. 5.15). Radiographic analysis however, showed little osseous 
formation in any sample of the polymer scaffold groups during the study period (Figs. 
5.16 and 5.17). 
 
Fig. 5.18 demonstrates the typical pattern of new bone formation in each group: in the 
empty  defects  there  was  minimal  osteogenesis  that  formed  into  a  conical  pattern, 
mainly  from  the  proximal  cortices;  in  the  scaffold  alone  group,  increased  bone 
formation was evident from both the proximal and distal bone ends that appeared more 
evenly throughout the structure of the scaffold polymer; in the scaffold and cells group, 
most bone formation occurred within the central cannulation of the scaffold. Although 
minor areas of calcified tissue are seen projecting particularly from the proximal bone 
ends in all groups (Fig. 5.18), union was not demonstrated in any specimen after 12 
weeks. 198 
 
 
 
Fig. 5.15  Incremental lateral radiographic analysis of the fixated tibiae of sheep 1-4 in 
the empty defect group analysed immediately post-operatively (0 weeks) and at 2, 6 and 12 
weeks post operatively. Images show region of interest, which includes four of the six Schanz 
pins and the defect. There is little new bone formation within the defect site, although after 12 
weeks some calcification is visible emanating from the proximal portion of the ostectomy.  199 
 
 
 
Fig. 5.16  Incremental lateral radiographic analysis of the fixated tibiae of sheep 5-8 in 
the scaffold alone group analysed immediately post-operatively (0 weeks) and at 2, 6 and 12 
weeks post operatively. Images show region of interest, which includes four of the six Schanz 
pins and the defect. There is little new bone formation within the defect site, although after 12 
weeks some calcification is visible emanating from the proximal portion of the ostectomy in most 
samples, and also the distal aspect in some specimens. 
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Fig. 5.17  Incremental lateral radiographic analysis of the fixated tibiae of sheep 9-12 in 
the scaffold and cells group analysed immediately post-operatively (0 weeks) and at 2, 6 and 
12  weeks  post  operatively.  Images  show  region  of  interest,  which  includes  four  of  the  six 
Schanz pins and the defect. There is little new bone formation within the defect site, although 
after  12  weeks  some  calcification  is  visible  emanating  from  the  proximal  portion  of  the 
ostectomy in most samples, and also the distal aspect in some specimens. 
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Fig. 5.18  The typical pattern of new bone formation in each group: In the empty defects 
(3) there was minimal osteogenesis that formed into a conical pattern, mainly from the proximal 
cortices; in the scaffold alone group (5), increased bone formation was evident from both the 
proximal  and  distal  bone  ends  that  appeared  more  evenly  throughout  the  structure  of  the 
scaffold polymer; in the scaffold and cells group (11), most bone formation occurred within the 
central cannulation of the scaffold. 
 
 
5.5.2.3 µCT analysis 
Analysis using quantitative CT radiography techniques produced reformatted images of 
each specimen centred upon the defect site (Fig. 5.19). These images largely confirm 
the plain radiographic findings that empty defects undergo a process of atrophic non-
union. There is little difference in bone formation between the two scaffold groups, 
although more regeneration is confirmed in these latter groups compared to empty 
defect controls. 
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Fig. 5.19  Quantitative  µCT  analysis  at  12  weeks  post-operation.  There  is  minimal 
regenerative  activity  in  the  empty  defect  specimens.  Some  bone  formation  is  seen  in  both 
scaffold groups, although there is no certain difference in the group with added SSCs. 
 
Quantitative analysis of the volume of new bone formation within the ostectomy site 
revealed  a  trend  towards  increasing  bone  formation  with  scaffold  and  again  with 
scaffold and SSCs when compared to the empty defect, however this failed to reach 
statistical significance (p=0.07) (Fig. 5.20). 
 
 
Fig. 5.20  Quantitative µCT analysis of new bone formation after 12 weeks incubation. 
Error bars: SD 203 
 
5.5.2.4 Mechanical testing 
Bones were tested to failure at 1° per second. Only samples which demonstrated a 
definite failure before 40° were included in the analysis to ensure accurate values could 
be ascribed to a specific point of failure. This excluded all the empty defect samples 
and one of the scaffold-containing samples (Fig. 5.21). 
 
 
Fig. 5.21  Results  of  mechanical  testing  for  the  sheep  tibiae  under  torsional 
compression demonstrating a) Maximum torque and b) Maximum shear stress before failure. 
Control refers to the contralateral intact tibia. Error bars: SD 
 
 
5.5.2.5 Macroscopic analysis 
Following  mechanical  testing,  macroscopic  analysis  of  each  specimen  (Fig.  5.22) 
confirmed  atrophic  non-union  had  occurred  in  every  empty  defect  specimen.  As 
demonstrated by plain radiographic and µCT analysis, minimal osteogenesis had taken 
place  in  these  specimens,  forming  a  conical  projection  mainly  from  the  proximal 
cortices. In the scaffold alone group, increased bone formation was evident from both 
the  proximal  and  distal  bone  ends  obscuring  the  interface  between  the  bone  and 
polymer scaffold, except in one case (white arrow in Fig. 5.22). Only the central portion 
of the scaffold exterior was visible in the remaining specimens, although this still had 
structural integrity. The interface between scaffold and diaphysis appeared even more 
indistinct in the scaffold + SSCs group, with coverage of the scaffold by soft reparative 
tissue in continuity with bone. In three of the four specimens in each scaffold group 
failure occurred through the scaffold itself, usually as a transverse or short oblique 
fracture  line  (Fig.  5.22),  however  failure  occurred  at  the  distal  scaffold-diaphysis 
interface in one specimen of each scaffold group (white and black arrows, Fig. 5.22 - 8 
and 11).  
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Fig. 5.22  Macroscopic  specimen  analysis  following  mechanical  testing.  Regions  of 
interest in each image show the proximal diaphysis (left), the distal diaphysis (right) and defect 
containing no scaffold (1-4), scaffold alone (5-8), or scaffold with cells (9-12). Failure occurred 
through the scaffold itself in three of the four specimens in each scaffold group; however failure 
occurred  at  the  distal  scaffold-diaphysis  interface  in  one  specimen  of  each  scaffold  group 
(arrows in 8 and 11). 
 
 
A feature of new tissue growth that was seen only in specimens from the scaffold + 
SSCs group was intramedullary growth up the central canal of the polymer scaffold 
(Fig. 5.22 – 11 and Fig. 5.23). The extent of this tissue growth was not appreciated by 
radiographic imaging modalities as the tissue was not fully calcified and has a similar 
density to the surrounding polymer scaffold, but provided full continuity between the 
proximal and distal bone segments in these specimens. 
 
 
 205 
 
 
 
 
Fig. 5.23  Macroscopic image of a tibia treated in the scaffold + SSCs group (specimen 9 
in Fig. 5.22). The polymer scaffold in this case was largely fragmented following mechanical 
testing and has been carefully removed to reveal a central bridge of new tissue formation within 
the  medullary  cavity  of  the  scaffold.  Note  full  continuity  between  the  proximal  and  distal 
diaphyseal segments. 
 
 
5.5.2.6 Histology 
Histological examination of the three regions of interest as defined previously (Section 
5.4.4.9.4) revealed a consistent pattern of tissue regeneration within the defect site in 
both  groups  containing  polymer  scaffold  (Fig.  5.24).  Insufficient  tissue  was  formed 
within the empty defect group to enable histological processing and analysis. In both 
the scaffold alone and scaffold with SSCs specimens, there was significant infiltration 
of new tissue into the polymer scaffold at the bone-scaffold interface (region A), as 
demonstrated by staining of collagen type I with Sirius red. In this zone, most pores 
within the scaffold had been filled by new bone and entirely surrounded the polymer 
‘islands’. In region B, near the surface of the mid-section of scaffold, new osseous 
tissue was consistently seen in both scaffold groups, with direct contact of this red-
staining tissue with the polymer and deep penetration of tissue into the porous network. 
Region C, within the inner face of the scaffold mid-section showed no new osseous 
tissue formation in either scaffold group. The polymer in this region remained intact 
with some surrounding cells, but no new bone formation. 
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Fig. 5.24  A/S histological analysis of the ovine segmental tibial defect model after 12 
weeks in vivo incubation. Only the scaffold groups are displayed, as insufficient tissue was 
formed  within  the  empty  defects  for  histological  processing.  In  region  A  (bone-scaffold 
interface),  there  was  significant  infiltration  of  new  tissue  into  the  polymer  scaffold  at  the  as 
demonstrated by red staining of collagen type I. In region B (near the surface of the mid-section 
of scaffold), new osseous tissue was seen in both scaffold groups, with deep penetration of 
tissue into the porous network. Region C (within the inner face of the scaffold mid-section) 
showed no new osseous tissue formation in either scaffold group. The polymer in this region 
remained intact with some surrounding cells, but no new bone formation. Polymer is marked 
with *, scale bars: 100 µm. 
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5.6  Discussion 
 
The purpose of this study  was to establish an appropriate large animal model that 
could be used consistently for the evaluation of putative tissue engineering constructs 
for  skeletal  regeneration,  as  a  necessary  prequel  to  potential  clinical  trials  and 
subsequent clinical application. Although the initial introduction of a new large animal 
model into a research establishment is often fraught with difficulties, this is a pivotal 
and essential step towards a systematic process of product testing and development. 
This study therefore evaluated both the inception of a new skeletal regeneration model 
as  well  as  assessing  the  efficacy  of  a  binary  blend  polymeric  scaffold  (PLLA/PCL 
(80/20)) that had already proven successful in vitro and in a small animal in vivo model 
(Khan et al. 2010). Following substantial preliminary investigations to define the most 
appropriate animal and anatomical site for testing, an ovine tibial segmental defect 
model with external fixation was chosen. Sheep are readily available, economical and 
docile. In addition, sheep share important similarities to humans (similar body weight, 
bone dimensions  and osseous micro-architecture), which  make them useful as test 
subjects  for  musculoskeletal  investigations.  External  fixators  are  particularly 
appropriate to this study as they are used clinically in bone defect surgery, but they 
have additional advantages during experimental procedures as they do not affect the 
defect site and allow easier radiographic and histological analysis. 
 
Preliminary experiments to assess the polymer structure demonstrated a good network 
of interconnected pores with a wide range of diameters and good permeability. A thin 
film of polymer was noted to cover each scaffold and had to be removed manually to 
ensure continuity of the porous network. This is a result of the manufacture process 
and would have to be addressed prior to high output production of a similar polymer in 
future applications. Aspiration, storage and processing of ovine BMA was successful 
and in vitro growth of ovine SSCs on the polymer was rapid and appeared to penetrate 
deeply  within  the  structure  of  the  scaffold  without  observed  cellular  necrosis. 
Furthermore,  osteoblastic  activity  was  observed  in  these  cells  following  culture  in 
osteogenic conditions. Thus, an ovine SSC collection, seeding and in vitro incubation 
protocol has been defined for application to large polymeric scaffolds, which could be 
replicated in future similar studies. 
 
Most aspects of the segmental defect operative procedure itself were successful. Apart 
from an explained death following general anaesthesia and a single incidence of minor 
fixator  slippage,  which  was  easily  rectified,  all  aspects  of  sheep  handling, 208 
 
premedication,  anaesthesia,  aspiration,  preparation,  ostectomy,  fixation,  recovery, 
analgesia,  post-operative  care,  radiography,  termination  and  sample  harvesting 
proceeded without incident. 
 
Several aspects of post mortem analysis required modification to account for the large 
specimens  resulting  from  the  study.  Consequently,  some  of  the  analysis  was 
rationalised to allow processing within the limitations of the equipment and facilities 
available  in  our  laboratories.  Histological  preparation  in  particular,  was  limited  by  a 
requirement to decalcify all tissue prior to processing. Consequently, only small regions 
could be analysed separately, rather than the ideal scenario where an entire cross-
section  through  the  un-decalcified  defect  would  be  mounted  on  a  single  slide  for 
analysis. In order to maximise useful data, implementation of necessary equipment and 
expertise for this technique should be considered when planning future large animal 
studies. 
 
Plain radiographic and µCT results correlated closely: the technique has been shown to 
create  a  replicable  critical  sized  segmental  defect  using  all  analytical  modalities. 
Furthermore,  addition  of  the  scaffold  tended  to  enhance  bone  formation  when 
compared to the empty defect, although this did not reach statistical significance, and 
addition of SSCs did not demonstrably enhance bone formation. Soft tissue formation 
however did appear to be enhanced by the addition of SSCs to the construct and was 
only  visualised  macroscopically  and  on  histological  analysis.  This  may  indicate  a 
prequel to eventual osteogenesis, and although the time periods involved for this model 
to demonstrate complete union are too long to be clinically favourable, they do provide 
encouragement  for  future  studies  based  on  this  ovine  model  and  similar  polymer 
blending technology. 
 
Mechanical strength testing confirmed the contralateral (un-operated) tibiae possessed 
similar  strength characteristics to previously published results for mammalian bone: 
shear moduli for human and bovine cortical bone have been published as 3.51 and 
4.14  GPa  respectively  (Cowin  1989),  which  correspond  with  our  mean  ovine  tibial 
values  of  2.45  GPa  (SD  0.73).  The  mean  maximum  torque  for  ovine  tibiae  in  the 
current  study  was  66.82  Nm  (SD  2.88),  which  correlates  closely  with  previously 
published  ovine  tibia  destructive  tests  (Jamsa  and  Jalovaara  1996).  Additionally, 
torsional  stiffness  values  are  similar  to  those  previously  published  for  ovine  tibiae 
(Reichel  et  al.  1998,  Gao  et  al.  1997).  These  studies  validate  our  methods  for 
mechanical strength testing and justify the assumption required for calculation that the 209 
 
tibiae are cylindrical. The findings that all mechanical strength modalities tested were 
significantly lower for the test tibiae, and that no significant increase was obtained by 
the addition of scaffold or scaffold and SSCs are therefore valid. 
 
Histological  analysis  demonstrated  several  encouraging  findings:  1)  the  polymer 
scaffold was still present and had maintained its structural architecture at 12 weeks 
incubation;  2)  furthermore,  in  the  scaffold  groups,  there  was  close  apposition  and 
penetration of tissue staining for collagen type I into the porous scaffold network. The 
toxic effect of by-products formed during polymer scaffold breakdown is frequently cited 
as a reason for failure of a tissue engineering construct, although it appears in this 
case not to have adversely affected the surrounding tissue. Even though little new 
calcified bone was seen on radiographic analysis, the histological results demonstrate 
regenerative  tissue  forming  throughout  the  circumference  of  the  scaffold,  and 
penetrating to some extent into the porous scaffold substance. However, no new tissue 
was seen within the central scaffold area (region C). This area would be expected to 
regenerate  last  because  it  is  located  deep  within  the  polymer,  furthest  away  from 
osteogenic  influences  of  the  bone  ends  and  periosteum,  and  poorly  exposed  to 
surrounding  vasculature.  Tissue  that  was  formed  stained  uniformly  with  Sirius  red, 
implying  a  high  concentration  of  type  I  collagen.  Conversely,  modest  Alcian  blue 
staining  was  seen,  confirming  osteogenic  rather  than  chondrogenic  differentiation, 
appropriate to a skeletal regeneration strategy. The presence of abundant uncalcified 
matrix suggests that relatively small changes in the protocol may lead to substantial 
bone development. 
 
All the analyses confirmed a trend towards increasing bone formation with the polymer 
scaffold when compared to the empty defect, although this effect has not been proven 
to be significant. Furthermore, the addition of autologous SSCs to the construct does 
not  categorically  further  enhance  skeletal  regeneration,  but  may  accelerate  the 
formation of precursor tissue. 
 
There  are  multiple  additional  factors  which  must  be  considered  when  up-scaling  a 
successful  small  animal  study,  and  each  may  account  for  the  failure  of  additional 
regeneration seen in this study (Table 5.6). A systematic approach to critically evaluate 
each aspect of study design and technique is required to refine and improve future 
studies; however it is particularly difficult to define the cause of failure in this study as a 
simultaneous evaluation of multiple unknown variables was attempted – neither the 
validity of the large animal model, nor the efficacy of the large-scale polymer scaffold 210 
 
with ovine SSCs had previously been assessed. Consequently, it is not possible to 
conclude whether the regenerative model, the scaffold or some technical aspect of 
implantation was at fault. Despite this, the failings of a technique can often only be 
seen in retrospect, no matter how carefully the procedure is planned and there is no 
substitute for direct experience when carrying out such a study. 
 
There  are  particular  aspects  of  this  model  that  will  require  further  confirmation, 
adaptation or modification before it can be adopted as a standard technique for large 
animal scaffold evaluation, and these will have to be undertaken prior to subsequent 
work. Although the scaffold was shown to have porous interconnections, work should 
continue to refine manufacture of these polymers to avoid the thin film of non-porous 
polymer coating that was encountered in this study and to maximise overall porosity 
and nutrient diffusion without adversely affecting its structural properties. 
 
Assessment of cell viability and ALP activity prior to implantation confirmed the ovine 
SSCs  adhered  and  grew  throughout  the  polymer  scaffold,  although  further  work  is 
warranted to refine ovine cell culture protocols to maximise osteogenic differentiation. 
Unfortunately,  due  to  the  significant  transit  time  between  the  laboratory  and  the 
operating  facility,  scaffolds  were  removed  from  the  incubator  and  stored  in  culture 
medium within an insulated airtight container for approximately two hours immediately 
prior  to  surgery.  Therefore,  it  would  have  been  useful  to  re-evaluate  cell  viability 
immediately prior to implantation, as this process is likely to have led to significant peri-
operative cell death. If such transit times cannot be avoided in future studies, attention 
should  be  turned  to  higher  initial  cell  seeding  density  or  dynamic  seeding  and 
incubation. 
 
In  common  with  many  clinical  operative  procedures,  a  local  anaesthetic  agent 
(bupivacaine)  was  infiltrated  around  the  ostectomy  site  to  provide  post-operative 
analgesia.  Subsequent  in  vitro  testing  suggests  significant  toxicity  to  human  SSCs 
following exposure to local anaesthetic agents (see Chapter VI) and this may account 
for the lack of enhanced regeneration seen in the scaffold and cells group. 
 
The stiffness of the external fixation construct may have had a significant effect on the 
rate  of  bone  regeneration.  It  is  known  that  relative  stability  allows  secondary  bone 
healing by callus formation, whereas absolute stability leads to primary bone healing. 
Primary bone healing tends to occur most favourably when two bone ends are closely 
opposed and osteonal remodelling can occur by the advancement of cutting cones. 211 
 
However, in a construct where a large defect is present, such as in a 35 mm segmental 
defect, relative stability is desirable to promote callus formation and secondary bone 
healing. The external fixator was applied in this study in a very stable configuration with 
high stiffness and little relative movement. This combined with complete removal of the 
periosteum, would have adversely affected both the mechanical and biological stimuli 
for bone healing. Although many authors suggest a defect of greater than 30 mm is 
required  to  be  considered  critical,  it  is  likely,  because  of  these  factors,  that  our 
technique would produce a much smaller critical sized defect. Therefore, much less 
bone regeneration would be expected. This may be overcome in future by preserving 
periosteum,  adopting  a  less  rigid  fixation  construct  or  allowing  some  form  of 
dynamisation. 
 
 
Table 5.6  Factors  which  should  be  considered  and  modified  prior  to  further  large 
animal skeletal engineering biomaterial evaluation 
Initial in vitro scaffold incubation 
Scaffold porosity and pore interconnectivity 
Absence of impermeable scaffold surface coating 
Dynamic cell seeding and incubation – consider using a bioreactor 
Confirmation of cell viability, differentiation and scaffold penetration prior to implantation 
Reduce transit time prior to implantation 
In vivo incubation 
Size of segmental defect 
Operative technique – removal of periosteum 
Potential toxicity of operative adjuncts e.g. local anaesthetic infiltration 
Construct stiffness, stability and micromotion 
Duration of incubation 
Analytical factors 
Requirement for decalcification prior to analysis 
Ability to analyse large specimens for microscopic and macroscopic signs of integration 
Ability to differentiate between scaffold and new tissue growth 
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These  factors  highlight  some  of  the  hurdles  that  need  to  be  overcome  before 
successful  outcomes  can  be  expected  from  large  animal  trials  in  our  laboratories. 
There  are  many  unexpected  factors  that  influence  the  formation  of  a  valid  tissue 
engineering construct and these can often only be identified in retrospect. This also 
serves to underline the critical importance of well-conducted large animal studies in the 
assessment of therapeutic products, so that any adverse factors can be resolved prior 
to human clinical application. 
 
 
In conclusion, the first objective; to establish a consistent tibial critical defect model in 
sheep, has been fulfilled. The second objective; to demonstrate a living cell composite 
using cultured skeletal stem cells on synthetic scaffold to augment bone formation in a 
large animal segmental defect model, has been partially fulfilled. The null hypothesis: 
that the polymeric binary blend biomaterial PLLA/PCL (20/80) does not function 
as  a  suitable  scaffold  for  skeletal  regeneration  strategies  in  an  ovine  tibial 
segmental defect model cannot be rejected, thus further work should be performed 
to  refine  the  ovine  segmental  defect  model,  the  polymeric  scaffold  and  large  scale 
analytical techniques used in these studies. 
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Chapter VI 
 
Hurdles to successful clinical translation – 
The effect of commonly used local anaesthetics on 
skeletal stem cell viability and function 
 
 
 
 
The in vitro work and analysis within this chapter was performed jointly with Mr Edward Tayton. I 
am also grateful to Mr Alexander Aarvold, Ms Spandan Kalra and Miss Esther Ralph whose 
support was crucial for successful completion of this study. 
 
 
 
 
 
 
A  paper  containing  the  in  vitro  work  has  been  published  in  the  Journal  of  Bone  and  Joint 
Surgery (Br) under joint first authorship 
 
A presentation based in this study was awarded first prize at the Gauvain Scientific Meeting, 
Southampton, 2011 
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6.1  Introduction 
 
Despite  some  excellent  recent  advances  in  the  field  of  tissue  engineering  and 
consistent high levels of government research funding, only a small proportion of the 
successful basic science research currently reaches  in vivo analysis with a view to 
clinical  translation.  Critically,  even  fewer  strategies  are  successfully  scaled-up  for 
commercial manufacture and clinical use (Mason and Manzotti 2010). This translational 
gap often referred to in financial venture capital circles as the ‘Valley of Death’ is highly 
relevant for the development of regenerative medicine (Hollister 2009). There is no 
single  cause  for  this  disparity;  rather,  it  is  the  result  of  a  complex  of  practical, 
regulatory,  logistical  and  financial  factors,  which  serve  to  ensure  only  the  most 
promising strategies ultimately succeed. 
 
One  factor  which  may  have  presented  a  particular  confounder  to  the  successful 
progression of the tissue engineering strategy described in Chapter V of this thesis was 
the potential of local anaesthetic (LA) agents to cause toxicity to the developing cell 
construct. In light of this, an in vitro study was devised to assess the effects of these 
agents on the viability of SSCs. 
 
LA infiltration is recommended in both large animal veterinary practice and in human 
clinical procedures for peri-operative analgesia.  In regard to the  large animal study 
(presented in Chapter V), and also for potential clinical translation of new strategies, it 
is of fundamental importance to establish any effects this may have on the implanted 
construct,  particularly  the  SSCs  contained  therein.  Methods  of  LA  administration, 
routinely employed to ensure analgesia in orthopaedic practice, include intra-articular 
injection or infusion, and subcuticular wound infiltration (Moiniche  et al. 1999, Scott 
2010).  These  techniques  could  lead  to  considerable  exposure  of  implanted  tissue 
engineered constructs to the LA. The toxic effects of common LAs on a number of 
differentiated cell types have previously been documented (Piper and Kim 2008, Quero 
et al. 2011, Jacobs et al. 2011). Therefore any loss of viability or function of SSCs as a 
consequence of exposure to LA would indicate the need to seek alternative analgesic 
strategies.  We  therefore  designed  an  in  vitro  analysis  to  investigate  the  effects  of 
commonly used local anaesthetics on the morphology, biology, function and survival of 
human adult SSCs. 
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6.2  Aims 
 
The aim of this in vitro study was to investigate the effects of three LAs in routine use in 
orthopaedic practice on SSC function and survival, in order to establish their individual 
toxicities over a range of physiological concentrations, and instruct the implementation 
of appropriate analgesia during the application of skeletal tissue engineering strategies. 
 
 
6.3   Null Hypotheses 
 
1.  The  exposure  of  SSCs  to  LA  agents  does  not  affect  their  function  or 
viability. 
 
2.  Incubation of SSCs in basal medium following exposure to LA agents does 
not affect their function or viability. 
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6.4   Materials and methods 
 
6.4.1  Reagents, hardware & software 
 
Tissue culture reagents and all staining agents were purchased from Sigma, Aldrich, 
UK unless otherwise stated. CTG and EH-1 were purchased from Molecular Probes, 
Leiden, Netherlands. 
 
 
6.4.2  Cell culture 
 
Skeletal cell populations (primary passage) were obtained from the bone marrow of 
three patients (male aged 66 years (M66), female aged 72 years (F72) and male aged 
39 years (M39)) undergoing primary THR at University of Southampton Hospital NHS 
Foundation Trust with the approval of the Local Research Ethics Committee (LREC 
194/99)  and  informed  patient  consent  as  previously  described  (Chapter  III,  3.4.2). 
Following isolation and monolayer culture in basal medium, cells were released using 
trypsin in EDTA, centrifuged and re-suspended in basal medium. The total cell count 
was  determined  using  a  haemocytometer.  Cell  populations  were  diluted  with  basal 
medium to a concentration of 5x10
4 cells/ml, and 1 ml of this solution was added to 
each well of a standard 12 well plate. 10 plates in total were seeded for each patient 
(20 plates for M39, in order to perform further analysis at day 7 following LA exposure – 
see  Section  6.4.4),  giving  a  total  of  120  wells  per  patient  (240  wells  for  M39)  for 
experimentation.  The  cells  were  then  grown  to  confluence  over  a  period  of 
approximately 7 days, with PBS washes and medium changes every 2-3 days. 
 
 
6.4.3  LA preparation 
 
Three  local  anaesthetic  solutions  i)  1%  lidocaine  hydrochloride  (Hameln 
pharmaceuticals  Ltd,  Gloucester,  UK),  ii)  0.5%  bupivacaine  hydrochloride 
(AstraZeneca UK Ltd, Luton, UK) and, iii) 0.5% levobupivacaine hydrochloride (Abbott 
Laboratories Ltd, Kent, UK) were obtained from commercial sources in their ‘ready to 
use preparation’, and diluted in basal medium to produce 50:50, 25:75, and 10:90, LA 
to basal medium solutions by volume. 
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6.4.4  Incubation in LA 
 
Upon  cell  confluence,  1  ml  of  each  of  the three  LA  solutions  at  each  of  the three 
concentrations (9 groups per patient) was added to 12 wells (108 wells in total), with 
1ml  basal  medium  alone  added  to  the  remaining  12  wells  to  act  as  controls.  The 
procedure was repeated for the second set of M39 cells. Following incubation in LA 
solutions for 2 hours, the LA solutions were removed, the cells washed in PBS, and 
then incubated overnight in basal medium before analysis. The second set of M39 cells 
underwent 7 days further incubation in basal medium following LA exposure, with PBS 
washes every 3 days prior to analysis. 
 
In  order  to  prevent  cellular  insult  through  lack  of  nutrients  alone  and  to  ensure 
adequate basal medium was always present for cellular metabolism and diffusion, the 
maximal concentration of LA used was a 50:50 (v/v) dilution. 
 
 
6.4.5  WST-1 assay 
 
Cell number and cell viability following LA exposure at the three concentrations were 
quantified using the WST-1 assay (9 groups per patient cell population + controls).  
After removal of the incubation medium and washing in PBS, 1 ml of 1:10 dilution 
WST-1 substrate (Roche Ltd, Welwyn Garden City, UK) was added to 4 of the 12 wells 
of each group. At 2 hours, three 100 µl aliquots of substrate were removed from each 
well and read using a BioTek ELx-800 universal microplate spectrophotometer (BioTek, 
Potton, UK) at a wavelength of 410 nm. An increase in absorbance value (i.e. increase 
in optical density of the substrate) indicated increased cell number and viability. Mean 
and standard deviation  were calculated for  the optical densities of each group and 
percentage reduction compared to controls.  
 
 
6.4.6  DNA assay 
 
Cell number (but not viability) was also determined using a standard DNA PicoGreen
® 
assay. Cells were washed in PBS and fixed in 90% ethanol prior to air drying. The cells 
were then rewashed in PBS and lysed in 1 ml of 0.5% Triton X-100 before undergoing 
three  freeze-thaw  cycles  and  mechanical  lysis.  Cell  lysate  was  measured  for  DNA 
content  using  PicoGreen
®  (Molecular  Probes,  Paisley,  UK)  according  to  routine 219 
 
manufacturer protocol. 10 µl of lysate was run in triplicate for each well on a plate 
against standards, analysed using a BioTek FLx-800 microplate fluorescent reader. 
 
 
6.4.7  Live/dead immunostaining 
 
CTG was used to label viable cells and EH-1 for necrotic cell nuclei. The samples were 
washed  in  PBS  and  then  incubated  for  90  minutes  in  1  ml  of  standard  CTG/EH-1 
solution (10 µg/ml CTG, 5 µg/ml EH-1). Samples were fixed in ethanol and stored in 
PBS prior to fluorescent microscopy using a standard FITC filter. 
 
  
6.4.8  Alkaline Phosphatase assay 
 
ALP  assay  was  used  as  a  measure  of  osteoblastic  differentiation  at  seven  days 
following LA exposure. ALP in the cell lysate (as obtained for the DNA assay) was 
measured  using  p-nitrophenyl  phosphate  as  the  substrate  in  2-amino-2-methyl-1-
propanol  alkaline  buffer  solution  (Sigma,  Poole,  UK)  according  to  manufacturer 
protocol. 10 µl of lysate was run in triplicate for each well on a plate against standards, 
analysed using a BioTek ELx-800 microplate reader.  
 
 
6.4.9  Alkaline Phosphatase stain 
 
Cell morphology and expression of ALP was examined in the final two of 12 wells for 
each group. In brief, cells  were fixed in 95%  ethanol followed by incubation for 45 
minutes in 1 ml of 40 µl/ml naphthol AS-MX phosphate solution with 0.24 µg/ml fast 
violet salt followed by rinsing prior to microscopy. 
 
 
6.4.10  Statistical analysis  
 
All experiments were run at least three times. Statistical analysis was performed using 
SPSS Ver. 18.0. Statistical comparison was made using Student’s unpaired t-test with 
a p value less than 0.05 taken to be significant. 
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6.5  Results 
 
6.5.1   Effect of LAs on skeletal cell proliferation 
 
6.5.1.1 Lidocaine 
Analysis of cell viability and proliferation using the WST-1 assay demonstrated a toxic 
effect  of  lidocaine  on  skeletal  cell  populations  which  was  concentration-dependent. 
Negligible toxicity was observed in each of the three primary skeletal cell populations 
following culture in 10% lidocaine (Fig. 6.2). However, incubation in both 25% and 50% 
solutions resulted in a significant decrease in cell viability with a mean reduction in 
optical density of 33% (p=0.03) and 70% (p<0.001) respectively. Similar observations 
were  recorded  for  DNA  analysis  (Fig.  6.3)  with  a  reduction  in  measured  DNA 
concentration  for  25%  and  50%  solutions  of  47%  (p<0.05)  and  74%  (p<0.05) 
respectively. Furthermore, the inhibition of cell proliferation was maintained 7 days after 
LA exposure with a significant reduction of 18% (p=0.03) and 45% (p<0.001) in both 
the 25% and 50% solutions respectively as measured by WST-1 assay (Fig. 6.4), with 
a  corresponding  persistent  drop  in  DNA  concentration  of  70%  (p<0.01)  and  75% 
(p<0.01) respectively (Fig. 6.5). 
 
6.5.1.2 Bupivacaine 
Similar concentration-dependent toxicity was observed in cells exposed to bupivacaine. 
As  illustrated  in,  WST-1  assay  demonstrated  no  significant  difference  in  the  cells 
exposed to the 10% solution compared to the controls (p=0.1) (Fig. 6.2). However, the 
drop in activity was significant for both the 25% and 50% solutions where the mean 
drop  in  activity  was  68%  (p<0.001)  and  72%  (p<0.001)  respectively.  These  results 
were supported by DNA analysis (Fig. 6.3), where a mean drop in DNA concentration 
from the cell lysate of 59% and 61% was observed in the 25% and 50% solutions 
respectively (p<0.05). This appeared to be an enduring effect in those cells exposed to 
the 50% bupivacaine solution where a 59% reduction was measured on the WST-1 
assay (p<0.001) (Fig. 6.4) and 73% decrease in DNA concentration (p<0.001) (Fig. 
6.5). 
 
6.5.1.3 Levobupivacaine 
The  toxic  effects  of  levobupivacaine  were  not  as  intense  as  either  lidocaine  or 
bupivacaine. WST-1 assay showed no significant mean loss of cell viability in the 10% 
solution (p=0.14) and in both the 25% and 50% solutions the mean reduction in cell 
viability  was  only  24%  (p=0.01  and  p=0.002  respectively)  (Fig.  6.2).  This  was 221 
 
supported by DNA analysis (Fig. 6.3). Furthermore, the toxic effect of levobupivacaine 
was  transient,  permitting  the  recovery  of  cell  viability  at  all  LA  incubation 
concentrations, following a 7 day recovery period. This cell recovery observed by WST-
1 analysis was also seen following DNA analysis (Fig. 6.4 and 6.5). 
 
Fig. 6.1  WST-1 cell proliferation assay at 2 hours (+ SD) for the cells from three patients, 
24 hours following exposure to different concentrations of LAs for 2 hours. Cell viability 
was reduced with increasing concentration of LA, although the effect is less marked for cells 
exposed to levobupivacaine (* p<0.05, ns = no significant difference). 
 
 
Fig. 6.2  Combined  DNA  assay  (+  SD)  of  cells  from  all  3  patients  24  hours  following 
exposure to different concentrations of LAs for 2 hours. A reduction in cell number with 
increasing concentrations of lidocaine and bupivacaine was observed (* p<0.05). There was no 
significant change in DNA for cells exposed to levobupivacaine at all concentrations examined 
(ns). 222 
 
 
Fig. 6.3  WST-1 cell proliferation assay at 2 hours (+ SD) 7 days following exposure to 
different  concentrations  of  LAs  for  2  hours.  A  persistent  reduction  in  cell  viability  was 
observed with increasing concentrations of lidocaine and bupivacaine. Note restoration of cell 
viability  in  cells  exposed  to  levobupivacaine  following  7  days  recovery  (*  p<0.05,  ns  =  no 
significant difference). 
 
 
 
Fig. 6.4  DNA  assay  of  cells  (M39,  mean  +  SD)  following  exposure  to  different 
concentrations of LAs for 2 hours and subsequent 7 days further incubation. There was a 
persistent  reduction  in  cell  numbers  exposed  to  high  concentrations  of  lidocaine  and 
bupivacaine, but similar numbers in samples exposed to levobupivacaine compared to controls. 
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6.5.2  Effect of LAs on cell viability and necrosis 
 
Cell viability and necrosis were examined using CTG/EH-1 immunocytochemistry. In all 
three patient skeletal cell populations examined, necrosis was observed to increase in 
proportion with LA concentration, as shown by the number of cell nuclei staining red 
with EH-1 (Fig. 6.6 and 6.7). Necrosis was exacerbated further in those cells exposed 
to  lidocaine  or  bupivacaine.  However,  cells  exposed  to  levobupivacaine  displayed 
markedly reduced evidence of cell death, often limited to cytoplasmic damage. 
 
Fig. 6.5  Representative live/dead immunostains of cells after 2 hours incubation in LAs 
and 24 hour recovery time. The cytoplasm of live cells stain green with CTG and apoptotic cell 
nuclei  stain  red  with  EH-1.  (A-C)  controls.  (D-F)  cells  incubated  in  10%  solution,  showing 
negligible toxicity in any LA. Cells incubated in 25% lidocaine (G) and bupivacaine (H) show 
significant  cell  necrosis,  whereas  cells  in  25%  levobupivacaine  (I)  remain  essentially  viable, 
even at 50% concentration (L). Scale bars: 200 µm 
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Fig. 6.6  High magnification representative live/dead immunostains of cells after 2 hours 
incubation in LAs and 24 hour recovery time. The cytoplasm of live cells stain green with 
CTG and apoptotic cell nuclei stain red with EH-1. (A-C) controls. (D-F) cells incubated in 10% 
solution,  showing  negligible  toxicity  in  any  LA.  Cells  incubated  in  25%  lidocaine  (G)  and 
bupivacaine (H) show significant cell necrosis and a change in phenotype of remaining viable 
cells. Cells incubated in 25% and 50% levobupivacaine (I and L) show cytoplasmic perforation 
within  viable  cells,  suggesting  early  toxicity,  although  no  viable  cells  remain  in  samples 
incubated with 50% lidocaine (J) or bupivacaine (K). Scale bars: 50 µm. 
 
Following a 7 day period of recovery culture (Fig. 6.8), cells incubated in all the 10% LA 
concentrations (D-F) maintained a normal phenotype and cell growth, comparable to 
control samples (A-C). At 25% concentration, cells exposed to bupivacaine (H) and 
levobupivacaine (I) recovered to control cell densities, however cells incubated with 
lidocaine remained sparsely populated and phenotypically abnormal (G). There was no 
or limited recovery of cells after incubation with 50% lidocaine (J) or bupivacaine (K), 
although normal appearances with levobupivacaine (L). The absence of red nuclear 
staining with EH-1 in these cultures may be a consequence of repeated media changes 
and cell washing over a 7 day period, removing all non-adherent cells and leaving only 
viable cells. 
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Fig. 6.7  Representative live/dead immunostains of cells after 2 hours incubation in LAs 
and  7  day  recovery  time.  Note  the  absence  of  cell-nuclei  staining  red  with  EH-1.  It  is 
hypothesised that all dead cells became non-adherent and were washed away during media 
changes. There is no recovery in live cell number in the lidocaine 25% or 50% groups (G and 
J). Some recovery has occurred in the 25% bupivacaine group (H), but not at 50%, where no 
live cells remain (K). In contrast, cells incubated  with levobupivacaine, maintain confluence, 
even following incubation with 25% and 50% LA (I and L). Scale bars: 200 µm. 
 
 
6.5.3  Effect of LAs on cell differentiation 
 
ALP assay was used as a measure of osteoblastic differentiation of M39 cells one 
week  following  LA  exposure.  There  was  a  reduction  in  mean  ALP  activity  in  cells 
exposed to all LAs (Fig. 6.9), although this was only significant in the 25% and 50% 
lidocaine solutions where the reduction was 83% in both groups (p<0.05), and in the 
25%  and 50%  bupivacaine solutions where the mean reduction recorded was 86% 
(p<0.05) and 100% (p<0.01) respectively. 
A 
J  K  L 
G  H  I 
F  E  D 
C  B 
lidocaine  bupivacaine  levobupivacaine 
10% LA 
25% LA 
50% LA 
control 226 
 
 
Fig. 6.8  ALP assay (+ SD) of cells following exposure to different concentrations of LAs 
and 7 days further incubation. There was a reduction in ALP activity in all groups following LA 
exposure,  however  this  was  only  significant  at  higher  concentrations  of  lidocaine  and 
bupivacaine, (* p<0.05, ns = no significant difference). 
 
These findings were also observed following analysis of ALP staining (Fig. 6.10), a 
measure  of  surviving  cell  number  and  function  and  further,  may  indicate  potential 
mechanisms  of  LA  toxicity  through  analysis  of  cell  morphology.  The  concentration-
dependent  decrease  in  ALP  staining  is  in  concordance  with  the  reduction  in  ALP 
activity detected quantitatively. Furthermore, the toxic effect was less pronounced in 
the cells exposed to levobupivacaine. There was also a substantial reduction in cell 
density corresponding to increasing concentrations of lidocaine and bupivacaine. This 
effect was less dramatic with levobupivacaine. In addition, altered cell morphology with 
condensed/  fragmented  nuclei  and  cytoplasmic  perforations  were  seen  in  higher 
concentrations of lidocaine and bupivacaine exposure, indicative of cell necrosis. 
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Fig. 6.9  Representative  photomicroscopy  of  cells  stained  for  ALP,  after  2  hours 
incubation in LAs and 7 days recovery time.  Cells incubated in 10% LA solutions  (D-F), 
showed minor reduction in ALP staining, compared to controls (A-C). Cells incubated in 25% 
lidocaine (G) demonstrated significant reduction in ALP stain, whereas cells incubated in 25% 
bupivacaine  (H)  and  levobupivacaine  (I)  showed  only  a  slight  reduction.  For  the  50%  LA 
solutions, there was significant loss of cell number and ALP stain in both the lidocaine (J) and 
bupivacaine (K), where cells showed altered morphology and condensed/ fragmented nuclei 
probably due to necrosis. Note cells incubated in 50% levobupivacaine displayed robust cell 
density and positivity for ALP stain after 7 days recovery. Scale bars: 200 µm 
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6.6  Discussion 
 
These studies indicate that certain LAs used at clinically relevant concentrations are 
deleterious  to  the  survival  of  skeletal  stem  cell  populations  in  vitro.  Specifically, 
bupivacaine,  the  most  widely  used  anaesthetic  for  post-operative  intra-articular  use 
(Moiniche et al. 1999), showed significant toxicity to cells following exposure for just 
two hours, even at 25% original concentration. Similarly, lidocaine was observed to 
induce  toxic  effects  at  only  25%  normal  clinically-used  concentrations.  Only 
levobupivacaine  (the  S-enantiomer  of  bupivacaine),  displayed  reduced  cell  toxicity 
compared to the other LAs, an effect maintained at 7 days culture following removal of 
the LA, where negligible cell toxicity was recorded in the levobupivacaine group. Thus 
the  null  hypothesis,  that  the  exposure  of  SSCs  to  LA  agents  does  not  affect  their 
function or viability can be rejected, although the cytotoxic effect was more pronounced 
for lidocaine and bupivacaine, as compared to levobupivacaine. In addition, incubation 
of SSCs in basal medium following exposure to LA agents does not appear to allow 
recovery of cell viability and function following toxicity. 
 
We chose to test the LAs at the concentrations they are used clinically, rather than 
comparing the three LAs at the same concentrations. This provides a more suitable 
comparison  from  a  clinical  perspective  and  addresses  the  fact  that  each  LA  is  a 
different  drug that  has been  manufactured to be  used  within  specific concentration 
ranges.  Although  this  does  not  allow  direct  comparison  between  each  LA  at  each 
individual  concentration,  it  does  enable  an  evaluation  of  each  drug  from  a  clinical 
viewpoint. 
 
As  the  use  of  intra-articular  constructs  that  incorporate  SSCs  becomes  more 
commonplace,  particularly  during  cartilage  regeneration  procedures  (Haleem  et  al. 
2010),  but  also  in  other  evolving  tissue  engineering  strategies,  the  choice  of  LA  is 
becoming more critical. The present in vitro study suggests that intra-articular use of 
bupivacaine in such applications should be avoided. In addition, lidocaine is often used 
subcutaneously  during  minor  procedures  such  as  digital  ring  blocks  (Reichl  and 
Quinton  1987),  and  would  be  a  prime  candidate  for  use  in  a  tissue  engineering 
strategy.  Despite  administration  of  this  LA  several  centimetres  from  any  reparative 
constructs, given the concentration required to produce toxicity is so low, this may still 
prove harmful to the cells. Levobupivacaine is less commonly used in clinical practice, 
but is still indicated for local anaesthesia including infiltration, nerve block, ophthalmic, 
epidural  and  intrathecal  anaesthesia  in  adults;  and  infiltration  analgesia  in  children 229 
 
(Chang et al. 2005). The comparatively reduced toxicity of levobupivacaine on SSCs 
found in the present study is consistent with the recorded reduction in cardiovascular 
and central nervous system toxicity in animal and human studies (Leone et al. 2008). 
Although  current  evidence  suggests  levobupivacaine  exhibits  a  similar  therapeutic 
profile to racemic bupivacaine, in terms of its analgesic effect and duration, further 
research, including in vivo analyses are warranted to determine if, as evidenced from 
these findings, levobupivacaine offers a safer LA for use in clinical procedures involving 
cells such as SSCs (Burlacu and Buggy 2008). 
 
The toxic effects of LAs on a number of cell types have been extensively investigated 
both  in  vitro  and  in  vivo.  Nole  et  al.  found  reduced  proteoglycan  synthesis  in  both 
explanted  porcine  and  canine  cartilage  when  exposed  to  bupivacaine  (Nole  et  al. 
1985). Furthermore, Gomoll et al. showed that continuous infusion of bupivacaine into 
the rabbit shoulder resulted in significant histopathological and metabolic changes in 
the articular cartilage, advocating a cautious approach for the use of continuous post-
operative analgesic infusions (Gomoll et al. 2009). From an orthopaedic perspective, 
reductions in specific cellular activities as a consequence of cell necrosis have also 
been  attributed  to  bupivacaine  exposure  in  myocytes  and  intervertebral  disc  cells 
(Quero  et  al.  2011,  Nouette-Gaulain  et  al.  2009).  A  similar  study  to  the  present 
investigation was carried out by Piper  and  Kim, who compared the toxic effects of 
bupivacaine and ropivacaine (which differs only by the replacement of the butyl group 
with  a  propyl  group)  on  human  articular  chondrocytes  (Piper  and  Kim  2008).  The 
authors found that this small change to the molecular structure resulted in significantly 
reduced toxicity  of ropivacaine  to  chondrocytes,  both  in  intact  human  cartilage  and 
when cultured in vitro. However these effects were only analysed up to twenty-four 
hours  following  exposure,  and  a  subsequent  study  observed  toxic  effects  of 
ropivacaine when measured at 120 hours (Grishko et al. 2010).  
 
Lidocaine has similar harmful effects to other certain differentiated cell types. Grishko 
et al. showed lidocaine (as well as bupivacaine and ropivacaine) exposure resulted in 
mitochondrial dysfunction and apoptosis in cultured human chondrocytes (Grishko et 
al. 2010), whereas Karpie and Chu also reported chondrotoxic
 effects of 1% and 2% 
lidocaine on bovine chondrocytes (Karpie and Chu 2007). The toxicity of lidocaine on 
mature human articular chondrocytes appears to be both dose and time-related in vitro 
(Jacobs  et al.  2011).  Lidocaine also has toxic effects on other cell types,  including 
retinal ganglion cells (Grosskreutz et al. 1999) and urothelial cells (Drewa et al. 2005). 
Lidocaine has been shown to disrupt intercellular adherence, and this property has 230 
 
been utilised to replace the use of trypsin in a tissue-culture technique, to re-plate cell 
suspensions with no apparent detrimental effects (Rabinovitch and DeStefano 1975). 
Such effects could interfere with the normal function of these cells, however, and be 
detrimental  to  tissue  engineering  techniques  that  rely  on  cellular  adherence  and 
replication upon a construct.  
 
To  date,  the  mechanisms  of  LA-induced  cell  toxicity  remain  unclear,  although  the 
induction  of  apoptosis  via  mitochondrial  damage,  caspase  activation,  inhibition  of 
tyrosine kinase, and blockage of sodium channels, as well as direct necrotic effects, 
including altered calcium metabolism, free radical damage and changes in membrane 
fluidity have all been implicated (Johnson  et al. 2002, Johnson et al. 2004, Klemm 
1985, Werdehausen et al. 2007). Correlation has been made between LA lipophilicity 
and toxicity, as well as low LA pKa and the induction of cell apoptosis (Onizuka et al. 
2011).  Mechanisms  involved  in  LA  induced  cell  toxicity  are  thus  a  pivotal  area 
warranting further examination. 
To our knowledge this is the first study to report the toxic effects of LAs on skeletal 
progenitor  cells.  Kim  et  al.  have  examined  the  effects  of  lidocaine  on  rat  muscle-
derived progenitor cells (MDC) in a urinary incontinence model (Kim et al. 2009). The 
authors  found  minimal  cytotoxicity  of  lidocaine  at  a  physiologic  concentration, 
concluding  that  this  LA  could  be  safely  used  for  analgesia  in  a  periurethral  MDC 
injection  without  decreasing  the  efficacy  of  the  therapy.  However,  this  model  was 
wholly different to the current study because only lidocaine was tested, and the cells 
under  test  were  specifically  cultured  such  that  they  were  highly  enriched  for 
differentiated myogenic cells. 
 
Significant progress has been made to identify and synthesise efficacious cell-scaffold 
combinations  for  tissue  engineering  techniques  to  treat  skeletal  pathology. 
Furthermore, significant resources have been invested to develop reliable, reproducible 
and  effective  therapeutic  strategies  to  maximise  the  regenerative  potential  of  such 
reparative constructs. As more strategies are translated to clinical use, the practical 
aspects necessary for delivering such successful approaches will become increasingly 
important. The refinement of such strategies requires a holistic understanding of the 
cellular science through to clinical care, and relies upon pre-emptive identification and 
removal of factors that may prevent optimal clinical outcomes. This study highlights an 
important  issue  for  regenerative  medicine.  As  the  use  of  tissue  engineering  and 
regenerative clinical strategies become more commonplace, the survival of cells on a 231 
 
construct will prove integral to success, and thus care with, or avoidance of the use of 
certain local anaesthetics in the vicinity of the construct is advocated. Such relatively 
simple  modifications  to  established  clinical  protocols  will  help  to  ensure  optimal 
therapeutic efficacy of the reconstructive strategy. These findings are not just important 
for consideration in the implementation of  novel  reconstructive techniques, but may 
have  significant  impacts  upon  the  success  of  strategies  in  current  use  for  skeletal 
regeneration, such as microfracture treatment, mosaicplasty and MACI (see section 
1.8.1). 
 
In  conclusion,  the  null  hypotheses  that  ‘exposure  of  SSCs  to  LA  agents  and 
further incubation of SSCs in basal medium following exposure to LA agents 
does not affect their function or viability’ can both be rejected. Specific LAs have a 
direct toxic effect to SSCs in vitro at clinically relevant concentrations and following 
exposure to a threshold concentration, these cells do not recover once the LA has 
been removed. 
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7.1  Conclusions 
 
Given the increasing frequency and considerable morbidity associated with damage or 
loss of musculoskeletal tissues, coupled with the inherent disadvantages associated 
with  many  current  orthopaedic  therapies,  there  is  a  clear  and  urgent  mandate  to 
translate  musculoskeletal  research  into  clinical  use.  With  the  advent  of  tissue 
engineering  and  the  appreciation  that  its  principles  could  be  readily  applied  to 
musculoskeletal regeneration, there has been an accumulation of promising strategies 
to regenerate skeletal tissue. The approaches outlined in Chapter I provide a snapshot 
of  future  potential,  but  despite  an  abundance  of  promising  in  vitro  results,  the 
necessary validation of these strategies using robust small and large animal in vivo 
studies  is  scarce,  with  even  fewer  studies  progressing  to  clinical  trials.  This 
translational  gap  prohibits  the  routine  clinical  use  of  many  of  these  promising 
techniques. 
 
The therapeutic panacea for skeletal tissue engineering would be the integration of a 
custom-sized immuno-modulated package containing an absorbable synthetic scaffold 
and  impregnated  with  sustained-release  growth  factors,  with  viable  autogenous 
skeletal  cells  (in  the first  instance, followed  by  allogeneic  skeletal  populations)  that 
have been stimulated to commit to appropriate differentiation pathways. This would 
have to be presented within a sustained environment that provides adequate nutrition 
and oxygenation and removes metabolic waste products. The development of such a 
construct  clearly  requires  close  co-ordination  within  a  multidisciplinary  framework, 
involving cell scientists, biomedical engineers, mathematicians, clinicians and patients. 
This  thesis  has  demonstrated  how  such  inter-disciplinary  collaborations  can 
successfully  target  each  of  these  requirements  to  evaluate  different  aspects  of  an 
evolving  tissue  engineering  approach,  including  cellular  concentration,  and 
manipulation and scaffold characterisation and selection. In addition, this thesis has 
detailed  the  inception  and  evaluation  of  a  large  animal  in  vivo  model  for  skeletal 
regeneration  and  analysed  some  of  the  hurdles  preventing  promising  new  tissue 
engineering strategies from reaching clinical practice. 
 
The  conclusions  from  each  of  the  experimental  objectives  (presented  in  Chapter  I, 
1.12) are summarised below: 
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Chapter  II:  Development  of  an intra-operative strategy to enrich skeletal stem 
cells from bone marrow for orthopaedic application 
 
Objective 1 
Negative pressure filtration was demonstrated to provide an efficient and inexpensive 
alternative  to  the  current  clinical  intra-operative  strategies  for  administration  of 
concentrated  BMA,  suitable  for  application  with  cells  from  an  elderly  cohort.  This 
solution  to  cell  enrichment  was  found  to  be  amenable  for  development  towards  a 
single-use  device  that  can  be  applied  intra-operatively  within  the  sterile  field,  thus 
offering considerable potential for clinical benefit.  
 
Objective 2 
The  importance  of  BMA  concentration  for  cell  differentiation  and  seeding  onto 
allogeneic bone graft was established. 
 
Chapter III: Tantalum Trabecular Metal – Addition of human skeletal cells to an 
established orthopaedic implant to enhance bone-implant interface strength and 
clinical application 
 
Objective 3 
TTM was demonstrated to support skeletal cell growth and osteogenic differentiation 
comparable to allograft and autograft in vitro. 
  
Objective 4 
The addition of skeletal stem cells to TTM in vitro was shown to enhance early bone-
TTM interface strength and confirmed the potential of TTM with the addition of human 
SSCs  in  tissue  engineering  applications  as  an  alternative  to  the  current  accepted 
standard treatments for loss of skeletal tissues. 
 
Chapter  IV:  In  vivo  evaluation  of  novel  ternary  polymer  blend  scaffolds  for 
skeletal tissue engineering strategies using a murine model 
 
Objective 5 
In vitro and in vivo analyses for skeletal regeneration applications of candidate polymer 
scaffolds selected by a High Throughput screening approach, confirmed that selected 
polymeric  ternary  blend  biomaterials  do  function  as  suitable  scaffolds  for  skeletal 237 
 
regeneration strategies, although it is unclear what additional effect was provided by 
the addition of SSCs to the construct in vivo. 
 
Chapter V: In vivo evaluation of a candidate binary polymer blend scaffold for 
skeletal tissue engineering strategies using an ovine model 
 
Objective 6 
A consistent and reproducible technique was achieved for stabilisation of a 35 mm 
ovine tibial critical segmental defect, using an external fixator construct, for subsequent 
trialling of tissue regeneration strategies. 
 
Objective 7 
A living cell composite using cultured skeletal stem cells on synthetic polymeric binary 
blend biomaterial PLLA/PCL (20/80) scaffold was demonstrated. However this was not 
proven to augment bone formation in an ovine tibial segmental defect model. Practical 
and experimental reasons for this failure were discussed and the need for further work 
to  refine  the  ovine  segmental  defect  model,  the  polymeric  scaffold  and  large  scale 
analytical techniques, was proposed. 
 
Chapter VI: The effect of commonly used local anaesthetics on skeletal stem cell 
viability and function 
 
Objective 8 
Potential  hurdles  to  the  successful  implementation  of  tissue  engineering  strategies 
were  presented  with  reference  to  bridging  the  translational  gap.  Specific  in  vitro 
investigations  demonstrated  significant  dose-dependent  toxic  effects  of  three  local 
anaesthetic agents, in routine use in orthopaedic practice, on skeletal stem cell function 
and survival. These findings were used to instruct the implementation of appropriate 
analgesia during the application of skeletal tissue engineering strategies. 
 
The major null hypotheses that ‘enriched skeletal stem cells applied as tissue 
engineered  constructs  do  not  augment  bone  formation’  can  therefore  be 
rejected. 
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Orthopaedic surgeons are frequently required to evaluate new techniques, products or 
interventions,  based  upon  information  gained  during  research,  to  ensure  evidence-
based best practice for patients and also for professional development. 
 
Each element of study within this research project has provided significant insight into 
the  processes  behind  clinical  improvement,  research  and  product  development. 
Furthermore,  this  thesis  highlights  the  caution  required  before  extrapolating  an 
association seen in vitro to a clinical scenario, and the vast effects on experimental 
outcome  that  can  be  initiated  by  a  change  in  a  trivial  or  peripheral  parameter. 
Conversely, there is also a need for caution in over-interpreting results from studies – a 
highly  significant  research  finding  may  still  translate  to  a  relatively  modest  clinical 
benefit, and in the current economic climate of budgetary restrictions it is necessary to 
balance this with cost, acceptability of the treatment and alternatives. 
 
In  addition,  it  has  been  clear  during  the  interactions  with  laboratory  scientists 
throughout the preparation of this work, how important the perspective of a practising 
clinician is to direct research to a useful output. An understanding of the holistic needs 
of  a  patient  within  the  context  of  disease  is  fundamental  to  ensuring  these  are 
appropriately met by a potential treatment, and without this understanding it is difficult 
to direct research to a pragmatic solution that is clinically acceptable. It has become 
clear that the participation of multiple personnel and agencies, with frequent discussion 
and  feedback,  is  necessary  to  produce  a  coherent  research  protocol,  targeted  to 
answering a specific, simple question or hypothesis. Such a strategy, where the clinical 
applicability of any intervention or finding is constantly borne in mind, is more likely to 
produce findings and products with relevant outcomes and applications for therapeutic 
benefit. 
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7.2  Next steps 
 
Although  the  work  presented  in  this  thesis  has  answered  some  questions  and 
progressed  the  science  of  bone  tissue  engineering  to  a  modest  extent,  further 
questions have inevitably arisen as a result of some of the findings. Therefore, several 
key next steps which require specific further investigation have been identified and are 
detailed below: 
 
 
Chapter  II:  Development  of  an intra-operative strategy to enrich skeletal stem 
cells from bone marrow for orthopaedic application 
 
In vitro analysis is required to define any additional therapeutic benefit derived from 
further incremental BMA enrichment.  
 
The established importance of BMA concentration for cell differentiation and seeding 
onto allogeneic bone graft in vitro should be defined in an in vivo model, such as a 
subcutaneous  mouse  model.  This  would  also  enable  any  additional  effects  of  host 
vasculature on tissue formation to be analysed. 
 
Following  refinement,  the  efficacy  and  safety  of  the  filtration  apparatus  should  be 
assessed  in  small  and  large  animal  skeletal  regeneration  models  prior  to  clinical 
evaluation.  This  is  likely  to  require  significant  multidisciplinary  input  and  capital 
expenditure. 
 
 
Chapter III: Tantalum Trabecular Metal – Addition of human skeletal cells to an 
established orthopaedic implant to enhance bone-implant interface strength and 
clinical application 
 
Further  enhancement  of  the  properties  of  TTM  should  be  investigated.  Potential 
strategies could involve the incorporation of temporally-released chemical mediators or 
modulation of surface nanotopography to direct cellular growth and differentiation. 
 
The  enhanced  biological  and  mechanical  properties  of  TTM  cultured  with  SSCs 
demonstrated in the current study, should be confirmed in a small animal in vivo study. 
A rabbit spinal fusion model would be particularly appropriate.  240 
 
Chapter  IV:  In  vivo  evaluation  of  novel  ternary  polymer  blend  scaffolds  for 
skeletal tissue engineering strategies using a murine model 
 
Work on the translation of high throughput technology to larger scale clinical models 
(ovine  condylar  and  segmental  defects)  are  ongoing  to  validate  the  ternary  blend 
biomaterials for functionality with respect to weight-bearing and remodelling capacity 
prior to clinical application. 
 
 
Chapter V: In vivo evaluation of a candidate binary polymer blend scaffold for 
skeletal tissue engineering strategies using an ovine model 
 
Work  is  required  to  refine  polymer  scaffold  manufacturing  processes,  to  maximise 
nutrient diffusion and porosity without adversely affecting structural properties. 
 
In vitro ovine cell differentiation and culture protocols are required to define optimal 
conditions and techniques for seeding and osteogenic cell growth on scaffolds prior to 
implantation. 
 
The effect of changing construct stability on the size of a critical-sized segmental defect 
should be defined in ovine tibial models. 
 
 
Chapter VI: The effect of commonly used local anaesthetics on skeletal stem cell 
viability and function 
 
The  current  study  identified  a  significant  toxic  effect  in  vitro  of  selected  local 
anaesthetic  agents  on  undifferentiated  SSCs.  The  relative  sensitivity  of  more 
differentiated  skeletal  cells,  particularly  following  chondrogenic  and  osteogenic 
differentiation should be assessed in vitro, prior to in vivo studies.  
 
Investigation is required to identify other routinely used pharmaceutical or therapeutic 
agents that may hinder reconstructive strategies. Candidate materials for further testing 
include analgesics (such as non-steroidal anti-inflammatory drugs) and bone cement. 
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7.3  Future perspectives 
 
Although  some  skeletal  tissue  engineering  strategies  have  been  successfully 
implemented  in  clinical  practice,  the  rate  of  translation  of  potential  new  techniques 
remains  low.  In  addition  to  the  scientific  and  technical  challenges  that  need  to  be 
overcome, development and manufacture of putative scaffolds and ancillary products 
require continued financial input, which may become harder to secure in the current 
fiscal climate until greater numbers of translated therapies reach the market. Seemingly 
peripheral concerns of finance, regulation, manufacturing and ethics are increasingly 
preventing  some  innovative  and  promising  strategies  from  progressing  beyond  the 
laboratory.  Efforts  should  therefore  be  made  to  ensure  research  developments  are 
closely allied at an early stage to the processes involved in large-scale manufacture for 
clinical  use.  These  processes  include  ethical  and  regulatory  approval,  good 
manufacturing  practices,  logistical  planning,  appropriate  marketing  and  financial 
commitment.  Clearly  then,  there  is  a  need  to attract  appropriate  personnel  with  an 
understanding  of  these  requirements  and  to  foster  an  entrepreneurial  ethos  within 
research groups to facilitate such a multidisciplinary approach. 
 
The last ten years have seen a dramatic expansion of potentially exciting treatment 
options to address the increasing burden of orthopaedic morbidity. Although many of 
these  strategies  remain  theoretical  or  in  small  scale  development,  the  coordination 
required  to  effectively  screen  and  translate  the  most  promising  options  to  clinical 
application, has now been recognised. Recent development of techniques to modulate 
cellular growth and differentiation, and scaffold characteristics are now being combined 
with analytical tools to develop constructs with appropriate physico-chemical properties 
for  varying applications. It is likely that the wealth of experience accumulated by a 
variety of multidisciplinary research groups will be combined to produce an increasing 
catalogue of efficacious tissue engineering products for specific applications that will 
soon become a routine part of clinical medicine. 
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Anaesthetic protocol for sheep 
 
 
Pre-medication 
Rompun 2% (Xylazine) – 0.1 mg/kg  
Bayer Health Care 
Strawberry Hill 
Newbury 
Berkshire 
RG14 1JA 
 
Induction 
Ketaset (Ketamine) – 2mg/kg    
Fort Dodge Animal Health Ltd 
Southampton 
SO30 4QH 
 
Hypnovel (Midazolam) – 2.5mg flat rate 
Roche Products Ltd 
Welwyn Garden City 
Hertfordshire 
AL7 3AY 
 
Maintenance 
Isoflurane (IsoFlo)  – approx 2% inhaled in pure oxygen         
Abbott Laboratories Ltd. 
Abbott House 
Vanwall Road 
Maidenhead 
Berkshire 
SL6 4XE 
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Peri- and post-operative protocol for sheep 
 
 
Analgesic 
Durogesic 75mcg/hr (Fentanyl) – 2 patches, 12 hrs before and 60hrs after surgery 
Janssen-Cilag 
50-100 Holmers Farm Way 
High Wycombe 
Bucks 
HP12 4EG 
 
Vetergesic (Buprenorphine) – 0.6mg approximately 72hrs after second 
application of fentanyl patches 
Alstoe Animal Health 
Pera Innovation Park 
Nottingham Road  
Melton Mowbray 
LE13 0PB 
 
 
 
Antibiotic Cover 
Betamox LA (Amoxicillin) 150mg/ml – 15mg/kg given preoperatively 
NorbrookLaboratories (GB) Limited 
The Green 
Great Corby 
Carlisle 
CA4 8LR 
 
Ceporex (Cefalexin) – at 5ml/animal for four days 
Schering-Plough Animal Health 
Division of Schering-Plough Ltd 
Welwyn Garden City 
AL7 1TW   
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Euthanasia   
Pentobarbital solution 20% – 0.7mg/kg (approx 40mg per sheep) 
Pharmasol Ltd. 
North Way 
Andover 
Hampshire 
SP10 5AZ 
 
 